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Abstract
There is strong evidence to support a hypothesis that inflammation in rheumatoid 
arthritis (RA) may in part be driven by hypoxia resulting from poorly vascularized but 
highly proliferative tissue. Much work has been carried out that demonstrates hypoxia and 
hypoxic changes in rheumatoid but not in non-rheumatoid joints.
In this thesis I use the rat adjuvant arthritis model, which mirrors much o f the 
pathology o f rheumatoid arthritis to identify hypoxic cells, cytokines and transcription 
factors involved in joint inflammation. My study demonstrates for the first time the use of 
Hypoxyprobe-1, a commercially available exogenous probe, to identify hypoxic cells in all 
structures o f the inflamed joint including the synovium, pannus, bone marrow and articular 
cartilage chondrocytes. It showed that as the clinical symptoms o f adjuvant arthritis 
develop, so the inflamed joint becomes hypoxic and that this hypoxia is significantly higher 
than naive controls. Increased cellular hypoxia was associated with a concurrent increase 
in the expression o f Ets-1 transcription factor during the inflammatory response in adjuvant 
rat joints and in synovial fibrblasts from RA patients. From this I concluded that hypoxia 
and HLF-la may be involved in the upregulation of ets-1 during joint inflammation. My 
localisation o f  ets-1 in the invasive pannus is indicative of ets-1 involvement in the invasion 
of synovial join t cartilage and bone by proliferating synovium.
The results are discussed in light o f novel hypoxia targeted therapies and clearly 
show the suitability o f adjuvant arthritis for future in vivo research into the likely efficacy 
of hypoxia-regulated therapies like bioreductive and hypoxia mediated gene therapy in the 
treatment of rheumatoid arthritis.
2
Acknowledgements
I would like to thank my supervisor Dr. Chris Morris for his support, encouragement and
enthusiasm throughout this research project.
Hugs to Dr. Viv Winrow and Dr. Tuls Bodamyali for their dedicated proof-reading and an
ear for a good whinge.
For the provision o f sample tissue and technical advice thanks to Dr. Paul Mapp.
Many thanks to the technicians o f 5west level 1 for their assistance.
I would like to thank my postgraduate and postdoctoral colleagues in 7west 2.9 for their 
friendship, help, advice and regular booze ups that have got me through the years.
I acknowledge financial support from the Arthritis Research Campaign UK.
Finally, I would like to thank my family and fiance, Rob, for their love and support.
3
Quotation
“To the doubters I say there is no force greater than self belief.”
Caren Lorraine Peters -  2003.
4
Table of Contents.




Table o f  Contents................................................................................................................................................................... 5
List o f Figures........................................................................................................................................................................ 8
List o f Plates........................................................................................................................................................................... 9
CHAPTER 1: INTRODUCTION....................................................................................................................................13
1.1 The Inflammatory Response................................................................................................................................ 13
1.2. Rheumatoid Arthritis - An Inflammatory Disease.............................................................................................13
1.2.1 The Anatomy o f the Synovial Joint...............................................................................................................14
1.2.2 The Aetiology o f Rheumatoid Arthritis........................................................................................................15
1.2.3 Genetic Contributions to Rheumatoid Arthritis......................................................................................... 16
1.2.4 Infective Contributions to Rheumatoid Arthritis.....................  17
1.2.5 The Histopathology o f Rheumatoid Arthritis..............................................................................................19
1.3 Hypoxia and Oxygen Measurement.................................................................................................................. 23
1.3.1 Direct Methods o f Oxygen Measurement.................................................................................................... 23
1.3.2 Indirect Methods o f Oxygen Detection....................................................................................................... 25
1.4. Evidence o f Hypoxia in the Rheumatoid Joint from Human and Animal Studies.....................................32
1.5 Mechanisms for Hypoxia in the Joint...................................................................................................................33
1.6 Angiogenesis and Vasculature in the Rheumatoid Joint..................................................................................34
1.7 High Intra-articular Pressure and Hypoxia..........................................................................................................36
1.8 Ischaemia-Reperfusion Injury Generated Free radicals and Tissue Damage................................................37
1.9 The Effects o f Hypoxia in Rheumatoid Arthritis.............................................................................................. 40
1.9.1 Hypoxia and cytokines................................................................................................................................... 40
1.9.2 Hypoxia and Matrix Metalloproteinases (MMPs)..................................................................................... 42
1.9.3 Hypoxia and Other Enzymes......................................................................................................................... 44
1.9.4 Hypoxia and Gene Control.............................................................................................................................47
1.9.5 Hypoxia and Bone Remodelling....................................................................................................................49
1.9.6 Concluding remarks......................................................................................................................................... 50
1.10 Treatment o f Rheumatoid Arthritis....................................................................................................................51
1.10.1 Analgesics.......................................................................................................................................................52
1.10.2 Non-steroidal Anti-inflammatory Dmgs (NSAIDs)................................................................................52
1.10.3 Corticosteroids................................................................................................................................................ 53
1.10.4 Disease Modifying Anti-rheumatic Drugs (DMARDs).......................................................................... 54
1.10.5 Therapies from research and development: Targeting hypoxia.......................................................... 56
1.10.6 Therapies from research and development: Anti Cytokine therapy.................................................. 58
1.10.7 Therapies from research and development: Angiogenesis Inhibitors................................................ 59
1.10.8 Therapies from research and development: Gene Therapy.................................................................61
1.10.9 Therapies from research and development: The final comment.........................................................64
1.11. Animal models in the study of rheumatoid arthritis.......................................................................................64
1.11.1 Detection o f hypoxia in the adjuvant arthritis m odel..............................................................................65
1.11.2 Other animal models......................................................................................................................................67
1.12 Study Hypothesis.................................................................................................................................................70
CHAPTER 2: MATERIALS AND METHODS...........................................................................................................71
2.1. Materials and methods for animal m odel...........................................................................................................71
2.1.1. Anim als.............................................................................................................................................................71
2.1.2. Materials for induction o f Adjuvant Arthritis in the animal m odel.......................................................71
2.1.3 Materials for labelling o f hypoxic cells in animal models using Hypoxyprobe.................................. 71
2.1.4 Animal husbandry............................................................................................................................................72
2.1.5 Induction of Adjuvant Arthritis..................................................................................................................... 72
2.1.6 Clinical assessment.......................................................................................................................................... 73
2.1.7 Labelling o f hypoxic cells using Hypoxyprobe.......................................................................................... 73
2.1.8 Termination o f the animal m odel..................................................................................................................73
5
2.2 Materials and methods for histological studies..................................................................................................74
2.2.1 Materials for tissue processing......................................................................................................................74
2.2.2 X-ray materials.................................................................................................................................................74
2.2.3 Materials for histological assessment...........................................................................................................75
2.2.4 Antibodies for immunohistochemical staining........................................................................................... 76
2.2.5 Tissue processing methods, paraffin embedding........................................................................................77
2.2.6 Tissue processing methods, snap freezing...................................................................................................77
2.2.7 X-ray o f jo ints..................................................................................................................................................77
2.2.8 Haematoxylin and Eosin staining of sections............................................................................................. 78
2.2.9 Immunohistochemical staining methods..................................................................................................... 79
2.2.10 Histology imaging......................................................................................................................................... 83
2.2.11 Histological assessment................................................................................................................................ 83
2.2.12 Immunohistochemical assessment.............................................................................................................. 84
2.3 Statistics.................................................................................................................................................................... 85
2.4 Materials and methods for tissue explant and cell culture................................................................................85
3.4.1 Cell and tissue culture materials....................................................................................................................85
2.4.2 Cell lines and tissue explants..........................................................................................................................86
2.4.3 Defrosting cells and culturing ce lls .............................................................................................................. 86
2.4.4 Passaging cells.................................................................................................................................................. 87
2.4.5 Freezing down cells......................................................................................................................................... 87
2.4.6 Culturing tissue explants................................................................................................................................ 88
2.5 Materials and method for hypoxia cabinet operation........................................................................................88
2.5.1 Materials for hypoxia cabinet operation...................................................................................................... 88
2.5.2 Method for hypoxia cabinet operation..........................................................................................................89
2.6 Materials and methods for protein isolation....................................................................................................... 91
2.6.1 Materials for protein isolation....................................................................................................................... 91
2.6.2 Method for protein isolation.......................................................................................................................... 91
2.7 Materials and Methods for Protein A ssay...........................................................................................................92
2.7.1 Materials for Protein Assay............................................................................................................................92
2.7.2 Method for Protein Assay............................................................................................................................... 93
2.8 Materials and methods for gel electrophoresis & western blotting................................................................. 93
2.8.1 Materials for Gel Electrophoresis & Western Blotting............................................................................ 93
2.8.2 Preparation o f the polyacrylamide gel plates...............................................................................................94
2.8.3 Sample solution Preparation...........................................................................................................................95
2.8.4 Gel Electrophoresis......................................................................................................................................... 95
2.8.5 Western Blot and Immunodetection by ECL...............................................................................................95
2.8.6 Assessment o f western blots...........................................................................................................................98
CHAPTER 3: Determining the Optimum Time Point for Administering the Hypoxyprobe...............................99
3.1 Introduction.............................................................................................................................................................. 99
3.2 Materials and Methods........................................................................................................................................... 99
3.3 Results......................................................................................................................................................................101
3.4 Discussion................................................................................................................................................................106
CHAPTER 4: Characterisation of the Time Course o f Hypoxia in the Synovial Joint o f Adjuvant Arthritis. 107
4.1 Introduction.............................................................................................................................................................107
4.2 Materials and Methods..........................................................................................................................................107
4.3 Results......................................................................................................................................................................108
4.3.1 Results o f Histological Assessment............................................................................................................ 110
4.3.2 Results o f Immunohistochemical assessment............................................................................................116
4.4 Discussion................................................................................................................................................................129
4.5 Conclusions.............................................................................................................................................................132
CHAPTER 5: Hypoxia, Cell Characterisation, Transcription factors and Cytokines.......................................... 133
5.1 Introduction.............................................................................................................................................................133
5.2 Materials and Methods......................................................................................................................................... 135
5.3 Results......................................................................................................................................................................136
5.3.1 Results o f Histological Assessment............................................................................................................ 136
5.3.2 Results o f Immunohistochemical Assessment.......................................................................................... 137
6
5.4 D iscussion.............................................................................................................................................................154
CHAPTER 6: Effect o f Induced Hypoxia on Transcription Factors Invitro ..........................................................159
6.1 Introduction..............................................................................................................................................................159
6.2 Materials and Methods.......................................................................................................................................... 160
6.3 Results.......................................................................................................................................................................161
6.3.1 Effect o f  hypoxia on ets-1 and H IF-la protein expression in synovial fibroblasts from rheumatoid 
patients (RSF).............................................................................................................................................................161
6.3.2 Effect o f hypoxia on ets-1 and H IF-la protein expression in rat tissue explants...............................163
6.3.3 Histological assessment o f rat tissue explants from normoxic and hypoxic culture.............................. 169
6.4 D iscussion............................................................................................................................................................. 174
CHAPTER 7: Summary o f Conclusions and General Discussion...................................................................... 178






Figure 1. Diagram o f a normal synovial jo in t...............................................................................................................14
Figure 2. Representative diagram o f the top view o f a hypoxia cabinet (Microflow Anaerobic System) 89
Figure 3. Western blotting tank setup.............................................................................................................................. 97
Figure 4. Changes in body weight during the development o f adjuvant arthritis.................................................. 109
Figure 5. Development o f clinical symptoms over time of adjuvant arthritis rats.................................................109
Figure 6. Change in the histological scores with development o f adjuvant arthritis............................................ I l l
Figure 7. Day 3 post adjuvant arthritis induction. Hypoxic area o f adjuvant rats (n=5) compared to naive
controls (n=5). P>0.05 (Mann Whitney test.).................................................................................................. ,.116
Figure 8. Day 7 post adjuvant arthritis induction. Hypoxic area o f adjuvant rats (n=5) compared to naive
controls (n=5). P>0.05 (Mann Whitney test.).....................................................................................................117
Figure 9. Hypoxic area o f  adjuvant rats with clinical score 1 (n=7) compared to time matched naive controls
(n=7). PO.OOl (Mann Whitney test.).................................................................................................................117
Figure 10. Hypoxic area o f adjuvant rats with clinical score 2 (n=7) compared to time matched naive controls
(n=7). P<0.001 (Mann Whitney test.).................................................................................................................118
Figure 11. Hypoxic areas o f adjuvant rats with clinical score 3 (n=9) compared to time matched naive
controls (n=9). PO.OOl (Mann Whitney test.).................................................................................................. 118
Figure 12. Summary o f immunohistochemical results in fresh frozen tissue....................................................... 137
Figure 13. Proportion o f nuclei with positive Ets- immunoreactivity.....................................................................152
Figure 14. Proportion o f hypoxic tissue........................................................................................................................153
Figure 15. Proportion o f nuclei HIFla-ir colocalizing with ets-1- ir..................................................................... 153
Figure 16a. Western Blot: Effect o f hypoxia on H IF-la protein expression....................................................... 162
Figure 17a. Western Blot: Effect o f hypoxia on ets-1 protein expression............................................................ 163
Figure 18. Effect of hypoxia on ets-1 protein expression by adjuvant and naive rat tissue explants................ 164
Figure 19a. Western Blot: Effect o f hypoxia on H IF-la protein expression by adjuvant and na'ive rat tissue
explants....................................................................................................................................................................... 165
Figure 20a. Western Blot: Effect o f hypoxia on H IF-la protein expression by adjuvant and nai've rat tissue
explants........................................................................................................................................................................166
Figure 21a. Western Blot: Effect o f hypoxia on H IF-la protein expression by adjuvant and naive rat tissue
explants........................................................................................................................................................................167





3.1 Hypoxyprobe negative control, without hypoxyprobe. 102
3.2 Hypoxyprobe negative control, without primary antibody. 102
3.3 Hypoxyprobe negative control, with irrelevant primary antibody. 102
3.4 30 min hypoxyprobe staining in the adjuvant hind foot. 103
3.5 2 hour hypoxyprobe staining in the adjuvant hind foot. 103
3.6 6 hour hypoxyprobe staining in the adjuvant hind foot. 104
3.7 18 hour hypoxyprobe staining in the adjuvant hind foot. 104
3.8 6 hour hypoxyprobe staining in the naive hind foot. 105
4.1 Day 3 H&E staining o f the hind foot of adjuvant arthritis rat. 112
4.2 Day 3 H&E staining of the hind foot o f naive rat. 112
4.3 Day 7 H&E staining of the hind foot o f adjuvant arthritis rat. 113
4.4 H&E staining of the hind foot o f adjuvant arthritis rat with 113
clinical score 1.
4.5 H&E staining of the hind foot o f adjuvant arthritis rat with 114
clinical score 2.
4.6 H&E staining of the hind foot o f adjuvant arthritis rat with 114
clinical score 3.
4.7 H&E staining of the hind foot o f adjuvant arthritis rat with 115
clinical score 4.
4.8 Hypoxyprobe staining in day 0 adjuvant hind foot. 121
4.9 Hypoxyprobe staining in day 0 naive hind foot. 121
4.10 Hypoxyprobe staining in day 3 adjuvant hind foot. 122
4.11 Hypoxyprobe staining in day 3 naive hind foot. 122
4.12 Hypoxyprobe staining in day 7 adjuvant hind foot. 123




4.14 Hypoxyprobe staining in adjuvant hind foot with clinical score 1. 124
4.15 Hypoxyprobe staining in adjuvant hind foot with clinical score 1. 124
4.16 Hypoxyprobe staining in time matched (C l) naive hind foot. 125
4.17 Hypoxyprobe staining in adjuvant hind foot with clinical score 2. 125
4.18 Hypoxyprobe staining in time matched (C2) naive hind foot. 126
4.19 Hypoxyprobe staining in clinical score 2 hind foot joint 126
chondrocytes.
4.20 Hypoxyprobe staining in clinical score 3 hind foot joint 127
chondrocytes.
4.21 Time matched (C3) naive hind foot chondrocytes. 127
4.22 Hypoxyprobe staining in adjuvant hind foot with clinical score 3. 128
4.23 Hypoxyprobe staining in adjuvant hind foot with clinical score 3 128
4.24 Hypoxyprobe staining in time matched (C3) naive hind foot. 128
5.1 Negative control: Adjuvant hind foot joint, stained using 139
irrelevant mouse antibody.
5.2 Negative control: Adjuvant hind foot joint, stained using goat 139
IgG.
5.3 Negative control: Adjuvant hind foot joint, stained using rabbit 139
IgG.
5.4 Naive hind foot stained with mouse anti-rat ED 1. 140
5.5 Naive hind foot stained with mouse anti-rat ED2. 140
5.6 Adj uvant hind foot stained with mouse anti-rat ED 1. 142
5.7 Adj uvant hind foot stained with mouse anti-rat ED 1. 142
5.8 Naive hind foot joint stained with rabbit anti-iNOS. 143
5.9 Adjuvant hind foot joint stained with rabbit anti-iNOS. 143


















Adjuvant hind foot joint stained with goat anti-VEGF.
Adjuvant hind foot joint stained with rabbit anti-etsl. 
Co-localizing with hypoxyprobe adducts in plate 6.13.
Adjuvant hind foot joint stained with mouse anti-Hypoxyprobe. 
Adjuvant hind foot joint stained with rabbit anti-etsl. Co- 
localizing with hypoxyprobe adducts in plate 6.15.
Adjuvant hind foot joint stained with mouse anti-Hypoxyprobe. 
Naive hind foot joint x40, wax section, stained with rabbit anti- 
etsl (insert xlO o f same section). Low level, staining for ets-1. 
Naive hind foot joint x40, wax section, stained with mouse anti- 
hypoxyprobe (insert xlO o f same section). Low level, non nuclei 
staining, no co-localization with plate 6.16 
Adjuvant hind foot joint stained with rabbit anti-etsl. Co- 
localizing with H IF -la  in plate 6.19.
Adjuvant hind foot joint stained with mouse anti-H IF-la. 
Adjuvant hind foot joint stained with rabbit anti-etsl. Co- 
localizing with H IF -la  in plate 6.21
Adjuvant hind foot joint stained with mouse anti-HIF-1. Co- 
localizing with ets-1 a  in plate 6.20.
Naive hind foot joint x40, wax section, stained with rabbit anti- 
etsl (insert xlO o f same section). Low level, staining for ets-1. 
Naive hind foot joint x40, wax section, stained with mouse anti- 
H IF -la  (insert xlO o f same section). Low level, no nuclear 
staining for H IF -la .
Adjuvant knee synovium (x5, wax section, haematoxylin and 


















6.2 Adjuvant knee synovium (x5, wax section, haematoxylin and 170
eosin) with a high clinical score (3). Cultured in 0% 02.
6.3 Adjuvant knee synovium (x5, wax section, haematoxylin and 171
eosin) with a high clinical score (3). Cultured in 20%O2.
6.4 Naive knee synovium (x5, wax section, haematoxylin and eosin) 171
with zero clinical score. Not cultured.
6.5 Naive knee synovium (x5, wax section, haematoxylin and eosin) 172
with a zero clinical score. Cultured in 0% 02.
6.6 Naive knee synovium (x5, wax section, haematoxylin and eosin) 172
with a zero clinical score. Cultured in 20%O2.
12
CHAPTER 1; INTRODUCTION
1.1 The Inflammatory Response
The inflammatory response is the process by which both the cellular and molecular 
components of the immune system are concentrated at a site o f infection or tissue damage 
(Reeves et al., 1991). Essentially it is a protective response by the body to confine damage 
and assist in the repair o f tissues, as well as preventing further invasion o f the tissue by 
foreign organisms. The inflammatory response is normally highly regulated but in some 
pathological conditions it may become deregulated leading to damage o f healthy tissue.
1.2. Rheumatoid Arthritis - An Inflammatory Disease.
Chronic inflammatory disease is a major cause o f morbidity and mortality and is 
well exemplified by rheumatoid arthritis (RA).
This disease is characterized by polyarthritis of synovial joints but because of its 
unclear aetiology it has been difficult to classify cases. However, the worldwide 
distribution is widely quoted as about 1-2% of the population according to the American 
Rheumatism Association criteria (Lawrence et al 1989). Disease onset is usually in the 
middle years o f life, with a female to male ratio of 3:1. There is also a crippling form of 
this disease that affects juveniles. RA patients suffer considerable morbidity resulting from 
joint pain, swelling, deformity and the resulting disability. The term rheumatoid arthritis
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was first used in 1858 by Sir Archibald Garrod and the pathological changes associated 
with the inflammatory response have been extensively described since.
1.2.1 The Anatomy of the Synovial Joint
Tendinous insertion
4 Bone end A
Synovium
* - *f'«
4 1! Articular cartilage
i 1
4 Bone end B
' ■ . ’W
4 Fibrous capsule
Figure 1. Diagram of a normal synovial joint
The above diagram (Figure 1) shows the complex structure of a synovial joint 
which is the principle site of inflammation in rheumatoid arthritis. The anatomy of the 
synovial joint allows two bone ends (A&B) to angle, slide and twist. The two bone ends 
are covered in hyaline cartilage surrounded by a fibrous capsule and ligaments, which 
enables the bone surfaces to be maintained in apposition. A specialized connective tissue 
layer called the synovium lines the inner surface of this capsule. Folding of synovial tissue 
forms villi which enable the joint to change shape during movement. The cells of the 
synovium can secrete and drain synovial fluid, which has hydraulic and lubricant properties
14
(Edwards, 1989). The synovial lining is partly in direct contact with the cartilage surface 
and brings vascular supply to the chondrocytes enabling the provision o f nutrients and the 
removal of waste products.
The intimal lining of the synovium has one side interacting with matrix fibres o f the 
synovium and one side towards the synovial fluid. It does not have a basement membrane 
or the tight junctions o f an epithelium. Two types o f synovial cells have been identified in 
the normal two to three cell thick synovium lining. They were originally classed ‘Type A ’ 
and ‘Type B ’ cells according to their ultrastructure (Barland et al., 1962) but are now more 
often referred to by their cell lineage, macrophage-like cells and fibroblast-like cells 
respectively (Firestein, 2003).
It has been suggested by Barland et al (1962) that the fibroblast-like cells originated 
from mesenchymal stem cells possessing secretory features and an active Golgi apparatus. 
Edwards et al (1982) have evidenced histological studies to show that it is the fibroblast­
like cells and not the macrophage-like cells that are responsible for joint cavity formation.
The macrophage-like cells have phagocytic capabilities and are responsible for the 
elimination o f microorganisms that may enter the joint via the blood supply and debris from 
articular wear and tear. As will be described later these cells play an important role when 
the joint becomes inflamed.
1.2.2 The Aetiology of Rheumatoid Arthritis
As previously mentioned the cause o f rheumatoid arthritis (RA) is unknown. The 
disease shows a large inter-patient variation and there are few animal models that 
accurately reflect the human disease to enable the study of causative factors. However,
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studies o f  the disease pathology have enabled identification o f some contributory factors, 
which fall into two broad categories.
i) Genetic.
ii) Infective.
1.2.3 Genetic Contributions to Rheumatoid Arthritis
Epidemiologists studying complex diseases use familial clusters and concordance in 
dizygotic and monozygotic twins to study disease prevalence. From these studies it was 
established that genetic factors account for approximately sixty percent risk for developing 
RA (Lawrence, 1970; MacGregor et al., 2000; Maini et al., 1995; Silman et al., 1993). The 
most extensively studied association was with polymorphic human leukocyte antigen 
(HLA) alleles within the major histocompatibility complex (MHC) and susceptibility to 
RA, particularly HLA-DR1 and HLA-DR4.
The particular nucleotide sequence for the gene encoding the constituent molecules 
of HLA-DR suggest that the structure associated with RA susceptibility resides on the cell 
surface adjacent to the T-cell receptor molecule (Sewell and Trentham, 1993; Panayi, 
1995). This combined with the presence of T cells in RA inflammatory infiltrate (Firestein 
and Zvaifler, 1990) indicated a crucial role for T-cells in the pathogenesis o f RA. This was 
supported by animal experiments that showed that T-cell clones from adjuvant arthritis 
transferred disease to naive recipients (Cohen et al, 1985a).
Levels o f rheumatoid factor (RF), auto antibodies specific for immunoglobulin G, 
correlate with disease activity and suggest a role for auto-immunity in the pathogenesis of 
RA; approximately 80% of patients are RF seropositive (Firestein, 2003). However, it has
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not been proven that RA is an autoimmune disease. Erosion of cartilage and bone can 
occur independent o f T-cell regulation (Muller-Ladner et al, 1995). Also Anti-T cell 
therapies in RA patients have had little beneficial affect (Fox, 1995). The lack of cures 
from therapies designed to target specific areas o f the immune system have lead to the idea 
that the out o f control immune response is not the primary cause o f disease.
1.2.4 Infective Contributions to Rheumatoid Arthritis
It has been suggested that an infectious agent may be the etiological trigger. One 
theory is that infection by agents that mimic host molecular structures cause autoimmune 
responses through the breakdown in tolerance o f self (Firestein et al, 2000). The concept 
that an infection could contribute to the etiology rheumatoid arthritis (RA) has been around 
for many years and in some cases there is a definite link i.e. removal o f the organism (or 
toxic products) by tissue or specific therapy can cause remission o f joint symptoms. This is 
the case in Lyme Disease caused by infection with the spirochete Borrelia burgdorferi 
which leads to inflammation in the joints (Burmester et al., 1995). This is also true for the 
reactive arthritis induced by either Chlaymidia trachomatis, Salmonella, Yersinia, Shigella 
or Campylobacter (Sieper et al., 1996.) Antigens for bacteria such as Streptococcus 
pyogenes and Mycobacterium tuberculosis have been found in the synovial fluid of 
individuals suffering from RA (Klasen et al., 1993) but the significance o f this is not 
known. The fact that arthritis can be induced in animals by injected bacterial preparations 
supports these studies. For example, rat adjuvant poly-arthritis is induced by 
Mycobacterium tuberculosis (Harris, 1990) and it has been shown that a mycobacterial 
protein demonstrates immunological cross-reactivity to a cartilage link protein (van Eden et
17
al., 1985). Even with PCR pan bacterial screens showing bacterial DNA in synovial fluid 
o f RA patients, it is still unclear whether the presence o f these organisms is specifically 
related to the disease process (Gerard et al, 2001).
Evidence showing that some viruses cause polyarthritis similar to RA has been used 
to support the case for their involvement in the etiology o f RA. Rubella can cause short 
term polyarthritis (Mitchell et al, 1993). Parvovirus B19 causes self-limiting non­
destructive arthritis in infected adults and progression to erosive RA has been reported 
occasionally (Harris, 1990; Gendi et al., 1996). The retrovirus, HTLV-1 can induce 
polyarthritis in humans and its similarity to RA has lead to the development o f a transgenic 
mouse model, which should help in the study o f the role o f retroviruses in pathogenesis 
(Iwakura et al, 1991).
Epstein - Barr virus (EBV) has been linked to RA, mainly due to the large titers of 
antibody to EBV antigens found in patients (Venables et al., 1988; Harris, 1990; Maini et 
al., 1995). A shared epitope has also been found between EBV and HLA-DR1 (Roudier et 
al., 1989), which could increase the susceptibility o f infection with the virus. Research in 
this line seems set to continue as more recently Balandraud (2003) and co-workers have 
used modem techniques of PCR to demonstrate an increase in EBV in RA patients 
compared to normal controls.
No one infectious agent has been found to trigger classical rheumatoid arthritis and 
it is clear that many different factors could over time play a key role in both the 
pathogenesis and prognosis of RA.
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1.2.5 The Histopathology of Rheumatoid Arthritis
There is a large variation in the histopathology both between patients and even 
within a single joint. However a common feature is cellular hypertrophy and hyperplasia 
within the synovium (Schumacher and Kitridou, 1972; Poulter et al., 1982; Cush and 
Lipsky, 1991; Fitzgerald and Bresnihan, 1995; Tak et al., 1997). In the early stages of RA 
there is an infiltration o f polymorphonuclear leukocytes but as the disease progresses and 
the inflammation becomes more chronic, lymphocytes and mononuclear cells predominate 
in the infiltrate (Cush and Lipsky, 1991). The synovium also contains lymphoblasts and 
plasma cells that migrate into the synovium and differentiate into immunoglobulin (Ig) - 
and rheumatoid factor (RF) - secreting plasma cells (Kobayashi and Ziff, 1973). There is 
evidence that supports a key characteristic of the rheumatoid joint, the rapid local division 
o f fibroblast-like cells in the synovial lining (Ghadially, 1983). This includes the 
expression o f some proliferation-associated genes c-myc, shown to be elevated in synovial 
tissues from patients with early destructive RA (Trabandt et al., 1992a, b).
Hyperplasia o f the rheumatoid synovium may be partly explained by the action of 
cytokines. Basic fibroblastic growth factor (bFGF), platelet-derived growth factor (PDGF), 
transforming growth factor P (TGF-p), granulocyte/macrophage colony-stimulating factor 
(GM-CSF) and interleukin 1 p (IL- p) have been show to stimulate DNA synthesis and 
proliferation o f human synovial fibroblast-like cells in culture (Butler et al., 1989; Bucala et 
al., 1991; Goddard et al., 1992). Production of platelet-derived growth factor B chain 
(PDGF-B/c-sis) and heparin binding acidic fibroblast growth factor-1 has been 
demonstrated in the rheumatoid synovium (Remmers et al., 1991). Additional to the 
actions o f  cytokines, the increase in fibroblast-like cells is also thought to be related to
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impaired apoptosis. Matsumoto et al., (1996) observed that apoptotic cells were mainly 
located in the deep sublining layers of the rheumatoid and that synovial fibroblasts located 
in the lining layer were not apoptotic and some expressed the anti-apoptosis gene product 
Bcl-2. They suggested that this would extend the life o f the fibroblasts invading the 
cartilage. Several other anti-apoptotic molecules have been identified including 
downstream modulators o f Fas-signaling, such as sentrin-I(Franz et al., 2000), small 
ubiquitin-like modifier (SUMO)-l and Fas-associated death domain-like interleukin (IL)- 
1 beta-converting enzyme-inhibitory protein (FLIP), as well as transcriptional regulators 
such as nuclear factor kappa B (NFkB), p53 tumour suppressor gene (p53) (Baier et al., 
2003).
As the disease progresses the hyperplastic synovium develops villous projections 
that protrude into the joint cavity. The tissue at the synovium-cartilage junction is 
described as fibrous and referred to as “pannus”. It is associated with erosion o f the 
underlying cartilage and bone. Mitrovic (1985) suggested that chondrocytes contribute to 
the formation of the pannus. Chondrocytes are activated by inflammatory cytokines, 
dedifferentiate, enlarge their lacunae, coalesce and finally break onto the cartilage surface 
to form a fibrous pannus. It has also been suggested that “pannus” forms after the collapse 
o f aggressive cell formation and is a relic of the aggressive phase (Fassbender, 1998).
Cells in rheumatoid synovial tissue also contain rhomboid cells that are frequently 
described as having a ‘transformed’ phenotype. They respond to stimulation by cytokines 
and growth factors produced in the local inflammatory milieu but also their cellular 
changes are maintained in the absence of external stimulation (Pap et al 2000).
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To date no single specific marker for this phenotype has been identified, instead a 
combination of characteristics has been observed which lead to the cells aggressive, 
invasive behavior. In 1989 Lafyatis et al observed the transformed phenotype of 
synoviocytes from arthritic joints and demonstrated that they were capable of anchorage- 
independent growth. In 1997 Zvailfler et al gave these cells the name pannocytes to 
distinguish them from fibroblast like synoviocytes. They have been described as having a 
rhomboid morphology, hypochromic nuclei with prominent nucleoli and they could also be 
maintained in culture for longer than fibroblast like synoviocytes (Zvalier et al, 1997).
Work has also been carried out to elucidate the genotype o f these cells. They have been 
shown to express mRNA for type I collagen, strong expression of vascular cell adhesion 
molecule-1 (VCAM-1) (Zvalier et al, 1997; Xue et al, 1997) and the cytokines, tumour 
necrosis factor alpha (TNF-a), interleukin-1 (IL-1), stromal cell-derived factor 1 (SDF-1) 
(Seki et al., 1998). Other characteristics include the expression o f members o f the activator 
protein-1 (AP-1) transcription factor family, c-jun and c-fos (Roivainen et al, 1996), which 
regulate the transcription o f pro-inflamatory molecules IL-1, IL-6, and metalloproteinases 
(Angel et al., 1991, Dooley et al, 1996). In 1992 Trabandt et al (199b) detected c-fos and 
fibroblast-type collagenase within synovial fibroblast-like cells attached to bone erosions. 
Tsuji et al (2000) have identified a role for cfos in cartilage destruction in rheumatoid 
arthritis. Shiozawa et al (1992) showed that c-fos transgenic mice develop an antigen- 
induced arthritis that occurs independently o f lymphocytic infiltration. When the lesions 
were examined ultra structurally, the majority of the cells invading the cartilage and bone in 
the destroyed joints were found to possess a ‘transformed’ appearance distinct from the 
macrophage-like and fibroblast-like synoviocytes.
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Other proteins have been identified in proliferating RA synovial cells including 
members o f the Ras and Raf family o f proteins (Muller-Lander et al, 1995). Ras proteins 
are GTPases involved in signalling pathways between cell surface receptors nuclei or 
cytoskeletal components. They can bind Raf proteins which can in turn activate the 
mitogen-activated protein kinase (MAPK) signaling pathways responsible for cell 
proliferation (Kitasato et al., 2001). In 1991 Trabandt and co workers reported that 
immunolocalization o f Ras and Myc proteins was found in about 70% of the RA cases and 
was restricted to the proliferating synovial lining cells. Trabandt et al. also demonstrated 
the enhanced transcription o f proteolytic enzymes, like cathepsin B in synovial cells when 
compared with normal fibroblasts and cathepsin L, a ras-induced protein, was detected in 
50% of the RA cases, predominantly in synovial cells attached to cartilage and bone at the 
site o f joint destruction (Trabandt et al., 1990 and 1991).
To be discussed in more detail later in 1.6, vascular changes have also been 
observed in the rheumatoid synovium; these include vascular congestion and oedema 
(Rothschild and Masi 1982). Stevens et al (1991a) observed that the capillary density in 
RA biopsies was reduced, and with greater spatial distribution compared to normal 
synovium. Also the average distance o f the capillaries from the joint cavity was increased. 
These vascular changes suggest that the rheumatoid joint may be subject to reduced oxygen 
supply leading to tissue hypoxia and indeed, as will be discussed further in 1.4 and 1.5, 
there is much evidence to support this. The next section 1.3 will first seek to define 
hypoxia and discuss the various techniques available for measuring oxygen tension and 
demonstrate hypoxia in the inflamed joint.
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1.3 Hypoxia and Oxygen Measurement
If  we consider the various oxygen tensions found in the body it is observed 
that arterial oxygen tension (PO2) is 80-90 mmHg and on the venous side it is 36-46 mmHg 
(Schaf et al., 1988). Low oxygen tensions are often associated with disease, for example in 
vivo models o f tumours the oxygen tension is typically 1-9 mmHg (Adam et al., 1999). In 
this situation the tissue is described as hypoxic. However, before reviewing the evidence 
for hypoxia in the rheumatoid joint this next section will deal briefly with the methods by 
which oxygen can be measured and therefore hypoxia detected.
Methods for oxygen measurement can be classified into two types:
1. Direct methods o f oxygen measurement.
2. Indirect methods o f oxygen measurement.
1.3.1 Direct Methods of Oxygen Measurement
1.3.1.1 Oxygen Probes
Oxygen probes are made from non metallic materials with a solid surface to which a
voltage is applied. Oxygen is reduced by this voltage and generates a current, which can be 
measured and related to concentration o f oxygen. These probes are sensitive to a wide 
range of physiological oxygen tensions. An example of a commercial employment of this 
technique is the Eppendorf Histograph. However, this method does have some 
disadvantages; the probes are invasive and therefore cause tissue damage which may in 
itself lead to inaccurate measurements. The electrodes may sample oxygen from both 
oxygenated and hypoxic areas at the same time, therefore specific hypoxic cells cannot be
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identified. Another disadvantage is the probe may consume some oxygen during 
measurement thus altering the oxygen concentration preventing accurate repeat 
measurements in the same area (Swartz, 2002). Blake et al (1997) used an Eppendorf 
oxygen probe intra-articularly to measure the partial pressure o f oxygen in the knees of 
rheumatoid and non- rheumatoid patients. They showed that only rheumatoid joints had a 
majority o f pC>2 measurements in the very low range o f 0-15mmHg.
1.3.1.2 Electron Spin Resonance Oximetry
This technique has utilises the ability o f paramagnetic materials, which have 
unpaired electrons, to interact with oxygen in a specimen. Examples o f commonly used 
paramagnetic materials include fusinite and lithium phthalocyanine. They are implanted 
into the tissue and the spectral line width as a function o f the local p0 2  can be measured 
non-invasively, frequently and repeatedly from the surface (Swartz, 2002). This technique 
has undergone considerable development by Swartz and co workers and has been suggested 
as a suitable technique for clinical measurements in tumours or vascular disease on account 
o f its accuracy, low toxicity and low invasiveness (Swartz and Walczak, 1998). However, 
most recently it has mainly been used in small animal studies measuring oxygen tension in 
the brain (Rolett et al., 2000, Lei et al., 2001, Hou et al 2003). Bruce (1992) explored the 
feasibility o f using the technique to measure oxygen tensions in inflamed joints in rats 
using fusinite and lithium phthalocyanine. However, I can find no further literature 
suggesting its use in studies of rheumatoid arthritis.
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1.3.2 Indirect Methods of Oxygen Detection
1.3.2.1 Nuclear Magnetic Resonance and Magnetic resonance imaging
Nuclear magnetic resonance (NMR) is a form of absorption spectroscopy and may 
be used in vivo studies. The specimen of interest is exposed to electro-magnetic radiation. 
The specimen nuclei absorb the energy from the electromagnetic radiation; they become 
excited and are promoted to a higher energy state. As the nuclei return to their original 
energy state they release an emission which can be measured. This emission varies 
dependent on the chemical species present. A variety o f parameters can be measured from 
this information including metabolite concentration and pH. NMR can also be used to 
directly measure P0 2  by measuring the oxygen sensitive Ti relaxation rate of 
perfluorocarbons injected into the tissue of interest its sensitivity is within ±2 mmHg 
(Swartz, 2002). Nuclear magnetic resonance analysis was used to demonstrate increased 
levels o f lactate and ketone bodies such as 3-D-hydroxybutyrate and acetoacetate, as well 
as decreased concentrations of glucose, chylomicron- and very-low-density lipoproteins 
(VLDL)-associated triacyclglycerols in RA synovial fluid and sera (Naughton et al., 
1993a,b).
1.3.2.2 Endogenous Markers of Hypoxia.
The previously described methods will give a global measurement o f oxygen in 
vitro and in vivo. However, they cannot identify hypoxia at a cellular level. It is known that 
cells in hypoxic conditions undergo a host o f molecular changes that can be detected using
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immunohistochemistry. Suggested markers come from the oxygen regulated stress 
proteins.
Hypoxia activates a basic helix-loop PAS transcription factor; hypoxia inducible 
factor 1 (HIF -1) (Wenger and Gassman, 1997) HIF-1 is a heterodimer composed of HIF- 
l a  and HIF-1 (3 subunits. The H IF-la  subunit is oxygen regulated and determines HIF-1 
activity (Jiang et al., 1996; Semenza, 2000a.) Under conditions of low oxygen, hypoxia 
inducible factor-1 trans-locates to the nucleus and binds to hypoxia response elements 
(HREs), unique promoters on genes whose expression is up regulated by hypoxia. 
Expression o f H IF -la  by macrophages in the rheumatoid synovium has been recently 
demonstrated (Hollander et al., 2001).
Hypoxic conditions also stimulate glucose transport by four facilitative glucose 
transporters and prolonged exposure to hypoxia results in enhanced transcription of the 
Glut-1 gene. Zhang et al. (1999) have extensively reviewed the two mechanisms behind 
this hypoxic regulation. One mechanism is the stimulation o f Glut-1 transcription 
secondary to the associated inhibition o f oxidative phosphorylation during hypoxia and the 
other is a response to hypoxia-signalling pathways for example HIF-1. Glut-1 expression 
has already been used to assess tumour hypoxia (Airley et al., 2001.) It has been shown 
that the Glut-1 gene contains binding sites for HIF-1 (Ebert et al., 1995, Chen et al., 2001). 
However, a disadvantage for these markers is that their precise affinity for oxygen is not 
known and so therefore the level o f hypoxia cannot be detected. Also hypoxia may not be 
the only stimulus to induce them. It is known that the pro-inflammatory cytokines, tumour 
necrosis factor-a (TNF-a) and Interleukin-1 (IL-1) also induce HIF-1 expression (Albina et 
al., 2001, Thoumton et al., 2000).
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1.3.2.3 Exogenous Markers of Hypoxia
This technique uses bioreductive compounds which under hypoxic conditions 
generate reactive metabolites that bind to cellular macromolecules, thus labelling hypoxic 
cells even if  they are subsequently re-oxygenated.
Nitroaromatic compounds have been extensively studied for this type o f labelling, 
the few that have worked successfully in vivo, having been based on 2-nitroimidazoles.
One of the first, such compounds was isotopically labeled misonidazole. It was found to 
localize in hypoxic regions in small cell lung cancer and malignant melanomas (Urtasun et 
al., 1986, Chapman, 1991). However, the use o f radioactive isotopes combined with 
subsequent patient radiotherapy made this method unsuitable for routine clinical use. In 
1984 Nitroaryl compounds were considered as potential fluorescent probes for hypoxia. 
Nitroakridin 3582 is an example of such compounds, which fluoresce only upon reduction. 
Although Nitroakridin 3582 when incubated with a cell line yielded fluorescence under 
conditions o f reduced oxygen, in vivo it was toxic at doses >0.19 pmol (Stratford et al., 
1984).
In the 1990’s these compounds were superseded by bioreductive compounds 
detectable using immunological techniques. In 1989 Millar and co workers used polyclonal 
antibodies raised against a series of radiation chemically produced 2-nitroimidazole-protein 
adducts in the indirect immunofluorescent detection o f hypoxic cells in EMT6/Ed 
spheroids. They discovered the advantages of this technique: speed, technical simplicity, 
economy, and independence from the requirement of radiolabeled precursor; thus opening 
the door for the use in a clinical setting. In 1994 Hodgkiss and co workers synthesized 
three novel compounds with a 1-substituent containing a biotin moiety. They demonstrated
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that bound adducts o f these compounds could be identified in hypoxic cells in vitro by the 
biotin binding proteins, avidin or streptavidin, labeled with fluorescein.
7-(4’-(2-nitroimidazole-l-yl)-butyl)-theophylline (NITP) represents one o f the 
modern generations of these compounds. The bioreductively bound adducts o f NITP are 
identified with a commercial anti-serum to theophylline. In 1994 Hodgekiss and co 
workers published the pharmacokinetics and discussed various administion methods for this 
compound. It was found to have limited water solubility and they also suggested that direct 
site injection was not a suitable method of administration in tumours as the bound 
metabolites of NITP localized to the injection site (Hodgkiss et al., 1995). This compound 
has mainly been used to visualize hypoxia in tumors in animal models. One of the 
disadvantages of this product is that it is not licensed for use in humans. In 1999 Soo used 
NITP to successfully label hypoxic cells in the rat air pouch pseudosynovial tissue (Days 1 - 
3 post-carrageenan challenge) and inflamed joints.
Pimonidazole is a modified 2-nitromidazole, in the presence of oxygen > 10mm Hg 
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Oxygen inhibits 2-nitromidazole adduct binding by reoxidizing the nitro radical, 
equation 2 (Arteel et al., 1998).
Cline and co workers (1990) used an immunoperoxidase technique to detect the in 
vivo binding o f a 2-nitroimidazole hypoxia marker in sections o f a variety o f excised canine 
tumours. They demonstrated the binding o f the marker was restricted to the cytoplasm of 
the cells. The marker appeared in regions adjacent to necrosis but also in regions free of 
necrosis. This compound has since gone into commercial production as Hypoxyprobe-1. 
Hypoxyprobe-1 is an injectable preparation o f pimonidazole (a modified 2-nitromidizole) 
which is taken up by all tissues in the body but binds only to cells with a pC>2 o f 10 mm Hg 
(or less) at 37°C.
Hypoxyprobe-1 MAB1 is a monoclonal antibody that binds to protein adducts of 
Hypoxyprobe produced in hypoxic cells and this allows their detection in tissues ex-vivo 
using a variety o f immunohistochemical techniques. 1997 saw its first use in combined 
immunohistochemical assays detecting hypoxia and proliferation in squamous cell 
carcinoma o f the cervix (Kennedy et al., 1997). Since then Arteel et al (1998) have 
demonstrated that the reductive metabolism o f this hypoxia marker is regulated by oxygen 
tension independent of pyridine nucleotide redox state. The additional advantages of 
pimonidazole over the previously mentioned compound are that it is readily soluble in 
water and is licensed for use in patients. To date there is no published work on the 
utilization o f Hypoxyprobe-1 in studies o f inflamed joints either in humans o f animals.
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1.4. Evidence of Hypoxia in the Rheumatoid Joint from Human and Animal Studies
Many studies have been carried out that demonstrate hypoxia and hypoxic changes 
in rheumatoid joint but not in non-rheumatoid joints. In 1970, Lund-Oleson examined 
eighty-five rheumatoid knees and found the mean oxygen tension o f the synovial fluid to be 
27mmHg. Falchuk et al (1970) observed low partial pressures o f oxygen (PO2), below 
SOmmHg in RA synovial fluid, combined with decreases in pH and increases in lactic acid 
concentrations and pC02. Other studies also report on a combination o f low p02, increased 
lactate, low glucose and acidosis (Geborek et al, 1989; James et al, 1990; Wallis et al, 
1985a,b). Treuhaft and McCarty, (1971) reported samples with extremely low p02 of less 
than 15.2mmHg in a study o f fifty-five samples of RA synovial fluid. More recently Blake 
et al (1997) used an Eppendorf oxygen probe intra-articularly to directly measure the partial 
pressure o f oxygen in the knees o f rheumatoid and non- rheumatoid patients. They showed 
that only rheumatoid joints had pC>2 measurements in the very low range of 0-15mmHg 
compared to the normal controls that were in the range o f 80-90mmHg.
This work has also been supported by studies in animal models. In 1992 Bruce used 
electron paramagnetic resonance oximetry to measure the partial pressure o f oxygen in vivo 
in joints o f the adjuvant arthritic rat and found a significant decrease in pC>2 between day 
seven and fourteen post adjuvant arthritis induction when inflammation in the joints was 
maximal. Claxson and co workers (1999) used high field proton NMR spectroscopy to 
investigate the metabolic status o f rat air pouch exudate after induction o f inflammation 
with carrageenan. They demonstrated substantially elevated levels o f lactate, low glucose 
levels and high levels o f the ketone body 3-d-hydroxybutyrate, data consistent with a 
hypoxic environment and consequent anaerobic metabolism. This reflects reported studies
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of RA synovial fluid and sera that also showed increased levels o f lactate, ketone bodies 
and decreased concentrations o f glucose using nuclear magnetic resonance analysis 
(Naughton et al., 1993a,b). In 1999 Soo used 7-(4’-(2-nitroimidazole-l-yl)-butyl)- 
theophylline (NITP) to successfully label hypoxic cells in the inflamed joints from adjuvant 
arthritic rats and in rat air pouch pseudosynovial tissue 1-3 days post-carrageenan 
challenge. Between these time points numbers of NITP positive cells were high in the air 
pouch reflecting the fact that it is poorly vascularized with consequent metabolic hypoxia in 
the proliferating pouch wall. This parallels the situation in the RA joint.
1.5 Mechanisms for Hypoxia in the Joint
Two mechanisms may explain why the rheumatoid joint is hypoxic:
1.) Inflamed and proliferating tissue has a high metabolic demand but poor 
neovasculature, which is unable to meet the oxygen demand.
2.) High intraarticular pressures resulting from increases in synovial tissue and fluid 
volume within a rigid capsule causing the collapse o f the subsynovial capillary 
network and a decrease in effective blood flow to the synovium.
The hypoxic environment o f the rheumatoid joint shows many metabolic changes 
these include: lowered glucose levels, raised lactate levels and a decrease in pH in the 
synovial fluid (Falchuk et al., 1970; James et al., 1992). Additionally, elevated activity of 
the glycolytic enzymes, glyceraldehyde-3-phosphate and lactate dehydrogenase, in the 
synovial lining cell population has been detected (Henderson and Glynn, 1981). Detailed 
analysis o f RA synovial fluid and sera by Naughton et al., (1993a,b) using nuclear magnetic 
resonance (NMR) showed increased levels o f lactate and ketone bodies such as 3-D-
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hydroxybutyrate and acetoacetate, as well as decreased concentrations o f glucose, 
chylomicron- and very-low-density lipoproteins (VLDL)-associated triacyclglycerols in RA 
synovial fluid and sera. These molecules are all indicative o f abnormal metabolic status in 
the inflamed joint which would require an increase in perfusion and the vascular changes to 
prevent tissue hypoxia. However, as evidenced in the next section of this chapter the 
vasculature in the rheumatoid joint is unable to keep pace with the metabolic demands.
1.6 Angiogenesis and Vasculature in the Rheumatoid Joint
Angiogenesis is a complex process that brings about the formation o f new blood 
vessels. It is essential in embryo genesis and wound healing but also occurs in tumours. 
Many studies consider rheumatoid arthritis (RA) to be an angiogenesis dependent disease 
(Colville-Nash et al., 1992; Walsh, 1999). This remains a controversial issue, for as will be 
discussed here, there is evidence for both presence o f inhibitors and stimulators of 
angiogenesis and there are differing views regarding the morphology o f vasculature in the 
rheumatoid j oint.
There is a large volume o f evidence showing the presence o f angiogenic regulators 
in the rheumatoid joint. Angiogenic stimulators include: Histamine (Frewin et al., 1986), 
nitric oxide (Farrell et al., 1992, Grabowski et al., 1997), Interleukin-8 (Koch et al., 1992), 
vascular endothelial growth factor (Koch et al., 1994), and the list continues to grow with 
new modulators being found in recent years. These include angiopoietins: Angl and Ang2 
and their receptors, which have key roles in the later stages of angiogenesis (Shahrara et al.,
2002). There are also chemokines present in the rheumatoid synovium that have been
34
shown to stimulate angiogenesis, including synoviocyte-derived CXCL12 (Pablos et al., 
2003) and ffactalkine (Volin et al., 2001).
Angiogenesis inhibitors are also found including thrombospondin (Koch et al., 
1993). These activate cell death in endothelial cells (Armstrong et al., 2003). Other 
chemokines for example tumour necrosis factor a  (TNFa) play the role of inhibitor and 
stimulator o f angiogenesis and this is dependent on the tissue concentration (Faijardo et al., 
1992). Perhaps morphometric studies could elucidate whether new blood vessels are being 
formed in the rheumatoid joint? Two studies looked at cell morphology in the inflamed 
synovium; they suggested that changes in endothelial morphology to tall endothelial cells 
or cells resembling high endothelial venules indicated that there was an increase in vascular 
proliferation in the inflamed synovium (FitzGerald et al., 1991 and Yanni et al., 1993). 
Other studies which have looked specifically at vessel morphology not cell morphology 
have produced contrary results. Stevens et al (1991a) observed that the capillary density in 
RA biopsies was reduced, and with greater spatial distribution compared to normal 
synovium. Also they observed that the average distance o f the capillaries from the joint 
cavity was increased. Ceponis et al, (1996) found a significant reduction in blood vessels 
in the superficial synovium compared to non-inflammatory controls and they also observed 
abnormal Von Willebrand factor (vWF) distribution which they suggested was indicative of 
either vascular damage and or induced release, perhaps as a result o f hypoxia, or reactive 
oxygen species. Other studies suggest that RA synovial neovascularization may be 
aberrant, microvessels in the inflamed synovium lacking pericytes and smooth muscle 
(Walsh, 1999). Blood vessels also lack substance P, calcatonin gene- related peptide and
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C- flanking peptide o f neuropeptide Y- immunoreactive fibres, neuropeptides involved in 
vascular regulation (Mapp et al., 1990).
In conclusion the evidence o f the presence o f angiogenic stimulators clearly shows 
that the signals for angiogenesis are available. However, the neovascularization is small 
relative to the amount o f tissue and there is all the evidence discussed in 1.4 to show that 
the rheumatoid joint is hypoxic. This paradox supports the hypothesis that inflamed and 
proliferating tissue has a high metabolic demand but poor neovasculature, which is unable 
to meet the oxygen demand.
1.7 High Intra-articular Pressure and Hypoxia
As early as 1967 it was observed by Nakamura et al, that perfusion in the RA joint 
was poor, with chronic rheumatoid knee effusions having the slowest rates of dye clearance 
when compared to acutely traumatised joints. Also chronically inflamed joints have been 
found to possess a higher intra-articular resting pressure than normal joints (Jayson and 
Dixon, 1970; Lund-Olesen, 1970; Merry et al., 1991; James et al., 1992). Gaffney and co­
workers (1995) found the intra-articular pressure in ankle joints o f patients with acute 
traumatic effusions at rest and during exercise was about -3 .0  mm Hg, compared to 92.0 
mm Hg in patients with chronic effusions. James et al (1990) found that in rheumatoid 
patients with knee effusions; the increases in intraarticular pressure encountered in normal 
daily activity could compromise blood flow. Generation o f high intraarticular pressures in 
rheumatoid joints plays a key role in ischaemia-reperfiision injury (also termed hypoxic 
reperfusion injury), which may also perpetuate synovitis in the rheumatoid joint (James et 
al., 1992; Edmonds et al., 1993; Halliwell, 1995). The rheumatoid joint cavity has
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increased tissue volume due to proliferation of the synovium and increased inflammatory 
infiltrate. In a small enclosed joint space this tissue becomes further squeezed during 
exercise. This results in a compression o f the synovial capillaries with resultant hypoxia in 
the joint. When the joint is relaxed, intra-articular pressure decreases sufficiently to allow 
restoration o f blood flow to the inflamed tissue and there is a surge in tissue oxygenation. 
Repeating this process leads to the inflamed joint being subject to ischaemia-reperfusion 
cycles. It has been suggested that when reperfusion occurs there is an uncoupling of 
intracellular redox systems and this leads to the production of reactive oxygen species 
(ROS) that damage the tissues (Gaffney et al., 1995).
1.8 Ischaemia-Reperfusion Injury Generated Free radicals and Tissue Damage.
A free radical has been simply defined as any species that contains one or more 
unpaired electrons and is capable o f independent existence (Halliwell, 1995). There is a 
growing body of evidence that suggests that they may contribute to various pathologies. 
Reactive oxygen species such as superoxide radical, hydrogen peroxide, hydroxyl radical, 
hypochlorous acid, and reactive nitrogen species (RNS), such as nitric oxide and 
peroxynitrite, contribute significantly to tissue injury in RA (Bauerova and Bezek, 1999).
As previously discussed in 1.7 it has been suggested that ischaemia-reperfusion 
injury lead to the production o f ROS, which damage tissues in RA. In the 1980’s Granger 
and co workers hypothesised that the enzyme Xanthine oxidoreductase (XOR) played a 
significant role in the generation o f ROS in ischaemia reperfusion injury (Granger et al., 
1986). Detailed immunolocalization studies were carried out which found this enzyme in 
the endothelial cells o f a broad range o f tissues (Jarasch et al. 1986, Kooij et al., 1992). Of
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particular relevance to rheumatoid arthritis is the localization of XOR in the synovial 
endothelium (Allen et al., 1987, Stevens et al., 1991b). It has also been detected in human 
mast cells and macrophages (Hellsten-Westing, 1993). In purine catabolism XOR is seen 
as the terminal enzyme, it catalizes the hydoxylation o f hypoxanthine to xanthine and 
xanthine to uric acid (Harrison, 2002).
The mammalian XOR enzyme exists in two interconvertible forms, xanthine 
dehydrogenase (XDH) and xanthine oxidase (XO). XDH preferentially reduces 
nicotinamide adenine dinucleotide (NAD+), whereas XO reduces oxygen and cannot reduce 
NAD+. Reduction o f molecular oxygen by either form o f the enzyme yields superoxide and 
hydrogen peroxide (Harrison, 2002). Granger and co-workers, (1986) theory for the role of 
XOR in ischaemia-reperfusion injury is that during ischaemia elevated calcium 
concentrations lead to the proteolytic conversion o f XDH to XO and the accumulation of 
hypoxanthine. When reperfusion occurs XO catalyzes the hydroxylation o f hypoxanthine 
and generates superoxide and hydrogen peroxide. Zhang et al., (1998b) demonstrated that 
the conversion of XDH to XO was not necessary for post-ischemic ROS generation as both 
XDH and XO were shown to oxidise NADH. Currently it is accepted that whilst the 
conversion o f XDH to XO may take place it not as important as the overall upregulation of 
XOR activity (Harrison, 2002). Indeed hypoxia has been shown to increase XOR activity 
in vitro (Poss et al., 1996) and elevated levels of xanthine oxidase have been demonstrated 
in patients with RA (Miesel et al., 1993).
Normally, ROS produced in the body are removed by antioxidant systems including 
the enzymes superoxide dimutases and catalase but it has been suggested that during 
ischaemia-reperfusion cycles, such excessive amounts o f ROS are produced that this
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defense system is saturated allowing local tissue damage (Halliwell, 1995). Indeed, ROS 
have been detected in rheumatoid synovial tissue (Singh et al., 1995).
Another means by which XOR could lead to the generation of reactive 
intermediates is via the generation o f nitric oxide (NO). Under conditions o f hypoxia XOR 
can catalyse the reduction of nitrite or nitrate to NO (Miller et al., 1998, Zhang et al., 
1998a), and in the rheumatoid joint production of both superoxide and nitric oxide would 
lead to the interaction o f the two and the formation peroxynitrite (ONOO*) which is 
cytotoxic (Radi et al., 1991). The nitration of proteins by RNS such as peroxynitrite can 
target mitochondrial enzymes, inhibiting cellular respiration and leading to cell death (Radi 
et al., 1994). Also peroxynitrite may facilitate cartilage damage in the RA joint by 
inactivating tissue inhibitors o f metalloproteinases (Frears et al., 1996, Hadjigogos, 2003).
The XOR catalyzed generation o f peroxynitrite has been demonstrated (Godber et 
al., 2000) and the localization of 3-nitrotyrosine (3-NT), a marker o f protein nitration by 
peroxynitrite (ONOO-) and other reactive nitrogen species, has been demonstrated in RA 
patients synovial tissues (Mapp et al., 2001, Sandhu et al., 2003).
There are several processes by which ROS can damage tissue. Lipid peroxidation 
products have been found in the synovial fluid (Lunec et al., 1981, Rowley et al., 1984, Dai 
at al., 1997) and synovial membrane (Winyard et al., 1993) o f RA patients. Lipid 
peroxidation of cellular membranes and lipoproteins occurs when a free radical reacts with 
a polyunsaturated fatty acid, setting off a chain reaction o f oxidizations and forming by­
products that are cytotoxic or capable of inhibiting cell function (Hessler et al., 1983, Morel 
et al., 1983).
39
As well as tissue damage it has been suggested that ROS may perpetuate synovitis 
by stimulating proliferation o f RA fibroblasts, ROS such as hydrogen peroxide, have been 
found to modulate fibroblast proliferation in culture (Murrell et al., 1990, Burdon, 1995; 
Burdon 1996).
Amino acids can also be damaged by ROS and RNS and this has lead to the theory 
proposed by Lunec in 1985 that autoantigens are formed by free radical damage to IgG. 
Indeed, free radical altered IgG in RA patients was found to be higher than normal controls 
(Blake et al., 1985). More recently Uesugi and co-workers (2000) demonstrated the 
modification o f IgG after exposure to hypochlorous acid (HOC1) and peroxynitrite 
(ONOO). They also showed rheumatoid synovial fluids contained significantly greater 
concentrations of nitrosated and chlorinated IgG compared with ostearthritic specimens.
Apart from damaging tissue by the formation o f free radicals via the ischaemia- 
reperfusion cycle, hypoxia can have other notable affects at a cellular level, which will be 
discussed in the next section.
1.9 The Effects of Hypoxia in Rheumatoid Arthritis
1.9.1 Hypoxia and cytokines
The importance o f the role cytokines play in the pathology of rheumatoid arthritis 
cannot be over emphasised. Leukocytes and other cells in the inflamed joint produce 
inflammatory mediators which include cytokines and chemokines (Harris 1990). 
Chemokines are chemotactic cytokines which exert their effect upon neutrophils, 
lymphocytes and monocytes leading to their recruitment, activation and persistence in the
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synovial tissue. At the time of writing chemokines are divided into four families based 
upon the location o f two conserved cystein residues: C-X-C, C-C, C, and CX3-C. The 
cytokine is considered to be a ligand and so is therefore give a ligand (L) designation. 
Cytokine receptors (R) exhibit non-specific affinity for their ligands (Szekanecz et al.,
2003).
A number o f cytokines can be evidenced that support the hypothesis that hypoxia 
stimulated cytokines may have an important role in the pathology of RA. These include a 
member o f the C-X-C family CXCL8 or interleukin-8 (IL-8), elevated levels o f which have 
been found in the joints o f RA patients (Endo et al., 1991). IL-8 regulates leukocyte 
adhesion molecules in RA (DeGendt, 1996) and studies on endothelial cells exposed to 
hypoxia have shown enhanced expression of this cytokine (Karakurum et al., 1994). 
Hypoxia followed by reoxygenation has been shown to stimulate IL-1 expression in 
monocytes (Koga et al., 1992) and increased expression o f IL-1 has been demonstrated in 
human endothelial cells exposed to hypoxia (Shreeniwas et al., 1992). IL-1 together with 
TNFa can stimulate the production of IL-8 by synovial fibroblasts (Hosaka et al., 1994). 
Both TNF-a and IL-1 can stimulate the release o f matrix metalloproteinases (MMPs) by 
synovial fibroblasts and chondrocytes (Abramson et al., 2002).
Another member o f the C-X-C cytokine family, CXCL12 or stromal cell-derived 
factor 1 (SDF-1) promotes migration and activation o f B lymphocytes and hypoxia has 
been shown to induce SDF-1 in parallel with vascular endothelial growth factor (VEGF) 
(Pablos et al., 2003).
Hypoxia/reperfusion has been implicated in the production of a number of 
other cytokines; TNFa (VanOtteren et al., 1995) stimulating the production of many other
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pro-inflammatory factors involved in rheumatoid arthritis and will be discussed in more 
detail later on. Basic fibroblastic growth factor (bFGF), is a potent mitogen and angiogenic 
factor which simulates growth in many cells including various tumour cell lines (Goddard 
et al., 1992) and could be responsible for inducing the transformed appearance o f the 
rheumatoid cells and transforming growth factor p (TGF-p), important because it 
modulates fibroblast recruitment and proliferation (Berse, 1999).
1.9.2 Hypoxia and Matrix Metalloproteinases (MMPs)
Articular cartilage possesses unique structural properties that make it particularly 
suited to a role in protecting the bone heads from damage. In rheumatoid arthritis 
proteolytic degradation of the extracellular matrix (ECM) o f cartilage by matrix 
metalloproteinases (MMPs) has been identified as a key step in joint destruction (Nagase 
and Woessner, 1999, Okada, 2000). Matrix metalloproteinases are a gene family o f zinc 
metalloproteinases that can degrade ECM components. Collagenases (MMP 1, 8 and 13) 
degrade collagen, stromelysins (MMP 3, 10 and 11) degrade proteoglycans and activate 
latent collagenases. Gelatinases (MMP 2 and 9) further degrade collagen that has already 
been clipped by collagenase. MMPs are composed o f three well-conserved domains: a 
propeptide domain, a catalytic domain and a hemopexin-like domain (Massova et al. 1998). 
They are secreted from the connective tissue cells such as fibroblasts, myoblasts, 
chondrocytes, osteoblasts, synovial cells, endothelial cells and inflammatory cells, 
including macrophages, monocytes, neutrophils and mast cells (Turto et al. 1977, Emonard 
and Grimoud 1990, Tozzi et al. 1998, Johnson et al. 1998). Matrix metalloproteinases such 
as collagenase 1 (MMP-1), stromelysin-1 (MMP-3) and gelatinase B (MMP-9) have been
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shown to be elevated in patients with RA (Vincenti et al., 1994, Klimiuk et al., 2002 ). 
MMP enzymatic activity is regulated at four levels: gene transcription, secretion, pro­
enzyme activation and enzyme inhibition by tissue inhibitors o f metalloproteinases 
(TIMPs). It has been proposed that it is an inequality in the TIMP to MMP ration that 
results in diseases like arthritis, associated with uncontrolled proteolysis o f connective 
tissue (Gomez et al. 1997). Indeed inactivation o f TIMP-1 by peroxynitrite has been 
demonstrated (Frears et al., 1996).
MMPs are synthesized in an inactive pro-enzyme form then converted to the active 
enzyme. In cardiovascular research it has been proposed by Novotna et al (2002) that 
activation of collagenolysis in the early phases of hypoxic exposure is related to the 
production of reactive oxygen species (ROS). This is o f particular relevance to rheumatoid 
arthritis; where ROS and RNS have been demonstrated (see section 1.8.). Superoxide, 
hydrogen peroxide, nitric oxide and peroxynitrite all react with the catalytic site o f the 
metalloproteinases (Rajagopalan et al. 1996), it has been shown experimentally that 
peroxynitrite activates MMP-8 (Okamoto et al. 1997), proMMP-1 and proMMP-9 
(Okamoto et al. 1997) and MMP-2 and MMP-9 (Rajagopalan et al. 1996). A secondary 
route by which hypoxia could stimulate the release of MMPs is through the cytokine IL-1. 
As mentioned in section 1.9.1 hypoxia followed by reoxygenation has been shown to 
stimulate IL-1 expression in monocytes (Koga et al., 1992) and increased expression of IL- 
1 has been demonstrated in human endothelial cells exposed to hypoxia (Shreeniwas et al., 
1992). IL-1 activates the release o f MMPs by chondrocytes and by synovial fibroblasts at 
the cartilage-pannus interface (Abramson et al., 2002).
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1.9.3 Hypoxia and Other Enzymes
As previously mentioned in section 1.8 a key enzyme found in RA synovium and 
whose activity is upregulated by hypoxia is xanthine oxidoreductase (XOR). XOR can 
generate tissue damaging reactive species, superoxide and hydrogen peroxide and under 
conditions o f hypoxia has the capacity to form peroxynitrite a reactive nitrogen species also 
capable o f detrimental effects within cells.
Another enzyme with the capacity to produce reactive intermediates is inducible 
nitric oxide synthase (iNOS). iNOS is one of three isoforms of nitric oxide synthase the 
others being neuronal form (nNOS) and endothelial form (eNOS). iNOS synthesises nitric 
oxide (NO) from the catalytic conversion of L-arginine to L-citrulline via a chemical 
reaction between the guanidino-nitrogen o f L-arginine, dioxygen and NADPH. (Gross et 
al., 1995). The activity iNOS can be induced by lipopolysaccharide (Xie et al., 1994) 
hypoxia (Melillo et al., 1995) and pro-inflammatory cytokines such as IL-1, fFN-y and 
TNFa (Wu, 1995). Also the mRNA initiation site o f the iNOS gene has a promoter and 
two binding regions for various transcription factors including nuclear factor kappaB (NF- 
kB) (Xie et al., 1994). iNOS is highly expressed in the rheumatoid synovium, particularly 
in synovial fibroblasts (Sakurai et al., 1995, Gabowski et al., 1997). NO production is seen 
in macrophages, neutrophils and mast cells (Stuehr et al., 1987, McCall et al., 1991, 
Salvemini et al., 1990). Also NO generation has been demonstrated in RA synovial 
cultures (Mclnnes et al., 1996) and this work is supported by animal models - adjuvant 
arthritis and collagen-induced arthritis, which show an increase in iNOS messenger RNA 
and increased nitrate urinary excretion (Cannon et al., 1996).
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NO may also have an anti-inflammatory function by preventing the adhesion and 
release o f oxidants by activated neutrophils in the micro vasculature (Abramson et al.,
2001), but for the most part is considered pro-inflammatory. It can, however, be seen as 
having two roles in rheumatoid arthritis. There is the previously described role in the 
generation o f tissue damaging reactive nitrogen species, by combining NO with superoxide 
to form peroxynitrite, (section 1.8). Peroxynitrite can target mitochondrial enzymes, 
inhibiting cellular respiration and leading to cell death (Radi et al., 1994) and may facilitate 
cartilage damage in the RA joint by inactivating tissue inhibitors o f metalloproteinases 
(Frears et al., 1996, Hadjigogos, 2003).
A subtler role for NO in cell signalling has also been recognised. NO was originally 
identified as endothelium derived relaxing factor (Palmer et al., 1987) and this is indicative 
o f its role in the regulation o f vascular tone. In rheumatoid arthritis this would enable an 
increase in blood flow at the site of inflammation. It has been shown that apoptosis can be 
induced by NO in cultured human fibroblasts and is associated with nuclear p53 protein 
expression (Borderie et al., 1999, Van’t Hof et al., 2000). Finally NO can also induce the 
expression o f two other enzymes associated with RA, cyclooxygenase-2 (COX)-2 and 
haemoxygenase-1 (HO)-l (Salvemini et al., 1993 Foresti et al., 1997).
The enzyme cyclooxygenase (COX) mediates prostaglandin (PG) production from 
arachidonic acid (AA) (Smith et al., 1991). Prostaglandins have been found in synovial 
tissue and fluid by many researchers (Egg, 1984, Henderson et al., 1987). The presence 
COX in rheumatoid synovium was observed in 1992 by Sano et al; and prostaglandin 
production has been shown to be maintained in hypoxic rheumatoid fibroblasts (McGough 
et al., 1997). Two isoforms of COX exist; COX-1 a constitutively expressed enzyme and
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COX-2 the inducible form involved in inflammatory responses. Synovial tissues from 
patients with RA are shown to contain COX-2 and to a less extent COX-1 (Trang et al., 
1977). COX-2 is stimulated by the same stimulatory factors as iNOS namely, hypoxia 
(Schmedtje, 1997 Cemanec et al, 2002), IL-1, TNF-a, EFN-y. Like iNOS, COX-2 has an 
NF-kB binding site, (Wu, 1995), and this will be discussed further in section 1.9.4. 
Peroxynitrite has been linked to the signalling pathways that induce COX-2 (Migita et al.,
2002). Prostaglandins play an important role in rheumatoid arthritis as they can increase 
vascular permeability, oedema and pain in synovial tissues and as early as the 1970’s there 
was evidence that PGs are mediators involved in the development of erosions o f articular 
cartilage (Robinson et al., 1975, Henderson et al., 1987).
Haem oxygenase (HO) like cyclooxygenase exists in two isoforms, inducible HO-1 
and constitutively expressed HO-2. HO catalyzes the cleavage o f haem to biliverdin and 
carbon monoxide, in the presence of nicotinamide adenine dinucleotide phosphate 
(NADPH) (Maines, 1988). HO-1 is recognized as the 32kDa heat shock protein (HSP) 
(Keyse et al., 1989). HSPs are highly conserved proteins classed by their molecular weight 
and are induced by stressful conditions like sudden changes in temperature or oxidative 
stress, they are a cells survival technique, a mechanism by which they might adapt to a 
changing environment. HO-1 can be induced in fibroblasts and other cell types by hypoxia, 
free radicals (Panchenko et al., 2000) and cytokines: IL-1 and TN Fa (Cantoni et al., 1991). 
It carries binding sites for AP-1 and NFkB transcription factors (Lavrovsky et al., 1994). 
Research into HO-1 in has been identified in arthritic synovia (Winrow et al., 1995). In 
normal bone, induction o f HO-1 mRNA has been demonstrated following physiological 
levels o f mechanical loading in vivo (Rawlinson et al., 1998). In a rat model o f carrageenin
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induced acute inflammation HO induction brought about the resolution o f the inflammation 
(Willis, 1995) HO-1 has also been shown to prevent cell death by virtue o f its capacity to 
cleave heme to biliverdin which has antioxidant properties (Stocker et a l , 1987). Finally, 
there is a regulatory loop between HO-1, COX and iNOS: Carbon monoxide produced by 
HO-1 can inhibit iNOS and COX (White et al., 1992). While NO conversely, can induce 
HO-1 and COX-2 (Salvemini et al., 1993 Foresti et al., 1997).
1.9.4 Hypoxia and Gene Control
The responses o f a cell to changes in the local environment ultimately lie at 
gene level. Each gene has a promoter with binding regions for transcription factors, the end 
result being the production o f a specific gene product.
Certain transcription factors are activated by oxidative stress caused by hypoxic 
reperfusion events. One transcription factor specifically activated by hypoxia has 
previously been mentioned in 1.3.2.2. The HIF-1 transcription factor is a dimer composed 
of 2 subunits belonging to the helix-loop-helix-per-amt-sim (bHLH-PAS) protein family. 
The subunits are termed H IF -la  and HIF-1 p (Semenza 1999). The H IF -la  subunit is 
oxygen regulated and determines HIF-1 activity (Jiang et al., 1996; Semenza, 2000.) Under 
conditions o f low oxygen, H IF -la  protein becomes stabilised and is able to bind to HIF-1 p 
to form a transcriptionally active complex (Salceda et al., 1997). The active HIF-1 complex 
translocates to the nucleus and binds to hypoxia response elements (HREs), unique 
promoters on genes whose expression is up regulated by hypoxia. There are a number of 
genes that are regulated by HIF-1, those o f particular relevance to rheumatoid arthritis 
being: iNOS, VEGF and PDGF (Ratcliffe et al, 1998). Also, with the recent development
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of commercial antibodies to H IF -la , expression o f H IF -la  by macrophages in the 
rheumatoid synovium has been demonstrated (Hollander et al., 2001).
Nuclear factor kappa B (NFkB) has been long established as a transcription factor 
that responds to oxidative stress (Schreck et al., 1992, Haddad, 2002) and hypoxia (Koong 
et al., 1994). It has been localised in the vascular endothelium and type ‘A ’ synovial cells 
from RA patients (Marok et al., 1996), a finding which has been supported by studies in 
adjuvant arthritis that localized NFkB to the intimal lining o f the synovium (Tsao et al., 
1997). In rheumatoid arthritis NFkB mediates expression o f many inflammatory factors 
including TN Fa (Foxwell et al., 1998), IL-2 and cell adhesion molecules ICAM-1 (Collins 
et al 1995), VCAM-l(Baeuerle et al., 1997, Manning et al., 1995) and E-selectin (Chen et 
al., 1995). NFkB is a heterodimer that exists in the cytoplasm in an inactive form, with 
critical binding sites masked by an inhibitory protein (IkB). Upon activation a signal 
cascade results in the degredation o f the inhibitory proteins enabling NFkB to translocate to 
the nucleus binding to target genes to be expressed (Allen and Tresini, 2000). Recently, 
ICAM-1 upregulation as a result o f NFkB activation by hypoxia/reoxygenation in synovial 
fibroblasts has been demonstrated, implicating hypoxia reoxygenation in the sequestering 
of lymphocytes in the inflamed joint (Han et al., 2003). iNOS, COX-2, and HO-1 possess 
binding sites for NFkB (Xie et al., 1994, Wu, 1995, Lavrovsky et al., 1994), confirming the 
key role NFkB plays in perpetuating inflammation in the rheumatoid joint.
Activator protein-1 (AP-1) is another transcription factor expressed in the 
rheumatoid synovium (Handel et al., 1995), stimulated by a variety o f inflammatory factors 
including cytokines TNFa an IL-1 (Firestein et al., 1990), growth factors and oxidative 
stress (Willoughby and Tomlinson, 1999). AP-1 consists of hetrodimers or homodimers of
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Jun- and -Fos. AP-1 mediates T cell activation and production o f cytokines and matrix 
metalloproteinases (MMPs) (Angel et al., 1991).
Hypoxic reperfusion injury and the resulting formation o f free radicals has 
previously been discussed with regard to rheumatoid arthritis in section 1.8. Transcription 
factor, p53 tumour suppressor gene (p53) can be induced by reactive oxygen metabolites 
(Hansson et al., 1996). Over expression of p53 has been observed in RA synovium 
(Firestein et al., 1996) and mutations of the gene have been found associated with synovial 
neoplasia (Han et al., 1999). In 1998 Aupperle et al., observed that inactivation o f p53 
protein decreased apoptosis in fibroblast-like synoviocytes thus attenuating their 
proliferation.
1.9.5 Hypoxia and Bone Remodelling
'Bone remodelling' is a continuous process o f renewal and repair carried out by two 
cell types: osteoclasts, which re-absorb bone, and osteoblasts, which form new bone. Old 
or damaged bone is removed by osteoclasts by the secretion o f acid and proteolytic 
enzymes on to the bone surface. Subsequently the osteoclasts migrate away from the area 
o f bone undergoing resorption and undergo apoptosis. They are replaced by osteoblasts, 
which lay down new bone matrix.
In rheumatoid arthritis focal bone erosions occur at the joint margins and in 
subchondral bone. The site of bone erosion contains cells with phenotypic characteristics 
o f osteoclasts, (Takayanagi et al., 1997). These erosions have been correlated with disease 
severity (Goldring, 2002) and analysis o f markers for bone metabolism in early stages of
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RA show an increase in osteoclast-mediated resorption that is not matched by new bone 
formation (Goldring et ah, 2000).
As previously discussed in section 1.9.3 iNOS is an enzyme that can be induced by 
hypoxia (Melillo et al., 1995) and synthesises nitric oxide. There is evidence to suggest that 
NO effects osteoclastic bone resorption. In vitro studies have shown that low 
concentrations o f NO potentiate IL-1 induced bone resorption and high concentrations 
inhibit bone formation (Ralston et al., 1995). The interactions o f NO with free radicals may 
attenuate bone erosion as superoxide and hydrogen peroxide can stimulate osteoclastic 
bone resorption (Hadjigogos, 2003) NO stimulates the production o f matrix 
metalloproteinases in chondrocytes, which may lead to further destruction o f the joint 
(Murrell et al., 1995).
Receptor activator o f nuclear factor-kB (RANKL) is a membrane-bound TNF- 
related factor that is expressed by osteoblast/stromal cells. The presence o f RANKL is vital 
for osteoclast differentiation (Suda et al., 1999). Recently Takayanagi et al. (2000) have 
shown that RANKL mRNA is highly expressed in synovial tissues from patients with RA, 
but not in OA synovial tissues. This expression has been demonstrated in synovial 
fibroblasts, as well as in activated T cells derived from RA synovial tissues, suggesting that 
these cells may contribute to osteoclast formation at the specific sites of bone destruction in 
rheumatoid arthritis (Horwood et al., 1999).
1.9.6 Concluding remarks.
The expression of many of the hypoxic activated inflammatory factors and 
transcription factors discussed in this section have been evidenced in the histopathology of
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rheumatoid arthritis discussed in section 1.2.5 lending strong evidence to support a 
hypothesis that inflammation in rheumatoid arthritis may in part be driven by hypoxia 
resulting from poorly vascularized but highly proliferative tissue. The next section will 
look at the current pharmacological therapies prescribed by conventional medicine today 
and take a brief look at the new frontier therapies.
1.10 Treatment of Rheumatoid Arthritis
The wide range o f therapies for rheumatoid arthritis (RA) include: surgery, 
physiotherapy, diet supplementation and combinations o f drugs. However, for the purpose 
o f this thesis the content in this section will concentrate on single drug therapies. Some of 
these have been around for years and can be divided into four groups based upon their 
mode o f actions:
1. Analgesics
2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
3. Corticosteroids
4. Disease Modifying Anti-rheumatic Drugs (DMARDs)
Recently, however, expanding knowledge of the molecular interactions within RA 
has lead the development of new therapies and these will be briefly browsed under the 
section o f ‘Therapies from research and development’, they include:
5. Therapies targeting hypoxia





Analgesics are used commonly in the treatment o f RA. They include peripheral 
(non-narcotic) analgesics like acetaminophen (paracetamol) and the centrally acting 
(narcotic) analgesics such as codeine. The mode o f action o f paracetamol still remain 
elusive, it is known that its antipyretic actions arise from the inhibition o f prostaglandin 
synthesis in the hypothalamus (Firestein et al., 2000). The advantage o f using paracetamol 
is it lacks the gastric toxicity associated with many non-steroidal anti-inflammatory drugs. 
However, in overdose levels paracetamol can lead to hepatotoxicity. The use o f codeine 
and other opioids is primarily for acute pain and is not suited to chronic pain management. 
This is because o f the risk to the elderly posed by the associated side effects of, 
constipation, drowsiness and impaired cognitive function (Firestein et al., 2000).
1.10.2 Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used in the treatment 
o f RA based on their ability to reduce inflammation. All NSAIDs are peripheral analgesics 
and provide some pain relief on account o f their anti-inflammatory effects. Acetylsalicylic 
acid (aspirin) originally derived from willow (salix) bark, is one o f the best known 
NSAIDs.
NSAIDs have a common chemical structure which means that their mode o f action 
is similar. They are essentially weak acids and function as inhibitors o f cyclooxygenases 
(Vane, 1971) which catalyse production of prostaglandins (a process discussed in section 
1.9.2). Prostaglandins cause pain and oedema by enhancing the effects o f other mediators 
such as bradykinin and histamine (Ferreira, 1981). Therefore by inhibiting
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cyclooxygenases, pain can be blocked locally. They also reduce the swelling and increased 
temperature o f inflamed joints (Abramson, 1989). However, these drugs are also 
associated with adverse side affects, involving the neurological, renal, cardiovascular and 
gastro intestinal systems. Migraines and impaired cognitive function have been associated 
with indomethacin (O’Brien et al., 1985) and kidney tissue damage with many NSAIDs 
(Clive et al., 1984). Blood pressure increases which can be additive to pre-existing cardiac 
problems (DeLeeuw, 1996) and erosions induced in the upper gastrointestinal tract by an 
increased gastric acid secretion as a result o f local prostaglandin inhibition (Ferreira et al., 
1979).
Newer NSAIDs such as etoricoxib and valdecoxib have been developed. These 
aim to selectively inhibit COX-2, which is predominantly induced in pathological states 
and therefore these drugs should have fewer side effects that result from the additional 
inhibition o f COX- 1. Recently, etoricoxib has been approved for treatment o f RA patients. 
Clinical trials show this drug has the equivalent clinical efficacy o f traditional NSAIDs 
without effecting COX1 activity (Patrignani et al., 2003).
It should be noted that NSAIDs reduce inflammation and provide pain relief but 
disease progression is not prevented. Indeed, NSAID therapy has been associated with 
cartilage damage (Rashad et al., 1989).
1.10.3 Corticosteroids
Humans synthesize the glucocorticoid, cortisol (hydrocortisone) as a response to 
stress. The effects of glucocorticoid are wide ranging and explain why synthetic 
administered glucocorticoids are useful in the treatment o f rheumatoid arthritis. 
Glucocorticoids bind to specific receptors that are located in the cytoplasm. Once bound,
53
the ligand-receptor complex can enter the nucleus where it binds to regulatory DNA 
sequences on genes that respond to glucocorticoids. Glucocorticoids suppress 
inflammation as a result o f their ability to interfere with transcription factors NFkB, AP-1 
(Cato et al., 1996) (previously mentioned in section 1.9.3.) and the expression o f multiple 
inflammatory genes including: IL-1, IL-2, IL6, TNF-a (Grabstein et al.,1986, Buttgereit et 
al., 1995). Glucocorticoids can also inhibit the trafficking o f neutrophils, macrophages and 
monocytes (Firestein et al., 2000). Synthetic glucocorticoids like prednisolone have 
therefore been developed and used in the treatment o f RA. Although they are good anti­
inflammatories they have not been found to inhibit the progression o f RA, and also have 
side effects. Little is known about the molecular mechanism involved in the side effects, 
which include suppression o f endogenous cortisol production in patients given oral 
corticosteroids or intraarticular steroid therapy (Jasani et al., 1967, Hupertz and Pfuller, 
1997). This could leave these patients at risk o f acute adrenal insufficiency and abnormal 
responses to stress. Long term usage has also been associated with induction of 
osteoporosis (Nielsen et al., 1988). Also, if  there is systemic inhibition of key 
inflammatory cells, then a patient undergoing glucocorticoid therapy is at risk of 
opportunistic infection from agents like staphylococci, fungi and viruses.
1.10.4 Disease Modifying Anti-rheumatic Drugs (DMARDs)
Disease Modifying Anti-rheumatic Drugs (DMARDs) were once seen as a ‘last line 
o f defense’ for when rheumatoid arthritis did not respond to conventional drug therapy. 
However, as more o f these agents are discovered and as the knowledge o f RA pathology
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increases, they are increasingly used in therapy combinations and earlier on in the disease 
course. DMARDs include: chloroquine, cyclosporine, gold salts, and various
immunosuppressive agents, they are slow-acting, their effects being seen after prolonged 
administration for 3-6 months.
The observation that antimalarials such as chloroquine and hydroxychloroquine 
induce remission o f RA was an incidental finding in RA patients that were using 
antimalarials for other reasons. (Pybus, 1982; 1984; 1985). Their mode o f action is thought 
to be due to the inhibition of antigen processing by macrophages and monocytes (Fox, 
1995). Another drug whose anti-rheumatic properties were incidental to a prime use in 
organ transplantation is cyclosporin. Its mode o f action is through the inhibition o f IL-2 
production and T-cell activation (Bentin, 1995).
Gold compounds such as aurothioglucose, sodium aurothiomalate and auranofin act 
by suppressing immune responsiveness at a humoral and cellular level and thereby stopping 
the progress o f active arthritis. Other immunosuppressive agents include azathioprine, 
methotrexate, leflunomide, and cyclophosphamide. Methotrexate, is particularly effective 
in treating patients with longstanding severe RA. Studies showed that patients were able to 
tolerate low doses o f the drug over prolonged intervals (Willkens and Watson, 1982). More 
recently it has been used in combination with anti-TNF therapy (Maini et al., 1998).
Thalidomide is an anti-angiogenic and immunomodulatory agent, it has been 
considered for the treatment o f RA, although it’s well known side effects of teratogenesis 
require a great deal o f caution in its administration. Its mode o f action is not fully 
understood, but it has been shown to suppress tumour necrosis factor alpha (TNF-a) 
production and to modify the expression of TNF-a-induced adhesion molecules on
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endothelial cells and on human leukocytes (Ossandon et al., 2002). Several open clinical 
trials have produced conflicting results. Keesal et al (1999) used thalidomide to treat 
refractory rheumatoid arthritis, they observed no significant improvement in any outcome 
measure. Other studies o f thalidomide in combination with pentoxyfylline have shown 
clinical improvement (Huizinga et al 1996). It seems probable that this drug is not likely to 
be widely administered, as positive outcome is out-weighed both by known historical 
toxicology and more recent reported adverse side effects, amenorrhea, peripheral sensory 
neuropathy drowsiness, constipation, and oedema o f the lower limbs (Gutierrez-Rodriguez 
et al., 1984, 1989).
All o f the agents described in this section have potentially serious or even lethal 
side-effects. They tend to be used in patients with severe active disease with erosions 
occurring early in the course o f the disease, where there is little or no response to intensive 
NSALD therapy (Klemp, 1983).
1.10.5 Therapies from research and development: Targeting hypoxia
Some o f the first therapies to target hypoxic tissue in oncological disease were 
bioreductive drugs. These pro-drugs are metabolised to either generate or release an active 
species in the presence o f reducing environment and are therefore preferentially cytotoxic 
towards hypoxic cells. There are three main classes o f bioreductive drugs: quinones, nitro 
compounds and benzotriazine di-N-oxides. The toxicity o f quinones results from their one 
electron reduction to a semi-quinone free radical that covalently interacts with and damages 
DNA. Nitro prodrugs are reduced by a series o f single electron transfers generating an
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reactive species. Benzotriazine di-N-oxides are also reduced to a reactive nitrogen species. 
The N-oxide free radical is thought to act as an oxidising radical that abstracts hydrogen 
from the bases within DNA (Kaye et al., 2001).
Endogenous reducing enzymes implicated in bioreductive drug activation include 
NADP(H) oxidoreductase, NADPH cytochrome c (P450) reductase, cytochrome b5 
reductase, carbonyl reductase and xanthine oxidase/xanthine dehydrogenase (Jaffar et al., 
2001). These enzymes act to varying degrees and at different stages in a given prodrug 
activation.
Bioreductive drugs are often used in combination with radiotherapy in the treatment 
o f cancer. One o f the first to be developed was the quinone-alkylating agent, mitomycin C 
which has been widely used in combination chemotherapy regimens for breast cancer 
(Kaye et al., 2001). Tirapazamine, a bioreductive drug o f the N-oxide class, has been found 
to be highly efficient in killing hypoxic cells and is extremely active when used in 
combination with fractionated radiation schedules (Adams and Stratford, 1994). Prodrugs 
are also used in treatment o f bacterial infections because they can demonstrate selective 
toxicity for microorganisms possessing specific activating enzymes. Nitazoxanide (NTZ) is 
a redox-active nitrothiazolyl-salicylamide prodrug that kills Helicobacter pylori (Sisson et 
al., 2002). It has been suggested that the specific bioreductive therapy could be used in the 
treatment o f rheumatoid arthritis by combining bioreductive therapy with hypoxia regulated 
gene therapy, where the therapeutic gene encodes an enzyme involved in the reductive 
metabolism o f the drug o f interest (Jaffar et al., 2001).
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1.10.6 Therapies from research and development: Anti Cytokine therapy
Throughout this introduction and in section 1.9.1 in particular the 
importance o f cytokines in the pathology o f rheumatoid arthritis has been discussed. It has 
been stated that there is a predominance of pro-inflammatory cytokines in the inflamed 
joint and this has lead to the development of a new concept, cytokines as a pharmacological 
target for RA therapies. Out o f this concept two therapeutic targets dominate the current 
research: TNF-alpha and IL-1. In RA they both promote inflammation by stimulating the 
production o f other pro-inflamatory cytokines (Feldmann et al., 1996) and the release of 
degradative enzymes at the cartilage-pannus interface (discussed in section 1.9.1). IL-1 
also stimulates the production o f nitric oxide and prostaglandinE2 (PGE2) from articular 
chondrocytes (Amin, 2000); mediators indicated in section 1.9.3 to contribute to attenuation 
o f inflammation in RA.
Anakinra is a recombinant human IL-1 receptor antagonist (IL-IRa) that binds to 
type 1 IL-1 receptors but does not stimulate any intracellular responses. Controlled studies 
in patients with RA treated with anakinra have led to the conclusion that IL-IRa is 
clinically effective and that it slows progression o f bone damage as measured 
radiographically (Bresnihan et al., 1998).
To date, two anti-TNF agents, infliximab and etanercept, have been approved for 
use in RA treatment, each having a different mode of action. Infliximab is a chimeric anti- 
TNF-alpha monoclonal antibody containing a murine TNF-a binding region and human 
IgGl backbone. Etanercept is a recombinant fusion protein o f the soluble type II TNF 
receptor on a human IgGl backbone. Both agents bind to TNF-a released in the inflamed 
joint and therefore prevent it from interacting with TNF-a receptors on target cells. Clinical
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trials o f these agents demonstrate efficacy and repeated administration resulted in a 
sustained reduction in symptoms and signs o f RA in the majority o f patients (Elliot et al., 
1994, Weinblatt et al., 1999) Combination with methotrexate also appears to be effective 
(Maini et al., 1998). However, as with all drugs anti TNF therapy is not without concerns 
about potential adverse side effects. This is bom out by a study that has linked anti TNF 
therapy to neurologic events suggestive of demyelination (Mohan et al., 2001) and as with 
all agents that suppress the immune system there is an increased risk o f opportunistic 
infection. Therefore patient screening should be carried out to avoid the reactivation of 
latent Mycobacterium tuberculosis infection (Criscione et al., 2002). The other 
disadvantages o f this therapy are it is very expensive and 20-40% o f patients are “non­
responders”. This has been linked to genetic polymorphisms that influence the balance of 
inflammatory cytokines (Padyukov et al., 2003).
The frontier o f anti cytokine therapies looks set to expand exponentially as other 
studies bring new targets to light. For example: the cytokines driving T-cells IL-12 and IL- 
15 and targeting cell recruitment through adhesion molecules like ICAM-1 (Haraoui et al., 
2000). Vascular endothelial growth factor (VEGF) has also been targeted with anti­
cytokine therapy, but this will be discussed in the next section.
1.10.7 Therapies from research and development: Angiogenesis Inhibitors.
As discussed in section 1.7 many studies consider rheumatoid arthritis to be 
angiogenesis dependent. Although this remains a controversial issue, it has lead to the 
concept o f a new therapeutic target with the suggestion that modulation o f angiogenesis in
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rheumatoid arthritis would restrict growth of the invasive pannus tissue and thus reduce 
subsequent cartilage and bone damage (Walsh, 1999).
Some disease modifying anti-rheumatic drugs (DMARDs) including bucillamine 
(BUC), gold sodium thiomalate (GST), methotrexate (MTX) and salazosulfapiridine 
(SASP) have been shown to inhibit vascular endothelial growth factor (VEGF) in synovial 
fibroblasts (Nagashima et al., 1999). As a cytokine VEGF is considered a potent inducer of 
angiogenesis (Brenchley, 2000). COX-2 inhibitors have also been shown to inhibit 
angiogenesis through their suppression of VEGF (Jones et al., 1999).
Some o f the first reports o f an agent that specifically inhibited neovascularization in 
animal models of arthritis were for AGM-1470 (TNP-470) (Peacock et al., 1992). This 
agent is toxic to endothelial cells. Inhibition o f av/p3 integrin has also demonstrated 
efficacy in a rabbit model o f arthritis (Storgard et al 1999) and endostatin, an anti 
angiogenic drug used in the treatment o f tumours, showed a dose dependent decrease in 
inflammatory cells and a reduction o f von Willebrand factor VIII and type IV collagen 
positive vessels in RA tissue grafted SCID mice (Matsuno et al., 2002).
Additionally, VEGF has been seen as a target for modem anti-angiogenic therapy in 
cancer research. Several synthetic VEGF receptor kinase inhibitors have been developed, 
o f which PTK787/ZK222584 and ZD6474 are being assessed in large size clinical trials 
(Manley et al 2002). A soluble vascular endothelial growth factor receptor 1 (VEGFR1) 
chimeric protein has been shown to strongly suppress proliferation o f RA endothelial cells 
invitro (Sekimoto et al., 2002). Other promising agents are monoclonal anti-VEGF 
antibodies which have demonstrated broad spectrum anti-tumour activity, are well-tolerated 
but may be associated with vascular toxicity such as haemorrhage and thromboembolic
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events (Jayson et al., 2002). They are being considered for treatment o f non-malignant 
conditions like rheumatoid arthritis, however in this situation it is worth considering careful 
monitoring for adverse side effects that may arise from anti-angiogenesis therapy such as: 
reduced wound healing, infertility and teratogenesis (Walsh 1999).
1.10.8 Therapies from research and development: Gene Therapy
The drugs discussed in the early part o f this section 1.10.1 to 1.10.4 can alleviate 
some of the symptoms associated with arthritis, but cannot stop disease progression. The 
therapies discussed in the later part o f this section 1.10.5 to 1.10.6 have been shown to have 
a great deal o f efficacy. However, this is at the cost o f systemic suppression of the whole 
immune system and reduced wound healing capabilities. All o f the therapies discussed so 
far result in a resurgence o f the disease upon cessation o f treatment. Therefore, gene 
therapy has been considered for rheumatoid arthritis as a way o f dealing with some or all of 
these problems.
The concept o f gene therapy has been around for a considerable time. The need for 
drastic therapy in the aggressive treatment o f life threatening diseases like cancer has 
resulted in a rapid progression o f this field. However, RA is not considered life threatening 
and this places constraints upon the types o f therapy that can be considered and the type of 
clinical trials that can be developed. Safety is all important.
Two types o f gene therapy exist:
1.) In vivo -  Genes are delivered directly to the patient, either to the local disease site
or systemically.
61
2.) Ex vivo -  Cells are genetically manipulated in culture and then delivered to the
patient locally or systemically.
Naked DNA can be used in gene therapy but it is an inefficient method because it is 
easily degraded and it’s uptake by cells is low. Therefore a number o f methods for gene 
delivery have been developed.
Viral vectors from retroviruses and adenoviruses are one o f the most commonly 
employed vehicles. Retroviral-based vectors integrate the therapeutic gene into the host 
DNA. However, they only infect dividing cells and are therefore used in ex vivo methods 
(Evans et al., 2000).
Adenoviruses infect non-dividing and dividing cells and have been used in direct 
delivery of therapeutic genes by, intraarticular injection. The results showed efficient, but 
transient expression o f genes. This was mainly due to an immune response generated 
against the virally-infected cells. (Roessler et al., 1993, Nita et al., 1996, Ghivizzani et al., 
1998). This has lead to the development o f adeno-associated virus vectors these have the 
genes coding for .proteins that induce an immune response deleted. They have been used 
with some success in the treatment of animal models of arthritis (Pan et al., 2000).
Some non-viral gene transfer methods have also been used, for example liposomes 
and DNA conjugates were used for local delivery. However, these have demonstrated a 
low efficiency compared to viral vectors and most tested were found to be pro- 
inflammatory (Ghivizanni et al., 2001).
There is a wide variety of functions for the therapeutic genes carried by these 
vectors and they are currently being evaluated for use in the treatment o f rheumatoid
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arthritis; the most recent being the modulation o f pro-inflammatory cytokines. The IL-1 
receptor antagonist (IL-IRa) is a natural receptor antagonist that competes with IL-1 for 
binding to type I IL-1 receptors and as a result blocks the effects o f IL-1 (Arend et al., 
1998). Transfer o f the IL-IRa gene into inflamed joints has been evaluated in several 
animal models. In rats with streptococcal cell wall arthritis, erosion of cartilage and 
subchondral bone was reduced significantly in joints expressing the transgene (Makarov et 
al., 1996). In rabbits with antigen-induced arthritis, the results showed reduced 
inflammation, nearly normalized cartilage matrix destruction and new matrix synthesis 
(Otani et al., 1996). The first double-blind trials o f IL-IRa gene therapy in humans have 
been carried out using ex vivo gene delivery. The entry criteria for patients into the trial 
required them to have advanced RA which would necessitate the surgical replacement of 
the 2nd-5th metacarpophalangeal (MCP) joints on one hand and at least one other joint. 
Autologous synovial tissue was collected from which synovial fibroblasts were grown. 
Half o f the cells cultured were transduced with an IL-IRa gene, while the other half was 
used as controls. The cells were injected intra-articularly into the MCP joints. After 1 
week, the MCP joints were surgically replaced and the retrieved tissues examined for 
evidence o f transgene expression. The results showed clusters o f cells expressing high 
levels of IL-IRa on the synovial surfaces o f the relevant joints and no adverse side effects 
related to gene transfer were reported (Evans et al., 2000). Other genes considered for gene 
therapy include: TNF receptors, TGF-b, p40 IL-12, soluble CD35 and IL-10 (Robbins et 
al., 2003). Also, blocking the transcription factor NF-kB (Tomita et al., 1999) and the 
‘genetic synovectomy’ o f the proliferating synovium by the delivery o f genes that induce 
the apoptosis o f cells within the synovium such as: FasL, TRAIL, and p53 (Robbins et al.,
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2003). Recently, extracellular superoxide dismutase (EC-SOD) and catalase genes were 
transfected into immortalized synoviocytes from Wistar rats. These transformed cells were 
then grafted into the knee joints o f animals induced with monoarticular antigen induced 
arthritis where they demonstrated over expression o f EC-SOD and catalase and lead to 
amelioration o f the disease (Dai et al., 2003). This demonstrates the potential therapeutic 
benefits in the treatment of rheumatoid arthritis to be gained from genetically enhanced 
antioxidant enzyme activity.
1.10.9 Therapies from research and development: The final comment
This section has given an indication o f the wide range o f therapies being developed 
for the treatment o f rheumatoid arthritis. Some o f them are not without their controversies, 
one such being the proposed use of stem cells as a means for tissue repair in arthritic 
disease (Jorgensen et al., 2001).
All o f them demonstrate the need for appropriate animal models for the screening of 
therapeutic modalities. This subject will be discussed in the final section o f my 
introduction.
1.11. Animal models in the study of rheumatoid arthritis
This introduction has demonstrated that rheumatoid arthritis is a complex disease. 
The knowledge we have so far, has been gained from patient studies, observations in vitro, 
and animal models. Historically, animal models have been widely used in medical 
research. They offer a number o f advantages to the study of a disease state:
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1.) They are genetically controlled thus facilitating the study of genetic links in the 
aetiology o f a disease and also enabling the study o f gene mutations to help 
understand the role o f specific genes in pathogenesis.
2.) The animal environment can be controlled enabling the continuous monitoring of 
disease progression without the influence o f external factors.
3.) Finally, it has been deemed by certain groups o f people morally and ethically 
acceptable to carry out procedures on animals that would not be considered 
acceptable to be carried out on humans.
Animal models have been shown to mirror much o f the pathology o f RA and are 
useful in the investigating the aetiology, pathology and efficacy of a therapy in rheumatoid 
arthritis (RA). However, there are limitations as no one model can reveal the all the 
intricacies o f a human disease. Therefore, in the study o f rheumatoid arthritis several 
models have been developed each one useful for studying particular aspects o f a disease. I 
have only used one model, adjuvant arthritis, in this thesis. Therefore this one is discussed 
in depth and other available models discussed briefly.
1.11.1 Detection of hypoxia in the adjuvant arthritis model
Adjuvant arthritis (AA) was the first animal model to be studied for rheumatoid 
arthritis. It was first induced in rats by Steork (1954) and later developed by Pearson in 
1956. It is induced by a single intradermal footpad or tail-base injection o f the cell walls of 
mycobacteria or their components suspended in paraffin oil, so called complete Freund’s 
adjuvant (CFA). 10-14 days after the injection o f adjuvant, swelling, warmth and erythema 
appear in the distal joints o f affected animals. Maximum severity of the disease can be
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observed between day 14 and 28 post-induction with inflammatory changes observed such 
as hyperplasia and hypertrophy o f the lining synoviocytes in the joints (Pelegri et al., 1995). 
In the subintimal lining layer of synovium, the cell density is high and there are a large 
number o f irregularly arranged collagenous fibres. In the joint space next to the synovial 
lining mononuclear cells and some neutrophils are seen. Pannus formation and bone 
erosions are also predominant features (Pearson et al., 1961; Stoerk et al., 1961). 
Subcutaneous injection o f CFA also induces a granulomous inflammation in other organs: 
spleen, skin, liver, eyes (Pearson et al., 1961). The disease is chronic; however, unlike RA 
it is self-limiting as the rats recover within 1-2 months. It has been suggested that this is due 
to the eventual activation of macrophages and the phagocytosis o f the CFA (Firestein et al 
2000). AA is restricted to rodents and the occurrence o f arthritis is dependent on genetic 
susceptibility. Lewis, Wistar and Sprague-Dawley rats are most commonly used with 
others, such as Buffalo, being resistant to AA (Bersani-Amado et al., 1990). This 
susceptibility is related to a gene closely linked to the rat major histocompatibility complex 
(Battisto et al., 1982).
The aetiology o f adjuvant arthritis rather like rheumatoid arthritis is not fully 
understood, since it requires not only the mycobacteria but also the mineral oil for a 
response to be generated, in fact, some models use avidine and pristine which contain no 
cell walls to induce an inflammation that is limited to the joints (Chang et al., 1980, 
Vingsbo et al., 1995). Heat-shock proteins (HSP) have been shown to play an important 
role in both AA and RA (de Graeff-Meeder et al., 1990; Ragno et al., 1995) Studies have 
shown that intra-articular injection of recombinant HSP and a purified protein derivative o f 
tuberculin (PPD), in rats immunised with Mycobacterium tuberculosis, induced a chronic
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persistent synovitis (Ragno et al., 1995). However, Lewis rats were also protected from 
developing AA when injected with recombinant mycobacterial 65-kDa hsp (Lopez- 
Guerrero et al., 1994; Ragno et al., 1997). AA was considered to be a T-cell driven disease, 
since elimination o f T-cells receptor binding was shown to suppress adjuvant arthritis 
(Yoshino et al., 1990), however, the antigen-specific T cell has not yet been identified 
(Billingham, 1995). With regard to hypoxia in adjuvant arthritis, as previously mentioned 
in section 1.4 Bruce (1992) used electron paramagnetic resonance oximetry to measure the 
partial pressure o f oxygen in vivo in joints o f the adjuvant arthritis model and found a 
significant decrease in pC>2 between day seven and fourteen post adjuvant arthritis 
induction.
1.11.2 Other animal models
In the 1980’s Sedgwick and co-workers developed a rat model o f prolonged 
immunological inflammation with structural resemblance to synovial changes seen in 
rheumatoid arthritis. This model was generated by producing a subcutaneous air-filled 
cavity in the skin of rats previously sensitized to pertussis vaccine. Pertussis vaccine was 
then injected into 6-day old air pouches (cavities) giving rise to an inflammatory response 
which lasted up to thirty days. Histological examination o f pouch wall tissue showed an 
early polymorphonuclear infiltration followed by the formation o f a lining consisting of 
mononuclear cells lymphocytes and plasma cells (Sedgwick et al., 1985a). Pertussis was 
replaced by carrageenan in the formation inflammatory air pouches and this model was 
used to examine the degradation o f articular cartilage in vivo. This work indicated that
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perhaps the role o f inflammatory products was not as significant as other environmental 
conditions in effecting cartilage destruction in human arthritis (Sedgwick et al., 1985b).
Claxson and co workers (1999) used high field proton NMR spectroscopy to 
investigate the metabolic status o f rat air pouch exudate after induction o f inflammation 
with carrageenan. They demonstrated substantially elevated levels o f lactate, low glucose 
levels and high levels o f the ketone body 3-d-hydroxybutyrate, data consistent with a 
hypoxic environment and consequent anaerobic metabolism. This reflects reported studies 
of RA synovial fluid and sera that also showed increased levels o f lactate, ketone bodies 
and decreased concentrations o f glucose using nuclear magnetic resonance analysis 
(Naughton et al., 1993a,b). Also as previously mentioned, Soo (1999) used 7-(4’-(2- 
nitroimidazole-l-yl)-butyl)-theophylline (NITP) to successfully label hypoxic cells in the 
rat air pouch pseudosynovial tissue. More recently this model has been used to 
demonstrate activated nuclear factor kappa B (NFkB) in the inimal and subintimal regions 
of the air pouch but not in the blood vessels (Ellis et al., 2000). These results contrast the 
situation in RA where NFkB has been localised in the vascular endothelium and type ‘A ’ 
synovial cells from RA patients (Marok et al., 1996).
As well as adjuvant arthritis, Freund’s complete adjuvant is used in another model 
of chronic inflammation, Freund’s adjuvant foot pad oedema model. In this model the 
animals are sensitized with FCA then injected with FCA in the foot pad six days later. Foot 
pad oedema develops in 24 hours with an intense acute inflammatory response followed by 
necrosis which intensifies over the next 48 hours.
Another model, monoarticular arthritis, entails pre-sensitization with antigen 
followed by single joint challenge with antigen. In this case the injected antigen is a
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foreign protein like ovalbumin or methylated bovine serum albumin. A chronic 
inflammatory response develops with bone and cartilage erosions in the challenged joint 
(Hang et al., 1982).
In recent years another model collagen-induced arthritis (CIA) has become 
increasingly utilized in the study o f rheumatoid arthritis. Immunization is with homologous 
collagen found in cartilage (type II collagen) and leads to an autoimmune response and 
severe arthritis (Trentham et al., 1977). Study of this model has revealed a great deal of 
information about the role o f major histocompatibility complex class II molecules and T 
cells in arthritis and auto-immune responses (Firestein et al., 2000, Morgan et al., 2003). 
This model has also been used for the screening o f target cytokines (Williams et al., 1992, 
Finnegan et al., 2003) and angiogenesis inhibitors (Peacock et al., 1992).
Adjuvant arthritis is the model to be used in my study because historically it has 
been used in previous studies o f hypoxia and it presents the disease aspects o f interest 




This introduction has shown that global assesments o f hypoxia, which have been 
undertaken in the diseased joint, do not reveal specific sites o f tissue hypoxia. My 
hypothesis is that hypoxic synovial cells produce pro-inflammatory cytokines and provide a 
potential target for bioreductive therapy and other novel therapies.
The aims o f my studies are to use the adjuvant arthritis model to:
1. Identify at what stage during disease progression the joint becomes hypoxic.
2. To examine the phenotype of hypoxic cells.
3. To identify cytokines and transcription factors produced.
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CHAPTER 2; MATERIALS AND METHODS
2.1. Materials and methods for animal model
2.1.1. Animals
Female Lewis rats (Charles River UK Ltd., Kent) weighing 130-150 g were used for 
induction o f adjuvant arthritis model.
2.1.2. Materials for induction of Adjuvant Arthritis in the animal model
Liquid paraffin - Thornton & Ross Ltd., Huddersfield, UK
Mycobacterium tuberculosis, freeze dried human strains C, DT and PN mixed - Central 
Veterinary Laboratories, Weybridge, Surrey, UK 
Pestle and mortar -  Mason & Cook, Stoke-on-Trent, UK.
Sterile syringes & needles - Becton Dickinson, UK
2.1.3 Materials for labelling of hypoxic cells in animal models using Hypoxyprobe
Hypoxyprobe -  Chemicon International.
8% Sterile Saline - Sigma, Poole, UK
Sterile syringes & needles - Becton Dickinson, UK
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2.1.4 Animal husbandry
The rats were housed in groups of 5 to a cage and exposed to a 12 hour light/dark 
cycle and an average temperature o f 20 + 2°C. Sawdust was used as bedding. All the 
animals were allowed access to tap water and a standard rat diet (SDS Ltd., Witham, UK) 
ad libitum. The animals were allowed to rest and acclimatize to their new surroundings for 
at least a week before commencement o f experiment.
2.1.5 Induction of Adjuvant Arthritis
Adjuvant arthritis was induced in female Lewis rats using the method o f Andrews et 
al., (1987a, b). A single intradermal injection o f a 0.1 ml aliquot of a 10 mg/ml suspension 
of freeze dried Mycobacterium tuberculosis in liquid paraffin oil was administered in the 
base o f the tail o f each rat. The suspension o f the M. tuberculosis was prepared by finely 
grinding the bacteria in paraffin oil using a pestle and mortar. A small particle size is 
essential for successful disease induction (Newbould, 1963.)
72
2.1.6 Clinical assessment
Daily weights were monitored and clinical scores were made on the hind feet 
according to the following criteria:
Score Value
0 - no inflammation
1 - slight redness and swelling of foot, tendons visible,
2 - redness, further swelling such that tendons not visible
3 - swelling o f whole foot including ankle joint.
4 - gross swelling o f the foot and deformity o f ankle joint.
(Andrews et al, 1987a, b)
2.1.7 Labelling of hypoxic cells using Hypoxyprobe
A single intraperitoneal injection o f a 1 ml aliquot o f a 60mg/Kg body weight 
Hypoxyprobe diluted in 0.8% sterile saline was administered to each rat. After termination 
o f the animal model the hypoxic cells were visualized in tissue sections using 
immunohistochemical techniques.
2.1.8 Termination of the animal model
Animals were killed by cervical dislocation.
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2.2 Materials and methods for histological studies
2.2.1 Materials for tissue processing
2-Methylbutane (isopentane) - BDH, Poole, UK 
Cork base mold -  RA Lamb Ltd., East Sussex, UK 
Fibrowax - BDH, Poole, UK 
Formic Acid - Sigma, Poole, UK
Histocentre2 -  Shandon Inc, Pittsburgh, Pennsylvania, USA 
Hypercentre2 -  Shandon Inc, Pittsburgh, Pennsylvania, USA 
Histological Formal Saline - BDH, Poole, UK 
Industrial methylated spirits (IMS) -  BDH, Poole, UK 
Liquid nitrogen -  BOC Ltd, Manchester UK 
Tissue-Tek - RA Lamb Ltd., East Sussex, UK 
Xylene - BDH, Poole, UK
2.2.2 X-ray materials
Film- Kodak X-ray Film -  K. J. Peling, Bristol, UK.
High Fixer -  Champion Photochemistry -  K. J. Peling, Bristol, UK. 
Universal developer - Champion Photochemistry - K. J. Peling, Bristol, UK. 
X-ray machine - Faxitron X-ray Corporation, Illinois, USA.
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2.2.3 Materials for histological assessment
Acetone - BDH, Poole, UK 
Aquamount - BDH, Poole, UK
Background reducing antibody diluent - DAKO, Ely, UK
Concentrated Hydrochloric acid - BDH, Poole, UK
Coverslips - BDH, Poole, UK
DPX mounting media - BDH, Poole, UK
Eosin - Sigma, Poole, UK
Fast Red tablets - Sigma, Poole, UK
Harris’s Haematoxylin - BDH, Poole, UK
Industrial methylated spirits (IMS) -  BDH, Poole,UK
Mayers Haematoxylin - Sigma, Poole, UK
Normal goat serum - Sigma, Poole, UK
Normal Horse serum - Sigma, Poole, UK
Normal Rabbit serum - Sigma, Poole, UK
Phosphate Buffered Saline (PBS) - BDH, Poole,UK
Pronase antigen retrieval solution - DAKO, Ely, UK
Superffost microscope slides -  BDH, Poole, UK
Tris (hydroxymethyl) methylamine/HCl Buffer (1.5 M, pH 8.8) -  Promega, Southampton, 
UK
Wet-boxes (sealed Perspex containers containing a 10ml water for the purpose of 
maintaining humidity) -  Constructed by University o f Bath Engineering Workshop 
Xylene - BDH, Poole, UK
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2.2.4 Antibodies for immunohistochemical staining
Alkaline phosphatase, Mouse, Vectastain ABC kit -  Vector Laboratories Ltd.,
Peterborough, UK
Alkaline phosphatase, Goat, Vectastain ABC kit -  Vector Laboratories Ltd., Peterborough, 
UK
Alkaline phosphatase, Rabbit, Vectastain ABC kit -  Vector Laboratories Ltd.,
Peterborough, UK
Goat Polyclonal Anti VCAM-1 -  Santa Cruz Biotechnology, California, USA.
Mouse Monoclonal Anti Hypoxyprobe -  Chemicon International.
Mouse Monoclonal Anti Fibroblast 5B5 clone -  DAKO, Ely, UK
Mouse Monoclonal Anti Aspergillus niger glucose oxidase -  DAKO, Ely, UK
Mouse Monoclonal Anti Rat EDI -  Serotec, Oxford, UK
Mouse Monoclonal Anti Rat ED2 -  Serotec, Oxford, UK
Mouse Monoclonal Anti H IF -la  -  Abeam Ltd., Cambridge, UK
Mouse Monoclonal Anti VEGF -  Santa Cruz Biotechnology, California, USA.
Rabbit IgG - DAKO, Ely, UK
Rabbit Polyclonal Anti Ets-1 -  Santa Cruz Biotechnology, California, USA.
Rabbit Polyclonal Anti iNOS -  BD Biosciences, Oxford, UK
Rabbit Polyclonal Anti Mouse Signal Amplification Kit - DAKO, Ely, UK
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2.2.5 Tissue processing methods, paraffin embedding
Tissues were fixed for 24 hours in histological formal saline. The joints were 
decalcified in a solution o f 10% formic acid in histological formal saline for two weeks 
changing the solution every three days. The joints were then x-rayed (see next section) to 
determine by loss o f radio-opacity whether they had been decalcified. The tissues were 
then processed through various stages of alcohol and xylene using a Hypercentre2 and 
embedded in fibrowax using a Histocentre2. Blocks were stored at room temperature until 
sectioning.
2.2.6 Tissue processing methods, snap freezing
Cork base molds were labelled and covered in tissue-tek a brand o f medium for 
embedding tissue which is frozen. Freshly dissected tissue was then placed on cork base 
mold and covered with more tissue-tek. Cork base mold was then plunged into 2- 
methylbutane pre-chilled in a dewer o f liquid nitrogen until the block solidified. The block 
is then removed placed in a bag and stored at -70°C until sectioning.
2.2.7 X-ray of joints
The joints were x-rayed to determine by loss of radio-opacity whether they had been 
fully decalcified. This was necessary to prevent damage to the microtome blade during 
subsequent histological sectioning. The x-ray film was placed inside a plastic cover and the 
joints were arranged on top o f the piece of plastic. The piece o f plastic was then placed in 
the x-ray cabinet o f the Faxitron and the film exposed for 20 minutes at 40 kilo-volts 
potential (kvp). Inside a dark room, the x-ray film was developed for 3 minutes and fixed
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for 2 minutes. The x-ray film was then rinsed in running water before being dried and 
examined using a light-box.
2.2.8 Haematoxylin and Eosin staining of sections
Sections (5 pm) were cut from wax embedded tissue blocks on a sledge microtome and 
mounted on Superfrost slides. The sections were allowed to air dry and were then baked in 
an oven at 60°C overnight. Tissue sections were dewaxed in xylene (x2) for 5 min, washed 
in 100% IMS (x2) for 2 min and immersed in running tap water for 5 min. The previous 
section was omitted for frozen sections which were cut 10pm thick, mounted on Superfrost 
slides, air dried for 1 hour fixed with acetone for 5 minutes and rehydrated in tap water 
before use. All slides were then stained as follows:
i) Stain in Harris’s Haematoxylin solution for 5 min.
ii) Wash in running tap water for 5 min.
iii) Differentiate in acid alcohol (1% hydrochloric acid in 100% IMS) for 1 min.
iv) Wash in running tap water for a further 5 min.
v) Stain in Eosin solution for 30 sec.
Vi) Wash in running tap water for 5 min.
vii) Wash in 100% IMS for 2 min. (x2).
viii) Clear in xylene for 2 min. (x2).
ix) Finally, the tissue sections were mounted under glass coverslips using DPX 
mounting media and were dried at room temperature overnight prior to microscopy.
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2.2.9 Immunohistochemical staining methods
2.2.9.1 Immunohistochemical staining with antigen retrieval and using alkaline 
phosphatase kit.
5pm thick sections were cut from wax embedded tissue blocks on a sledge microtome 
and mounted on Superfrost slides. The sections were allowed to air dry and were then 
baked in an oven at 60°C overnight. Tissue sections were dewaxed in xylene (x2) for 5 
min, washed in 100% IMS (x2) for 2 min and immersed in running tap water for 5 min. 
This section was omitted for frozen sections which were cut 10pm thick and mounted on 
Superfrost slides, air dried for 1 hour and fixed with acetone for 5 minutes before use. All 
slides were then stained as follows:
All procedures carried out at room temperature, unless otherwise stated
i) Rinse twice in phosphate buffered saline (PBS) for 5 minutes.
ii) Incubate with a 0.01% solution of Pronase diluted in Tris buffered saline pH 7.2
(TBS) at 40°C for 40 minutes in wet box
iii) Rinse twice in phosphate buffered saline (PBS) for 5 minutes.
iv) Incubate with a 1:5 dilution o f normal serum from species in which secondary
antibody was generated for 20 min in a wet box.
v) Tap off serum and incubate with the appropriate antibodies overnight at 4°C in a 
wet box.
vi) as in step (iv)
vii) Incubate with a 1:200 dilution of secondary antibody from an alkaline phosphatase, 
vectastain ABC kit for 30 min in a wet box.
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viii) as in step (iv)
ix) Incubate with a 1:100 dilution of avidin-alkaline phosphatase complex from an 
alkaline phosphatase, vectastain ABC from the kit for a further 30 min in a wet box.
x) as in step (iv)
xi) Develop to reveal phosphatase (red reaction product) using fast red tablets. Stop 
reaction using tap water when the tissue sections have been sufficiently developed.
xii) Lightly counterstain with Mayers haematoxylin for 1 min, then rinse in tap water.
xiii) The tissues are mounted under glass coverslips using aqua mounting media and left 
to dry overnight at room temperature prior to microscopy.
2.2.9.2 Immunohistochemical staining using alkaline phosphatase kit.
Sections (5pm) were cut from wax embedded tissue blocks on a sledge microtome and 
mounted on Superfrost slides. The sections were allowed to air dry and were then baked in 
an oven at 60°C overnight. Tissue sections were dewaxed in xylene (x2) for 5 min, washed 
in 100% IMS (x2) for 2 min and immersed in running tap water for 5 min. This section 
was omitted for frozen sections which were cut 10pm thick and mounted on Superfrost 
slides, air dried for 1 hour and fixed with acetone for 5 minutes before use. All slides were 
then stained as follows:
All procedures carried out at room temperature, unless otherwise stated
(i) Rinse twice in phosphate buffered saline (PBS) for 5 minutes.
(ii) Incubate with a 1:5 dilution of normal serum from species in which secondary 
antibody was generated for 20 min in a wet box.
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(iii) Tap off serum and incubate with the appropriate antibodies overnight at 4°C in a 
wet box.
(iv) Rinse twice in phosphate buffered saline (PBS) for 5 minutes.
(v) Incubate with a 1:200 dilution o f secondary antibody from an alkaline
phosphatase, vectastain ABC kit for 30 min in a wet box.
(vi) As in step (v).
(vii) Incubate with a 1:100 dilution o f avidin-alkaline phosphatase complex from an
alkaline phosphatase, vectastain ABC kit for a further 30 min in a wet box.
(viii) As in step (v).
(ix) Develop to reveal phosphatase (red reaction product) using fast red tablets. Stop 
reaction using tap water when the tissue sections have been sufficiently 
developed.
(x) Lightly counterstain with Mayers haematoxylin for 1 min, then rinse in tap 
water.
(xi) The tissues were mounted under glass coverslips using aqua mounting media 
and left to dry overnight at room temperature prior to microscopy.
2.2.9.3 Immunohistochemical staining using signal amplification kit.
Sections (5pm) were cut from wax embedded tissue blocks on a sledge microtome and 
mounted on Superfrost slides. The sections were allowed to air dry and were then baked in 
an oven at 60°C overnight. Tissue sections were dewaxed in xylene (x2) for 5 min, washed 
in 100% IMS (x2) for 2 min and immersed in running tap water for 5 min. This section
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was omitted for frozen sections which were cut 10 pm thick and mounted on Superffost 
slides, air dried for 1 hour and fixed with acetone for 5 minutes before use. All slides were 
then stained as follows:
All procedures carried out at room temperature, unless otherwise stated
(i) Rinse twice in phosphate buffered saline (PBS) for 5 minutes.
(ii) Incubate with 3% Hydrogen peroxide solution for 20 min.
(iii) Rinse twice in phosphate buffered saline (PBS) for 5 minutes.
(iv) Incubate with protein block from mouse signal amplification kit, for 20 min in a 
wet box.
(v) Tap off block and incubate with the appropriate antibodies diluted in
background reducing antibody diluent overnight at 4°C in a wet box.
(vi) As in step (IV).
(vii) Incubate with secondary antibody from signal amplification, mouse, kit for 15 
min in a wet box.
(viii) As in step (IV).
(ix) Incubate with strep-biotin complex from mouse signal amplification kit for 15
min in a wet box.
(x) As in step (IV).
(xi) Incubate with amplification reagent from mouse signal amplification kit for 15
min in a wet box.
(xii) As in step (IV).
(xiii) Incubate with strep-peroxidase complex from mouse signal amplification kit for 
15 min in a wet box.
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(xiv) Develop to reveal peroxidase (brown reaction product) using 3,3- 
diaminobenzidine (DAB) substrate (from kit). Stop reaction using tap water 
when the tissue sections have been sufficiently developed.
(xv) Lightly counterstain with Mayers haematoxylin for 1 min, then rinse in tap 
water.
(xvi) The tissues were mounted under glass coverslips using aqua mounting media 
and left to dry overnight at room temperature prior to microscopy.
2.2.10 Histology imaging
Histological sections were examined using a Zeiss Axioskope II (supplied by Zeiss, 
UK) with a JVC 3-CCD camera for digital imaging (supplied by Imaging Associates Ltd., 
Thame, Oxford, UK.) 5X, 10X, 20X and 40X microscope objectives were used with white 
light illumination and digital images stored as JPEG files.
2.2.11 Histological assessment
Changes in the morphology o f the joints using Haematoxylin and Eosin (H&E) 
staining were observed and scored on a scale o f 0-4 when compared to naive controls that 





(Kruijsen et al, 1983.)
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2.2.12 Immunohistochemical assessment
Blind sections o f hind feet were observed using a 10X microscope objective. Image 
analysis was carried out on all areas of joint tissue except skin to determine the percentage 













This program analyses a framed area o f 800 by 600 pixels. It removes from the 
analysis any area less than 10pm2, thus removing small histological artefacts. Large 
histological artefacts, for example, areas of folded tissue were manually removed from the 
analysis by outlining them. Hypoxic regions were thresholded based upon a pimonidazole 
adduct density converted to a red-blue-green level which was consistent throughout the
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images. Since spatial transition between peak density and 0% (non hypoxic area) was quite 
distinct this provided a reproducible method to demarcate hypoxic areas. Finally the 
program calculates the demarcated area as a percentage o f the whole framed area. These 
data were then tabulated using Graph Pad Prism software for statistical analysis.
2.3 Statistics
Comparisons o f data for naive and adjuvant arthritis joints were assessed using the 
Mann Whitney test.
2.4 Materials and methods for tissue explant and cell culture
3.4.1 Cell and tissue culture materials
Accutase- Innovative Cell Technologies, Inc, California, USA.
Antibiotic antimycotic, Penicillin/Streptomycin -  Invitrogen, Paisley, UK
Dimethyl sulfoxide (DMSO) - Sigma, Poole, UK
Dulbecco’s modified Eagle’s medium - Invitrogen, Paisley, UK
Dulbecco’s phosphate buffered saline (PBS) - Invitrogen, Paisley, UK
Foetal calf serum (FCS) - Invitrogen, Paisley, UK
Hank’s balanced salt solution - Invitrogen, Paisley, UK
Sterile T75 Flasks -  Triple Red, Oxon, UK
Sterile 6-well plates - Triple Red, Oxon, UK
Sterile pipettes - Triple Red, Oxon, UK
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2.4.2 Cell lines and tissue explants.
HeLa from American Type Culture Collection, Manassas, VA, USA.
Human neonatal foreskin fibroblast cells generously supplied by Dr. Vivek Mudera, 
Deputy Director o f Tissue Repair Unit and Tissue Engineering Centre and the Centre for 
Plastic and Reconstructive surgery at Royal Free University College Medical School, 
University college London.
Human rheumatoid arthritis synovial fibroblast cells generously supplied by Dr. D. Speden 
Department o f Medical Sciences University o f Bath.
Whole patella suspensory ligaments and synovium dissected from naive and adjuvant 
female Lewis rats(Charles River UK Ltd., Kent) generously provided by Dr Paul I. Mapp, 
Department o f Medical Sciences, University o f Bath.
2.4.3 Defrosting cells and culturing cells
Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with a 10% FCS and 1% Penicillin/Streptomycin solution. This will be called complete 
medium. All procedures in chapter 3.4.3 to 3.4.6 were carried out using aseptic techniques 
within a level two containment laminar flow cabinet. The cells were defrosted rapidly by 
placing the vial o f cells into a water bath at 37°C, and the contents were pipetted into a 
sterile 15 ml tube with a 10ml volume o f complete medium. The cells were then 
centrifuged at 1000 rpm before being resuspended in 10 ml o f complete medium. The cells 
were then grown in a T75 flask with complete medium in a humidified incubator at 37°C
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and a 5% CO2 / 95% air mix. The media were changed every 2-3 days and cells were 
allowed to grow until confluent.
2.4.4 Passaging cells
Confluent cells were either passaged for use in experiments or storage. Cells to be 
passaged were first washed with Dulbecco's phosphate buffered saline solution (PBS) and 
then 2ml Accutase was added. The flasks were then incubated at 37°C until the cells 
became detached (approximately 10 min). Once cells had become detached, an equal 
volume o f complete medium was added to prevent further enzymic action. The cells were 
centrifuged for 10 min at 1000 rpm and resuspended in 5 mis o f DMEM. They were then 
separated into 1 ml aliquots and either pipetted into T75 flasks for culturing or frozen down 
for storage.
2.4.5 Freezing down cells
Cells from confluent cultures were frozen down in liquid nitrogen and stored for 
later use. The cells were passaged as described previously in 3.4.4 and resuspended into 5 
mis o f complete medium. A 1 ml aliquot o f a 10% dimethylsulfoxide (DMSO) in FCS was 
added to the cryotube followed by a 1 ml aliquot o f the cells that had been resuspended in 
complete medium. The cryotubes were then placed into a freezing container in a -70°C 
freezer overnight before being stored in liquid nitrogen.
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2.4.6 Culturing tissue explants
Whole patella suspensory ligaments and synovium was dissected from naive and 
adjuvant female Lewis rats and placed in sterile bijou containing 4ml o f Hanks balanced 
salt solution with 1% Penicillin/Streptomycin solution. The explants were washed four 
times for 5 min with this solution before being aseptically transferred to individual wells in 
a six well plate containing 4ml o f complete medium. The explants were then incubated in 
either the hypoxia cabinet (see 3.5) or a humidified incubator at 37°C and a 5% CO2 / 95% 
air mix.
2.5 Materials and method for hypoxia cabinet operation
2.5.1 Materials for hypoxia cabinet operation
Microflow Anaerobic System (hypoxia cabinet) -  M.D.H Ltd., Hampshire, UK.
Gas supply cylinder with 0% O2 / 5% CO2 / 95%N 2 - BOC Ltd, Manchester UK 
Wet-boxes (sealed perspex containers containing 10 ml water for the purpose of 













A -  Interchange door A 
B -  Interchange door B
Figure 2. Representative diagram  of the top view of a hypoxia cabinet (Microflow 
Anaerobic System)
2.5.2 Method for hypoxia cabinet operation
i) Place wet boxes in main chamber (Figure 2). Ensure both interchange doors and 
gloved inlets are closed and use control panel to set the main chamber 
environmental conditions, temperature at 37°C and gas supply 5% C 02 / 0% O2 
/ 95% N 2 mix for 24 hrs before experiment commences, to allow cabinet to 
equilibrate.
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ii) Temperature and oxygen tension can be checked with additional probes placed 
in the main chamber.
iii) To commence the experiment open interchange door A and place plates and 
flasks in the interchange area close the door.
iv) Use control panel to run a vacuum cycle. This runs a three minute flushing 
cycle to fill the interchange area with the same environmental conditions set 
previously for the main chamber in step I). A green light will indicate 
completion.
v) Open gloved inlet and places hands in sealed gloves. Open interchange door B 
and remove plates and flasks place in wet boxes. Close all interchange doors and 
gloved inlets and incubate for fourteen days under the set environmental 
conditions.
Steps iii) to v) must be repeated to add or remove any equipment to the main chamber and 
to terminate the experiment under the set environmental conditions.
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2.6 Materials and methods for protein isolation
2.6.1 Materials for protein isolation
Biofuge - Heraeus Instruments, UK
Chloroform - Sigma, Poole, UK
Eppendorfs -  Alpha Labs, Hampshire, UK
Ethanol - Sigma, Poole, UK
Guanidine hydrochloride - Sigma, Poole, UK
Isopropyl alcohol - Sigma, Poole, UK
RNAase, Stat60 - AMS Biotechnologies, Oxford, UK
2.6.2 Method for protein isolation
Protein Precipitation
i) Protein was isolated from the cells by treatment with 2ml RNAase, Stat60, per 
T75 flask which was then stored in -70°C till use.
ii) Samples thawed at room temp for 5 min.
iii) Add 200pl Chloroform per 1ml o f protein and Stat 60 mix .
iv) Cover and shake vigorously for 15 min.
v) Leave at room temp for 15 min.
vi) Centrifuge at 12000 rpm for 15 min.
vii) Transfer aqueous phase to fresh tube and save for RNA isolation.
viii) Remove and overlaying liquid from remaining tube and add 1.5 ml Isopropyl 
alcohol used to organic phase.
ix) Store at room temp for 5 min.
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x) Centrifuge at 12000 rpm for 10 min.
Protein Wash
xi) Remove supernatant and add 2ml of 0.3M guanidine hydrochloride.
xii) Store at room temp for 20 min.
xiii) Centrifuge at 7500 rpm for 5 min
xiv) Add 2ml o f 100% ethanol.
xv) Vortex.
xvi) Store at room temperature for 20 min.
xvii) Centrifuge at 7500 rpm for 5 min.
xviii) Repeat protein wash steps x) to xvi) three times.
Protein Solubilisation
xix) Dry pellet at room temp for 10-15 min.
xx) Dissolve in 10% SDS for up to 16 hours at 50°C.
xxi) Sonication o f solution for 15 min may be required to dissolve protein.
xxii) Centrifuge at 10000 rpm for 10 min.
xxiii) Transfer supernatant to fresh tube.
xxiv) Use for protein assay, western blot or sample may be stored at -70°C.
2.7 Materials and Methods for Protein Assay
2.7.1 Materials for Protein Assay
Biofuge - Heraeus Instruments, UK 
DC Protein Assay Kit -  BioRad, Herts, UK
92
96-well Microplates -  Triple Red, Oxon, UK 
Protein Standard -  BioRad, Herts, UK
10% Sodium dodecyl sulphate (SDS) -  Promega, Southampton, UK
2.7.2 Method for Protein Assay
i) Use protein assay kit to prepare ‘working solution’ by adding 20pl o f reagent ‘S’ to each 
ml o f reagent ‘A ’ required for working.
ii) Prepare 5 dilutions of a protein standard containing 0.2mg/ml to 1.5mg/ml protein.
iii) In triplicate pipette 5 pi of standards and samples into clean, dry microtiter plate.
iv) Add 25pl o f ‘working solution’ into each well.
v) Add 200pi o f reagent ‘B ’ to each well and mix.
vi) After 15 min read at 750nm and generate standard curve to calculate protein in 
samples.
2.8 Materials and methods for gel electrophoresis & western blotting
2.8.1 Materials for Gel Electrophoresis & Western Blotting
Acrylamide -  Promega, Southampton, UK
Ammonium Persulphate (AMPS) -  Sigma, Poole, UK
Antibodies - Mouse Monoclonal Anti H IF -la  -  Novus, Littleton, CO, USA
- Rabbit Polyclonal Anti Ets-1 -  Santa Cruz Biotechnology, California, USA. 
Automated developer -  Fuji, UK 
Autoradiography film -  Kodak, UK 
Biofuge - Heraeus Instruments, UK
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Bromophenol blue (0.2%) -  Sigma, Poole, UK 
Butan-2-ol -  BDH, Poole, UK 
Chromic acid -  BDH, Poole, UK 
ECL detection kit -  Amersham, UK
Gel electrophoresis tank and peripheral equipment -  Jencons Scientific Ltd., Beds, UK 
Glycerol (40%) -  Sigma, Poole, UK 
Non-fat dried milk -  Sainsbury’s,
Nitrocellulose paper -  GRI, UK
Rainbow markers (molecular weights, 250-10kD) -  Amersham, UK 
SaranWrapTM -  BDH, Poole, UK
10% Sodium dodecyl sulphate (SDS) -  Promega, Southampton, UK
Tetramethylethylene-diamine (TEMED) -  Promega, Southampton, UK
Tris (hydroxymethyl) methylamine/HCl Buffer (1.5 M, pH 8.8) -  Promega, Southampton,
UK
Tris-HCl buffer (250 mM, pH 7.5) - Sigma, Poole UK 
Western blotting tank - Jencons Scientific Ltd., Beds, UK 
Whatman Paper - Whatman Limited, UK
2.8.2 Preparation of the polyacrylamide gel plates.
Two plates were cleaned by immersing into chromic acid followed by rinsing under 
running tap water. They were clamped together with a gasket inserted between them to 
create a space for the gel. A (7.5%) acrylamide running gel was prepared (see appendix A). 
The solution was then carefully poured in between the plates until it reached 2 cm from the 
top of the plates. An overlayer o f water-saturated butan-2-ol was added to remove the
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meniscus. Once the gel had polymerized (approximately 1 hour), it was drained and rinsed 
with distilled water. The plates were then filled to the top with a (5%) acrylamide stacking 
gel (see Appendix A). The well combs were inserted and the gel was left to polymerize. 
Once the gel had set, the combs were removed.
2.8.3 Sample solution Preparation.
An equal volume o f 2x reducing sample buffer (see appendix A) was added to each 
sample containing equal amounts of total protein (lOpg) in an Eppendorf and boiled for 3 
mins. The samples were then centrifuged at 10,000 rpm for 5mins.
2.8.4 Gel Electrophoresis
The gel plates were placed in the gel electrophoresis tank which was filled with 
electrophoresis buffer pH 8.3 (see appendix A). An equal volume (10-30pl) o f sample 
solutions were carefully loaded into the gel wells. The gel was then subjected to 
electrophoresis at a constant voltage of 100V for approximately 2 hours, or until the 
tracking dye reached the base o f the gel
2.8.5 Western Blot and Immunodetection by ECL.
Following electrophoresis the protein was transferred from the gel to nitrocellulose 
paper, on which the blots were prepared. This was achieved by the following process (all 
procedures carried out at room temperature unless otherwise stated):
i) After electrophoresis carefully transfer the gel to a container of blotting buffer, 
(see Appendix A) for 10 mins.
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Cut nitrocellulose paper and Whatman paper to the size o f the gel and incubate 
in the blotting buffer for lOmins.
Use a western blot cassette holder and place 6 filter papers on top of the sponges 
on both sides of the holder.
Place the nitrocellulose paper and the gel on one set o f filter papers, carefully 
remove all air bubbles.
Place the second set o f filter papers on top of the gel and close the cassette. 
Transfer cassette to a western blotting tank make sure that the nitrocellulose 







Figure 3. W estern blotting tank setup
vii) Add blotting buffer to the tank and run protein blot at 150mA for 2 hours.
viii) Remove cassette from the tank.
ix) Stain gel with Coomassie Brilliant Blue (see Appendix A) to check for complete 
transfer o f protein to the nitrocellulose paper.
x) Mark the positions of different molecular weight markers on the nitrocellulose 
paper with pencil.
xi) Incubate the nitrocellulose paper in blocking buffer consisting of 5% non-fat 
dried milk in 0.5% Tween 20/1 x PBS overnight at +4°C.
xii) Wash once with 0.5% Tween 20/1 x PBS for 5 min.
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xiii) Incubate in a square petri dish on a rocking plate with 5mls o f diluted primary
antibody in 5% non-fat dried milk in 0.5% Tween 20/1 x PBS for 2 hours.
xiv) Wash 3x in 0.5% Tween 20/1 x PBS 3 times, for 10 min each.
xv) Incubate with diluted secondary antibody 1:2500 dilution in 5% non-fat dried
milk in 0.5% Tween 20/1 x PBS) for 1 hour.
xvi) Wash as in step xiv).
xvii) Mix equal volumes o f solution A and solution B from the ECL Amersham
detection kit and add to the nitrocellulose paper making sure it is completely
covered. Incubated for 2 min.
xviii) Drain excess drain off excess liquid and cover in SaranWrap. Smooth out all 
bubbles and placed in a film cassette, protein side up.
xix) In a dark room, place a sheet o f Kodak autoradiography film on top of the 
membrane and expose for 30secs.
xx) Develop film using an automated developer.
xxi) Further films can be exposed and developed, up to 12 hours to ensure resolution
o f all details.
2.8.6 Assessment of western blots
Blots were analyzed by scanning densitometry (Scion Image Beta 4.02 - Scion 
Corporation, Maryland, USA.) Data plotted in Excel.
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CHAPTER 3: Determining the Optimum Time Point for Administering
the Hypoxyprobe
3.1 Introduction
Hypoxyprobe-1 is a commercially available injectable preparation o f pimonidazole 
(a modified 2-nitromidizole). It is taken up by all tissues in the body but binds only to cells 
with a p02 o f 10 mm Hg (or less) at 37°C. Hypoxyprobe-1MAB1 is a monoclonal antibody 
that binds to protein adducts o f Hypoxyprobe produced exclusively in hypoxic cells and 
this allows their detection in tissues ex-vivo. At the time that this study was carried out 
pimonidazole had only been used to measure low oxygen in animal and human tumours as 
an index o f radiation resistance (Kim et al., 1993, Kennedy et al., 1997). As this study 
uses the adjuvant arthritis model in Lewis rats a pilot study was carried out to determine the 
optimum time point (in terms o f labeling efficacy) for administering the hypoxyprobe prior 
to killing the animal. I felt that this initial study to establish labeling erricacy with 
pimonidazole was essential before the more complex time-course studies were undertaken. 
Previous studies from the department using oximetry have shown that the adjuvant joint is 
most hypoxic between days 7 and 14 post adjuvant induction when clinical disease was 
well developed (Bruce, 1992). Day 14 was therefore used as maximal hypoxia and 
maximal histological change were likely to be present.
3.2 Materials and Methods
Adjuvant arthritis was induced in 4 groups o f female Lewis rats (n=4) as described 
in part 2.1.5. Also there was one group o f naive control rats (n=4). Rats from each group 
were killed on Day 14. Hypoxyprobe was injected intraperitoneally as described in chapter
2.1.7 at 30 min, 2 hours, 6 hours or 18 hours before the rats were killed, to establish the
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optimal binding time for the hypoxyprobe. One group was left without hypoxyprobe. The 
rats were killed by cervical dislocation and their hind feet were then removed and used for 
subsequent histological investigations as described in chapter 2.2. Hypoxyprobe-1 adducts 
were detected using immunohistological method described in 2.2.9.1.
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3.3 Results
Three types o f negative controls for the mouse anti hypoxyprobe detection 
procedure were carried out:
1.) Sections from adjuvant arthritis hind feet from animals not injected with 
hypoxyprobe.
2.) Sections from adjuvant arthritis hind feet from hypoxyprobe injected animals 
but without the primary antibody, mouse anti-hypoxyprobe.
3.) Sections from adjuvant arthritis hind feet with hypoxyprobe using an irrelevant
primary antibody, mouse mti-Aspergillus niger glucose oxidase
All negative controls were clear o f staining and showing a lack o f antibody cross­
reactivity and non-specific staining (plates 3.1, 3.2 and 3.3.) Rats injected with 
hypoxyprobe 30 minutes and 2 hours prior to termination were found to have a high level 
o f staining for hypoxyprobe within the plasma (plates 3.4 and 3.5.) This indicates that the 
hypoxyprobe had not been adequately cleared from the circulation. Staining within the 6- 
hour and 18 hour injected animals had plasma clear o f unbound hypoxyprobe and distinct 
labelling o f cells bound to hypoxyprobe (plates 3.6 and 3.7.) All labelled adjuvant hind feet 
demonstrated the following characteristic staining:
Bone marrow staining for hypoxyprobe and chondrocyte staining on the surface of 
the cartilage near the invading pannus. Also staining o f distinct clusters o f cells within the 
inflammatory infiltrate was seen.
All naive 6 hour and 18 hour control rats showed very little staining; there was a 
discrete pale stain in some chondrocytes (plate 3.8.)
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3.3 Results
Plate 3.1 Negative control: 
Adjuvant hind foot joint, without 
hypoxyprobe (x 10,wax section, 
stained using mouse anti- 
hypoxyprobe.) Articular 
Cartilage [A]; bone [B] and 
synovium [S].
Plate 3.2 Negative control: 
Adjuvant hind foot joint, with 
hypoxyprobe (xl0,wax section, 
stained without using mouse anti- 
hypoxyprobe.) Articular Cartilage 
[A]; bone [B] and synovium [S].
Plate 3.3 Negative control: 
Adjuvant hind foot joint, with 
hypoxyprobe (x 10,wax section, 
stained using irrelevant mouse 
antibody.) Articular Cartilage [A]; 
bone [B] and synovium [S].
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Plate 3.4 30 min. hypoxyprobe: Adjuvant hind foot joint (xlO wax section, stained 
with mouse anti-hypoxyprobe.) Blood vessels[BV], bone [B] and synovium [S]. 
Note high background stain and unbound hypoxyprobe (red reation product) in the 
blood vessel lumen [arrows].
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Plate 3.5 2 hour hypoxyprobe: Adjuvant hind foot joint (xlO wax section, stained 
with mouse anti-hypoxyprobe.) Blood vessels[BV], bone [B] and synovium [S]. Note 







Plate 3.6 6 hour hypoxyprobe: Adjuvant hind foot joint (xlO wax section, stained 
with mouse anti-hypoxyprobe.) Blood vessels[BV], bone [B] and synovium [S]. 





Plate 3.7 18 hour hypoxyprobe: Adjuvant hind foot joint (xlO wax section, stained 
with mouse anti-hypoxyprobe.) Bone [B], articular cartilage [C] and synovium [S]. 




Plate 3.8 6 hour hypoxyprobe: Naive hind foot joint (xlO wax section, stained with 
mouse anti-hypoxyprobe.) Articular cartilage[A], bone [B] and synovium [S], Note 




Based on this preliminary study it was decided that a large study would be designed 
to establish at what point during the disease course of adjuvant arthritis the tissue o f the 
inflamed joint became hypoxic. This study would also be used to quantify the difference 
between the staining in the adjuvant rat joint and the staining seen in the naive controls. 
Finally based upon the evidence from the study (3.1), the 6-hour time point for dosage of 
the animals prior to termination was chosen because it was the shortest time that gave clear 
staining for hypoxyprobe adducts. It was decided that the 18-hour time point was 
unsuitable despite the clear staining for hypoxyprobe adducts this gave. The reason for this 
is based on the speed o f disease progression in the adjuvant rat. An animal with a clinical 
score o f 1 dosed with hypoxyprobe may well have a higher clinical score 18 hours later 
when it is killed.
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CHAPTER 4: Characterisation of the Time Course of Hypoxia in the 
Synovial Joint of Adjuvant Arthritis
4.1 Introduction
The objective o f this study was to quantitatively compare the level o f hypoxia in the 
adjuvant arthritis inflamed joint to the naive matched controls and establish at v/hat point 
during the disease progression the joint becomes hypoxic.
4.2 Materials and Methods
60 Female Lewis Rats were caged in groups o f five. Adjuvant arthritis was induced 
in thirty rats (n=30) as described in part 2.1.5. The remaining rats (n=30) were left as non­
diseased time matched controls. The disease progression was monitored by measuring 
body weight daily and clinically scoring the hind limbs according to the method of 
Andrews et al. (1987a,b). The method is fully described in section 2.1.6.
Rats were killed at time points and clinical scores shown in Table 1. Number of 
animals available with a particular clinical score on a specific day is dependent on disease 
progression in the groups.
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Time Point Clinical Score Num ber of Hind Feet 
Collected
Day 0 pre adjuvant arthritis 
(AA) induction 0 5
Time matched naive controls 
day 0 pre AA induction. 0 5
Day 3 post-AA induction. 0 5
Time matched naive controls 
day 3 post AA induction. 0 5
Day 7 post-AA induction. 0 5
Time matched naive controls 
day 7 post AA induction. 0 5
Clinical score of 1. 1 7
Time matched naive controls. 0 7
Clinical score of 2. 2 7
Time matched naive controls. 0 7
Clinical score of 3. 3 9
Time matched naive controls. 0 9
Clinical score of 4. 4 2
Time matched naive controls. 0 2
Table 1. Hypoxyprobe dosing time points
Hypoxyprobe was injected intraperitoneally 6 hours before the rats were killed as 
determined in part 2.1.8. Their hind feet were then removed and fixed for tissue processing 
and subsequent histological investigations as described in parts 2.2 and Hypoxyprobe-1 
adducts were detected using immunohistological method described in 2.2.9.1. The results 
were analysed using methods described in 2.2.10 to 2.3.
4.3 Results
The rats with adjuvant arthritis exhibited an initial weight loss during the 
first four days post-adjuvant induction then started to gain weight and followed a similar 
pattern of weight change to the naive control rats (Figure 4). The adjuvant arthritis rats then
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started to lose weight again from day 11 post-adjuvant induction until the end of the 
experiment on day 15. Weight loss coincided with the first clinical signs of inflammation 
present on day 11. Clinical score of hind feet increased to a maximum of 4, on day 15, the 
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No. of days post-adjuvant induction 
Figure 4. Changes in body weight during the development of adjuvant arthritis.
O 4-
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No. of days post-adjuvant induction
Figure 5. Development of clinical symptoms over time of adjuvant arthritis  rats.
109
4.3.1 Results of Histological Assessment
The histological scores of the amount o f synovial hyperplasia, cellular infiltration 
and bone erosions in the hind feet were made based on a comparison with naive rats whose 
histological scores were zero (Figure 6.6). It can be seen that the inflammatory response is 
present on day 7 post-adjuvant induction despite the lack o f clinical signs and increases to a 
maximum mean score o f 3.5 over the subsequent 8 days. Except for onset, the histological 
score generally reflects the clinical score.
Plate 4.1 is a hematoxylin and eosin (H&E) stained wax section from a day 3 post­
adjuvant hind foot. Histologically it is the same as its time matched nai've control (plate 
4.2.) Neither show any synovitis, cellular infiltration or bone erosion. Plate 4.3 
demonstrates the mild bone erosion and the hypertrophy and hyperplasia o f the synovium 
lining layer seen in section o f some day 7 adjuvant feet. Plates 4.4, 4.5, 4.6 and 4.7 are 
H&E wax sections from adjuvant rats with clinical scores o f 1, 2, 3 and 4 respectively. 
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Figure 6. Change in the histological scores with development of adjuvant arthritis.
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Plate 4.1 Day 3 adjuvant hind foot joint (xlO, wax section, haematoxylin and 
eosin) a zero histological score due to absence o f any cellular infiltrate and smooth 
appearance o f the articular surface [A] and bone [B]. Also note the thin synovium 
[S].
micron
Plate 4.2 Day 3 naive hind foot joint (xlO, wax section, haematoxylin and eosin) a 
zero histological score due to absence o f any cellular infiltrate and smooth 




Plate 4.3 Day 7 adjuvant hind foot joint, clinical score 0. (xlO, wax section, 
haematoxylin and eosin.) This appearance reflects a low histological score o f 0-1 
with some bone erosion [B] and hyperplasia and of the synovium [S].
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Plate 4.4 Adjuvant hind foot joint with a clinical score o f 1 (xlO, wax section, 
haematoxylin and eosin) and a low histological score 1-2 due to a mild increase in 






Plate 4.5 Adjuvant hind foot joint with a clinical score o f 2 and a histological score 
of 2-3 (xlO, wax section, haematoxylin and eosin). Note the increased cellular 
infiltrate [C].
Plate 4.6 Adjuvant hind foot joint with a clinical score o f 3 and a histological score 
o f 3(xl0, wax section, haematoxylin and eosin). Note the bone erosion [B], heavy 
cellular infiltrate [C]and extensive hyperplasia o f the synovium[S].
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Plate 4.7 Adjuvant hind foot joint with a clinical score of 4 and a histological score 
of 4 (xlO, wax section, haematoxylin and eosin). Note the extensive erosion of the 
bone [B] and heavy cellular infiltrate [C].
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4.3.2 Results of Immunohistochemical assessment
There were only two samples with a clinical score of 4 so these were not used in the 
immunohistochemical assessment. The percentage of hypoxic-labelled area in the hind feet 
joints of rats with adjuvant arthritis was analysed and compared to the time matched naive 
control rats (details of method in 2.4.7.)
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Figure 7. Day 3 post adjuvant arthritis induction. Hypoxic area of adjuvant rats 
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Naive feet Adjuvant feet
Figure 8. Day 7 post adjuvant arthritis induction. Hypoxic area of adjuvant rats 
(n=5) com pared to naive controls (n=5). P>0.05 (M ann W hitney test.).
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Figure 9. Hypoxic area of adjuvant rats with clinical score 1 (n=7) com pared to time 















Naive feet Adjuvant feet
Figure 10. Hypoxic area of adjuvant rats with clinical score 2 (n=7) com pared to time 
m atched naive controls (n=7). P<0.001 (M ann W hitney test.)
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Naive feet Adjuvant feet
Figure 11. Hypoxic areas of adjuvant rats with clinical score 3 (n=9) com pared to 
time matched naive controls (n=9). P<0.001 (M ann W hitney test.)
Day 0 sections (plates 4.8) from adjuvant feet were found to be histologically 
identical to their time-point matched nai've controls (plate 4.9) and so were not 
quantitatively analysed.
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Day 3 and 7 adjuvant feet sections were also comparable to their naive counterparts 
(plates 4.10, 4.11, 4.12 and 4.13). The adjuvant feet showed minimal staining for 
hypoxyprobe in the fatty area o f the synovium and in a few areas o f the lining cells o f the 
synovium. This similarity between the groups was reflected in the data in Figure 7 and 
Figure 8. which showed no significant difference in levels o f staining for hypoxyprobe 
between the adjuvant rats and their time-point matched naive controls, P>0.05 (Mann 
Whitney test.)
Figure 9. shows that when the first clinical signs o f disease appear clinical score 1 
(C l) after 11 days post adjuvant induction there is a concordant increase in the area staining 
for hypoxyprobe in the adjuvant rats. Statistical analysis o f the data shows this to be highly 
significant, P<0.001 (Mann Whitney test.) The staining for hypoxyprobe was found mainly 
in the proliferating synovium of C l hind feet and clusters o f cells within the synovium were 
found to stain specifically. These cell clusters were often associated with blood vessels as 
demonstrated in plates 4.14 and 4.15 and were not found in any sections of naive controls 
(plate 4.16). The data (Figure 10) for clinical score 2 (C2) adjuvant hind feet also show an 
increase in staining for hypoxyprobe compared to their time-point matched naive controls 
that is highly significant, P<0.001 (Mann Whitney test.) The very different staining levels 
are seen in plates 4.17 and 4.18 respectively.
Staining for hypoxyprobe in chondrocytes o f adjuvant rats with clinical symptoms 
was greatly increased and this can be seen in plates 4.19 and 4.20. By comparison only 
pale staining for hypoxyprobe was present in chondrocytes from naive control hind feet 
taken at all time points. An example o f this is shown in plate 4.21. Finally, adjuvant rats 
with a clinical score of 3 (C3) were found to have the highest levels o f staining for
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hypoxyprobe (Figure 11). Again the difference between the C3 rats and their time-point 
matched naive controls was highly significant, P<0.001 (Mann Whitney test.) Staining was 
found in most of the tissue structure involved in synovitis and bone erosion. There was 
staining in the bone marrow (plate 4.22), chondrocytes (plate 4.20) and synovium (plate 
4.23). This intensity of staining was not found in naive sections an example is seen in plate 
4.24.
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Plate 4.8 Day 0 adjuvant hind foot joint (xlO, wax section, stained with mouse 
anti-hypoxyprobe). Strong specific red staining is absent from the articular 
cartilage [A] and the synovium [S].
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Plate 4.9 Day 0 naive hind foot joint (xlO, wax section, stained with mouse anti- 





Plate 4.10 Day 3 adjuvant hind foot joint (xlO, wax section, stained with mouse 
anti-hypoxyprobe). Articular cartilage [A]. There is pale staining in the fatty area 





Plate 4.11 Day 3 naive hind foot joint (xlO, wax section, stained with mouse anti- 




Plate 4.12 Day 7 adjuvant hind foot joint (xlO, wax section, stained with mouse 
anti-hypoxyprobe). Bone [B]. The lining cells of the synovium [S] are weakly 
stained.
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Plate 4.13 Day 7 naive hind foot joint (xlO, wax section, stained with mouse anti- 
hypoxyprobe). Note the absence of red stain in the bone [B] and synovium [S].
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Plate 4.14 Adjuvant hind foot joint with a clinical score of 1 (xlO, wax section,
stained with mouse anti-hypoxyprobe). Bone [B]. There is strong red specific
staining of cells [arrows] in the synovium [S] near blood vessels [BV].
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Plate 4.15 Adjuvant hind foot joint with clinical score of 1 (x20, wax section, 
stained with mouse anti-hypoxyprobe). Erosion of bone [B] is visible at this higher 
magnification and also strong specific staining of cells [arrows] in the synovium 
[S] near blood vessels [BV].












Plate 4.16 Naive hind foot joint time matched (C l) control (x20, wax section,
stained with mouse anti-hypoxyprobe). Articular cartilage [A], blood vessels [BV].




Plate 4.17 Adjuvant hind foot joint with clinical score o f 2 (x5, wax section, 
stained with mouse anti-hypoxyprobe). Bone [B]. Positive red staining is present in 






Plate 4.18 Naive hind foot joint time matched (C2) control (x5, wax section,
stained with mouse anti-hypoxyprobe). Articular cartilage [A], blood vessels [BV].





Plate 4.19 Adjuvant hind foot joint with clinical score o f 2 (x40, wax section, 
stained with mouse anti-hypoxyprobe). Strong specific staining of chondrocytes 
[arrows] in the articular cartilage [A].
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Plate 4.20 Adjuvant hind foot joint with clinical score of 3 (x20, wax section, 
stained with mouse anti-hypoxyprobe). Strong specific staining of chondrocytes 
[arrows] in the articular cartilage [A].
100.00
Plate 4.21 Naive hind foot joint time matched (C3) control (x20, wax section, 
stained with mouse anti-hypoxyprobe). Bone end is shown [B]. Weak staining of 
chondrcytes [arrows] in the articular cartilage [A].
100 DO
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Plate 4.22 Adjuvant hind foot joint with clinical score of 3 (xlO, wax section, 
stained with mouse anti-hypoxyprobe). There is erosion o f bone [B] by invasive 
synovium [S] and specific staining of chondrocytes in the articular cartilage [A].
Plate 4.23 Adjuvant hind foot joint with clinical score o f 3 (x40, wax section, 
stained with mouse anti-hypoxyprobe). Erosion of bone [B] by invasive synovium 
[S] is well shown at this magnification. Note the strong specific staining of cells in 
the synovium [arrows].
Plate 4.24 Naive hind foot joint time matched (C3) control (x5, wax section, 
stained with mouse anti-hypoxyprobe). Bone erosion [B] is absent and bone 
and synovium [S]lack staining.
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4.4 Discussion.
As discussed in the introduction, the rat adjuvant arthritis model is useful in 
investigating the pathology and novel treatment o f rheumatoid arthritis (RA). Many 
features of the development and pathology o f adjuvant disease in rats are similar to those 
seen in humans with RA. The clinical signs o f joint swelling and destruction disscussed in 
this thesis are typical o f published descriptions o f adjuvant disease (Stoerk et al., 1961; 
Pearson et al., 1961) and are comparable to the clinical-pathological changes seen in RA 
joints. Examination o f the joint synovium from both RA patients and rats with adjuvant 
arthritis shows that both undergo hyperplasia and substantial cellular infiltration with the 
eventual destruction o f bone and cartilage (Cush & Lipsky, 1991; Fitzgerald & Bresnihan, 
1995; Pelegri et al., 1995; Zvaifler & Firestein, 1994).
Also previously reviewed in the introduction were studies that demonstrated 
hypoxia in rheumatoid but not non-rheumatoid joints (Falchuk et al, 1970; Lund-Oleson, 
1970; Treuhaft and McCarty, 1971; Blake et al, 1997). This work has also been supported 
by previous departmental studies in the rat model o f adjuvant arthritis that have 
demonstrated a significant decrease in pC>2 between day seven and fourteen post adjuvant 
arthritis induction (Bruce, 1992). None o f these studies identify or describe specific 
hypoxic cell populations within the joint.
Hypoxyprobe is a commercially available preparation o f pimonidazole which 
following dosing, is distributed to all tissues in the body but binds only to cells that have 
low oxygen concentrations equivalent to a pC>2 o f 10 mm Hg (or less) at 37°C. 
Hypoxyprobe-lM Abl is a monoclonal antibody that detects protein adducts of
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Hypoxyprobe produced in hypoxic cells. The reductive metabolism of this hypoxia marker 
is regulated by oxygen tension independent o f pyridine nucleotide redox state (Arteel el al, 
1998). Pimonidazole was first used to measure low oxygen in animal and human tumours 
(Raleigh et al., 1987; Azuma et al., 1997; Kennedy et al, 1997). My study represents the 
first use o f a definitive exogenous marker, Hypoxprobe-1, to detect hypoxic cells in the 
inflamed joint in vivo My results show for the first time that inflamed joints in the rat 
adjuvant model possess significantly more hypoxic tissue, as demonstrated by positive 
hypoxyprobe-1 adduct immunoreactivity, than those from naive controls. I have shown 
that as the rats develop clinical signs o f adjuvant arthritis the percentage o f tissue area 
staining for hypoxyprobe measured quantitatively increases significantly compared to naive 
controls. Qualitative assessment o f the distribution o f the hypoxyprobe shows that as 
adjuvant disease progresses tissue hypoxia involves all tissue structures including the 
synovium, bone marrow and articular cartilage chondrocytes. O f particular interest are the 
clusters of yet to be identified cells within the proliferating synovium that stain intensely 
with hypoxyprobe. These cells are unique to the adjuvant synovium and were not found in 
the synovium of naive rats. These cells were found near blood vessels, therefore it may be 
asked why are these cells hypoxic. The reason could be explained by two different 
mechanisms. The area may be subject to hypoxic episodes as a result o f hypoxic 
reperfusion events previously described in the introduction (section 1.8). Therefore this 
staining represents a “snapshot” o f a period o f hypoxia. The alternative suggestion is that 
these cells are migratory and have migrated from an area o f hypoxia the the area near the 
blood vessels which is not hypoxic. I suggest these cells might have the phenotype of the 
“transformed” aggressive, invasive fibroblast-type cells previously decribed in section 1.2.5
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of the introduction. To date no single specific marker for this phenotype has been 
identified. Instead a combination o f characteristics has been observed which lead to the 
cells aggressive, invasive behavior. These ‘transformed cells’ respond to stimulation by 
cytokines and growth factors produced in the local inflammatory milieu but also their 
cellular changes are maintained in the absence o f external stimulation (Pap et al 2000). 
Alternatively the clusters o f cells labeling with hypoxyprobe might be monocytes recruited 
from the inflammatory milieu.
Shapiro et al (1997) used EF5 a pentafluorinated derivative o f 2-nitroimidazole 
(etanidazole) that is metabolically reduced by nitroreductases to label hypoxic 
chondrocytes. In their study chondrocytes generally had low levels o f EF5 binding; 
however, exposing chondrocytes to hypoxic conditions significantly increased EF5 binding. 
My work supports these findings as I have shown staining for hypoxyprobe in chondrocytes 
of the naive controls was pale compared to the intense staining seen in chondrocytes o f the 
adjuvant group.
Chondrocytes can adapt to conditions o f low oxygen tensions by their capacity to 
switch to anaerobic metabolism (Rajpurohit et al., 1996). It is possible that the hypoxia in 
chondrocytes may be a result o f pannus development since the increase in metabolic 
demand o f the cells in the developing pannus and poor vascular supply may compromise 
the metabolic requirements o f the chondrocytes. The levels of hypoxia indicated by the 
hypoxyprobe staining in adjuvant cartilage chondrocytes could bring about deleterious 
changes in these cells. In 1985 Mitrovic suggested that chondrocytes contribute to the 
formation o f the pannus. Chondrocytes activated by inflammatory cytokines 
dedifferentiate, enlarge their lacunae, coalesce and finally break onto the cartilage surface
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to form a fibrous pannus. The fibrous pannus tissue is subsequently invaded by 
inflammatory cells to form the inflamed synovium. (Mitrovic 1985).
4.5 Conclusions
These results show, for the first time, as the clinical symptoms o f adjuvant arthritis 
develop so the inflamed joint becomes hypoxic and that this hypoxia is significantly higher 
than naive controls. Further work is needed to identify the cell types that are labelling with 
hypoxyprobe-1 adduct immunoreactivity.
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CHAPTER 5: Hypoxia, Cell Characterisation, Transcription factors and
Cytokines.
5.1 Introduction
The previous chapter demonstrated that as the clinical symptoms o f adjuvant 
arthritis develop so the cells within the inflamed joint become hypoxic and that this tissue 
hypoxia is significantly higher than in naive controls. The principle aim o f this chapter is 
to identify the cell types that are found in the hypoxic areas (as demonstrated by 
hypoxyprobe adduct detection). The overall hypothesis o f this thesis is that hypoxic cells 
in the inflamed joint produce proinflammatory cytokines and provide a potential target for 
bioreductive therapy and other novel therapies. Therefore, the second part o f this chapter 
describes studies aiming to show whether hypoxic cells produce proinflammatory factors. 
To do this several key markers were examined: iNOS, VCAM-1, VEGF, H IF -la  and ets-1. 
As previously described in the introduction (section 1.9.3) inducible nitric oxide synthase 
(iNOS) is considered a proinflammatory enzyme because o f its ability to form damaging 
free radicals and it is highly expressed in the rheumatoid synovium (Sakurai et al., 1995, 
Gabowski et al., 1997). Vascular cell adhesion molecule-1 VCAM-1 is a member of a 
family o f cell adhesion molecules that are responsible for the recruitment o f leukocytes 
from the circulatory system to a site o f inflammation. This process occurs via a multistep 
pathway which involves binding o f leukocytes to the vascular endothelium, a rolling 
mechanism, and finally a firm adhesion followed by passage o f the leukocyte between 
endothelial cells and into the tissue (diapedesis). VCAM-1 is an endothelial ligand 
responsible for the initial binding o f leukocytes to the endothelium. Increased VCAM-1 
expression has been demonstrated in the synovium from RA patients (Morales-Ducret et
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al., 1992). Also, soluble VCAM-1 has been implicated in exacerbation o f rheumatoid 
arthritis through the induction o f angiogenesis (Koch et al., 1995). The cytokine, vascular 
endothelial growth factor (VEGF), is considered a potent inducer o f angiogenesis 
(Brenchley, 2000). It is constitutively secreted by rheumatoid synovial fibroblasts and can 
be increased in vitro when the synoviocytes are exposed to hypoxia (Jackson et al., 1997). 
As mentioned in section 1.9.4, H IF-la is the oxygen regulated subunit of the transcription 
factor HIF-1 (Jiang et al., 1996; Semenza, 2000) and its expression by macrophages has 
been demonstrated in the rheumatoid synovium (Hollander et al., 2001). Therefore the 
distribution o f H IF -la  in the inflamed joint would be expected to colocalize with the 
distribution o f hypoxic cells detected by hypoxyprobe. There are a number o f genes that 
are regulated by HIF-1 o f particular relevance to rheumatoid arthritis are: iNOS, VEGF 
and PDGF (Ratcliffe et al, 1998).
Finally, the transcription factor, Ets-1, belongs to the Ets family o f transcription 
factors defined by a conserved DNA-binding Ets domain that forms a winged helix-tum- 
helix structural motif. Ets-1 has been identified in endothelial cells during angiogenesis both 
in the embryo (Vandenbunder et al., 1989) and in tumours (Wemert et al., 1992). C-Ets-1 
expression in cancer cells has been correlated with tumour invasion (Wemert et al., 1994) 
and it has been shown in vitro that hypoxia induces Ets-1 via HIF-1 in a human bladder 
cancer cell line (Oikawa et al., 2001).
At the time this part o f my thesis study was carried out, publications on ets-1 in 
rheumatoid arthritis were sparse and little was known except that over-expression of Ets-1 
has been observed in cultures o f TNFa-stimulated synovial fibroblasts from RA synovial 
tissue (Redlich et al., 2001). Therefore, the objective o f this study was to determine the
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relationship between hypoxia and expression o f the transcription factors, ets-1 and Hypoxia 
Inducible Factor-la (H IF-la), and cytokines in both normal and inflamed joints of 
adjuvant-induced arthritis (AA) as a model that mirrors many aspects o f rheumatoid 
arthritis.
5.2 Materials and Methods
20 Female Lewis Rats were caged in groups o f five. Adjuvant arthritis was induced 
in 10 as described in part 2.1.5. and 10 were left as non-diseased controls. The disease 
progression was monitored by measuring body weight daily and clinically scoring the hind 
limbs according to the method o f Andrews et al. (1987a,b) The method is fully described 
in section 3.1.6. When a maximum clinical joint score o f 4 was achieved in total o f two 
feet scores in the adjuvant group, all 20 rats were killed to comply with Home Office 
regulations which state that the animals must be killed when one foot reaches a score of 4. 
Hypoxyprobe was injected intraperitoneally 6 hours before the rats were killed as described 
in part 2.1.8. The rats were killed by cervical dislocation and their hind feet removed and 
fixed prior to tissue processing and histological investigations as described in chapter 2.2. 
Knee synovium was also removed and snap frozen as described in 2.2.6. 5pm thick 
alternate downward and upward facing (flip-flop) and consecutive wax sections were cut, 
mounted on glass slides and dried in an oven at 60°C overnight. 10pm thick consecutive 
frozen sections were cut, mounted on glass slides and dried for 1 hour before use. 
Hypoxyprobe-1 adducts were detected using immunohistological method described in 
2.2.9.1. VCAM-1, VEGF, iNOS, fibroblast and macrophage markers were detected using 
the immunohistological method described in 2.2.9.2. Transcription factor ets-1 and H IF -la
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expression was revealed using immunohistological methods described in 2.2.9.2 and 2.2.9.3 
respectively. The results were analysed using methods described in 2.2.10 to 2.3. Image 
analysis was limited to synovial tissue lining the joint cavity and synovial tissue attached to 
the bone. The KS 300 Imaging System V 3.0 was used to count nuclei with positive 
immunoreactivity for Ets-1 to be expressed as a proportion o f the total cell population 
counted in a framed area of 100 x lOOpm. The proportion o f nuclei showing 
immunoreactivity for both Ets-1 and H IF-la  was also assessed. This data was then 
tabulated using software (Graph Pad) for statistical analysis.
5.3 Results
5.3.1 Results of Histological Assessment
In the rat adjuvant model used in this study, marked changes were visible in 
inflamed joints within 10 days o f disease induction. Clinically detectable swelling was 
present in the distal joints which increased in severity and led to ankle joint deformation by 
day 13. Histological examination o f adjuvant rat foot sections revealed synovial 
hyperplasia, increased cellular infiltration and bone destruction. The disease progression 
and histological changes were reflected those seen in chapter 4.
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5.3.2 Results of Immunohistochemical Assessment.
5.3.2.1 Results of cell type, cytokine, hypoxia and transcription factor m arkers in 
fresh frozen synovial tissue.
None of the antibodies worked effectively enough in fresh frozen sections to enable 
data interpretation. A summary of observations is available below in Figure 12.
M arker Result
Fibroblast (5B5) No stain
Macrophage (ED2) No stain
Macrophage (EDI) High background and no specific stain
INOS High background and no specific stain
VEGF No stain
VCAM-1 No stain
Hypoxyprobe (1M AB1) No stain
H IF -la High background and no specific stain
Ets-1 No stain.
Figure 12. Sum m ary of immunohistochemical results in fresh frozen tissue.
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5.3.2.2 Results of cell type, cytokine, hypoxia and transcription factor markers in wax 
embedded tissue
Three types o f negative controls for the various antibodies were carried out, all were 
clear o f staining:
1.) Plate 5.1. Sections from adjuvant arthritis hind feet using an
Irrelevant primary antibody, mouse anti Aspergillus niger glucose oxidase.
2.) Plate 5.2. Sections from adjuvant arthritis hind feet using goat IgG.
3.) Plate 5.3. Sections from adjuvant arthritis hind feet using rabbit IgG.
Two markers failed to work in adjuvant rat wax sections these were: Fibroblast 
marker 5B5 and VCAM-1.
EDI macrophage marker labels a protein found on the lysosomal membrane of 
myeloid cells. It labels strongly in most tissue macrophages and weakly in peripheral 
granulocytes. It shows homology to human CD68 macrophage marker. ED2 labels a 
protein on peritoneal macrophages but not monocytes or microglial cells. Plates 5.4 and
5.5 show staining for EDI and ED2 respectively in naive hind feet. It can be seen that 
staining for EDI is sparse and mainly in the lining cells o f the synovium. By comparison 
ED2 stains more cells but again limited mainly to the synovial lining cells. Plates 5.5 and
5.6 show staining for EDI and ED2 respectively in adjuvant hind feet. It can be seen that 
more cells stained for EDI in the adjuvant joints compared to naive joints and in cells in the 
depths o f the synovium. Again, more cells in the adjuvant joint stained ED2 compared 
naive joint staining and it appears that there is a proliferation o f ED2 labelling cells deeper 
in the synovium. Areas o f increased staining did not colocalize specifically with areas of 






Plate 5.1 Negative control: 
Adjuvant hind foot joint,
(x 10,wax section, stained using 
irrelevant mouse antibody). Bone 
[B] and synovium [S].
Plate 5.2 Negative control: 
Adjuvant hind foot joint, (xl0,wax 
section, stained using goat IgG.) 
Bone [B] and synovium [S].
B
Plate 5.3 Negative control: 
Adjuvant hind foot joint, (xl0,wax 
section, stained using rabbit IgG.) 
Bone [B] and synovium [S].
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Plate 5.4 Naive hind foot (xlO, wax section, stained with mouse anti-rat EDI). 




Plate 5.5 Naive hind foot (xlO, wax section, stained with mouse anti-rat ED2). 
Articular cartilage [A]. The pattern o f stained cells on the lining of the synovium 
[S] is thicker compared to plate 6.4.
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Plate 5.7 shows that staining for iNOS in the naive hind feet is limited to the lining 
cells o f the synovium and the smooth muscle o f some but not all blood vessels. In the 
Adjuvant hind feet (plate 5.8) it can be seen that there is a very obvious increase in cells 
labelling for iNOS. The cells labelling for iNOS were in the pannus, the synovium and the 
leading edge o f sites where bone erosion was occurring. Again areas o f increased staining 
did not always specifically colocalize with areas o f hypoxia.
Plate 6.9 shows that staining for VEGF in the naive hind feet is limited to the inner 
most lining cells o f the synovium and the endothelial cells o f some but not all blood 
vessels. In the Adjuvant hind feet (plate 5.10) it can be seen that there is a very obvious 
increase in cells labelling for VEGF in areas that also demonstrate an increase in iNOS 
labelling. The cells labelling for VEGF were in the pannus, the synovium and the leading 
edge o f sites where bone erosion was occurring. Again areas o f increased staining did not 
always specifically colocalize with areas o f hypoxia.
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Plate 5.6 Adjuvant hind foot (xlO, wax section, stained with mouse anti-rat EDI). 




Plate 5.7 Adjuvant hind foot (xlO, wax section, stained with mouse anti-rat ED2). 
Articular cartilage [A]. There are more stained cells and they extend beyond the 




Plate 5.8 Naive hind foot joint (xlO, wax section, stained with rabbit anti-iNOS).
Staining of some blood vessel smooth muscle [BV] and lining cells o f the synovium
[S].







Plate 5.9 Adjuvant hind foot joint (xlO, wax section, stained with rabbit anti- 
iNOS). Note heavy red staining in cells of the synovium [S] particularly at site of 
bone invasion [B].
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Plate 5.10 Naive hind foot joint (xlO, wax section, stained with goat anti-VEGF).






Plate 5.11 Adjuvant hind foot joint (xlO, wax section, stained with goat anti- 





Plate 5.10 Naive hind foot joint (xlO, wax section, stained with goat anti-VEGF).






Plate 5.11 Adjuvant hind foot joint (xlO, wax section, stained with goat anti- 




Positive immunoreactivity (red reaction product) for Hypoxyprobe-1 adducts 
(IM A Bl-ir) and Hypoxia inducible factor-la (HIFla-ir, a brown reaction product) in the 
adjuvant foot tissue involved all structures including the synovium, pannus, bone marrow 
and articular cartilage chondrocytes.
A representative set o f stained sections presented in Plates. 5.12 and 5.14 show that 
cell nuclei with positive immunoreactivity for ets-1 (E tsl-ir - red reaction product) are 
mainly found in the inflammatory infiltrate and invasive pannus o f the inflamed synovial 
joint. There is co-localization with areas o f positive IM A B l-ir in flip-flop sections (Plates. 
5.13 and 5.15). The histologically normal hind feet from naive rats showed a low level o f 
ets-l-ir in the sub-intimal synoviocytes (Plates 5.16 and insert), that did not co-localise with 
IM A Bl-ir (Plates. 5.17 and insert).
A  representative set o f immunhistochemical sections is presented in Plates. 5.18 and 
5.20 showing cell nuclei with positive immunoreactivity for E tsl-ir mainly in the 
inflammatory infiltrate and the invasive pannus o f the inflamed synovial joint colocalizing 
with nuclei with strong positive H IFla-ir in flip-flop sections (Plates. 5.19 and 5.21). 
These sections are 5pm thick alternate downward and upward facing (flip-flop) therefore 
the stained cells are the same cells in both Plates. 5.20 and 5.21. The hind feet from naive 
rats showed a low level o f ets-l-ir in the sub-intimal synoviocytes (Plates. 5.22 and insert), 
that did not co-localise with H IFla-ir (Plates. 5.23 and insert).
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Plate 5.12 Adjuvant hind foot joint (xlO, wax section, stained with rabbit anti-
etsl). Red stain for ets-1 in blood vessel [BV] and inflammatory infiltrate.
Co-localizing with hypoxyprobe adducts in plate 6.13
BV
Plate 5.13 Adjuvant hind foot joint (xlO, wax section, stained with mouse anti- 
Hypoxyprobe). Red stain in blood vessel [BV] and inflammatory infiltrate.
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Plate 5.14 Adjuvant hind foot joint (xlO, wax section, stained with rabbit anti-
etsl). Red nuclear stain for ets-1 in proliferating cells o f synovium. Co-localizing
with hypoxyprobe adducts in plate 6.15
Plate 5.15 Adjuvant hind foot joint (xlO, wax section, stained with mouse anti- 
Hypoxyprobe). Red stain in proliferating cells o f synovium.
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Plate 5.16 Naive hind foot joint x40, wax section, stained with rabbit anti- 
etsl(insert xlO of same section). Low level, staining for ets-1.
Plate 5.17 Naive hind foot joint x40, wax section, stained with mouse anti- 
hypoxyprobe (insert xlO of same section). Low level, non nuclear staining, no co­




Plate 5.18 Adjuvant hind foot joint (xlO, wax section, stained with rabbit anti-
etsl). Red stain for ets-1 in blood vessels [BV] and lining cells o f the proliferating
synovium [S]. Co-localizing with H IF -la  in plate 6.19
100.00
Plate 5.19 Adjuvant hind foot joint (xlO, wax section, stained with mouse anti-HIF- 




Plate 5.20 Adjuvant hind foot joint (x40, wax section, stained with rabbit anti-
etsl). Red nuclear stain for ets-1 [arrows] in nuclei of lining cells o f the
proliferating synovium. Co-localizing with H IF -la  in plate 6.21
micron
100.00
Plate 5.21 Adjuvant hind foot joint (x40, wax section, stained with mouse anti-HIF- 
la ) . Brown nuclear stain for H IF -la  [arrows] in nuclei o f lining cells o f the 




Plate 5.22 Naive hind foot joint x40, wax section, stained with rabbit anti-
etsl (insert xlO of same section). Low level, staining for ets-1.
100.00
Plate 5.23 Naive hind foot joint x40, wax section, stained with mouse anti-HIF-la 
(insert xlO of same section). Low level, no nuclear staining for H IF -la
5.3.2.3 Quantitative Assessment of ets-1 and HIF-la immunohistochemistry
The hind feet from adjuvant rats showed a highly significant (p< 0.0001) increase in 
the proportion o f cells with positive nuclear ets-1 immunoreactivity (Etsl-ir) compared to 
naive control rats (Figure 13). They also showed a significant (p<0.0001) increase in 
hypoxic tissue as demonstrated by positive IM A Bl-ir compared to naive control rats 
(Figure 14). Figure 15 shows that the hind feet from adjuvant rats showed a highly 
significant (p< 0.0001) increase in the proportion of cells with positive neuclear Etsl-ir that 
also colocalized with HIFla-ir compared to naive control rats. Statistical comparisons were 
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Figure 15. Proportion of nuclei H IF la - ir  colocalizing with ets-1- ir.
5.4 Discussion
These results confirm that inflamed joints in the rat adjuvant model possess 
significantly more hypoxic tissue, as demonstrated by positive hypoxyprobe-1 adduct 
immunoreactivity, than those from naive controls. This concurs with the situation in the 
rheumatoid joint (Blake et al., 1997). However, the studies in this chapter have not 
identified any phenotypic specific marker associated with the cells labelling with 
hypoxyprobe seen in chapter 4.
There was also a clear increase in numbers o f cells expressing ED2 and to lesser 
extent EDI macrophage markers showing that cells proliferate and are recruited from the 
circulatory system to the site o f inflammation. However, the increase in EDI and ED2 
expressing cells did not involve co-localizations with hypoxyprobe adduct labelling. This 
indicates that it is likely to be other factors, cytokines for example, that play the key role in 
the expansion o f EDI and ED2 cell populations.
The fibroblast marker did not stain anything, this is probably because this antibody 
although generated against a peptide that shows apparent homology in humans and rats, is 
essentially derived from humans and shows no rat cross reactivity in my studies. This is 
probably also the reason for the lack of staining observed for the VCAM-1 antibody. I 
would expect both these markers to be present in cells in the inflamed joint. As discussed in 
chapter 1.3.2, the cells in the synovium possess characteristics that delineate them as 
macrophage-like or fibroblast-like synoviocytes. VCAM-1 would also be expected to be 
increased as it plays a key role in the trafficking o f leukocytes from the circulatory system 
to the site o f inflammation and increased VCAM-1 expression has been demonstrated in the
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synovium from RA patients (Morales-Ducret et al., 1992). Fresh frozen synovial tissue, 
generally did not demonstrate specific immunoreactivity. This was probably due to the 
lack of protein cross linking in the fixation technique which relied only on acetone to fix 
the proteins. Better antigenicity might have been achieved had the samples been perfusion 
fixed prior to snap freezing. It is highly probable, however, that the hypoxic cells identified 
in the inflamed joint are a heterogeneous population with phenotypical characteristics from 
both fibroblast and macrophage lineages.
My results did show a qualitative increase in both iNOS and VEGF expressing cells 
and these results mirror data previously published that demonstrate an increase in iNOS 
(Sakurai et al., 1995, Gabowski et al., 1997) and VEGF (Jackson et al., 1997) in the 
rheumatoid synovium. I believe that the localisation o f these two proinflammatory factors 
in areas where bone erosion was taking place is indicative o f the fact that they play a key 
role in this process. Neither iNOS nor VEGF expression colocalized with areas o f hypoxia 
as indicated by hypoxyprobe labelling, suggesting that hypoxia does not play a critical role 
in their expression. I speculate that initiating factors are likely to be cytokines like TNFa 
and IL-1. These results support recently published work showing that an increase o f the 
VEGF/KDR (kinase insert domain protein receptor) pathway occurs independent of 
increases in HIF-alpha expression in rheumatoid arthritis (Giatromanolaki et al., 2003). 
This disparity between hypoxia and cytokine expression is also reflected in other situations. 
Haroon et al (2000) used Hypoxyprobe-1 to demonstrated that early wound healing in a rat 
model exhibits a cytokine surge without evidence o f hypoxia. Their results showed that 
hypoxia peaked in the granulation tissue and correlated with increased cellular prolferation. 
In a study o f human squamous cell carcinomas tumour Hypoxyprobe-1 was used in a
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immunohistochemical comparison of hypoxia and VEGF protein expression and revealed 
no correlation between the two (Raleigh et al,. 1998).
In my study immunhistochemical localization o f hypoxia inducible factor-la 
involved all structures including the synovium, pannus, bone marrow and articular cartilage 
chondrocytes of the adjuvant foot tissue and this mirrors my work from chapter 5 using 
hypoxyprobe. This contrasts with work carried out by Hollander et al., (2001), who 
demonstrated that H IF -la  localised specifically to macrophages. My results are, however, 
comparble to similar studies carried out more recently in rheumatoid synovium. Two 
groups Hitchon et al., (2002) and Giatromanolaki et al., (2003) have published 
immunohistochemical studies that localized H IF -la  in synoviocytes lining the inflamed 
synovial tissue. Their images were a mirror o f my images o f H IF -la  in adjuvant inflamed 
synovium.
The ets-1 promoter has been shown to contain hypoxic responsive like 
elements (Oikawa et al., 2001) and I expected increased cellular hypoxia to be associated 
with a concurrent increase in the expression o f ets-1. This was verified by my results 
showing that in joints from all ten feet from animals with adjuvant arthritis a minimum of 
40 percent o f nuclei in the total cell population were positive for ets-1, compared to the ten 
naive joint samples in which no more than 15 percent expressed detectable ets-1. 
Furthermore, 65-75 percent o f nuclei expressing ets-1 in the adjuvant samples also 
expressed H IF-la. This clearly demonstrates an induction o f hypoxia and expression of 
ets-1 during the inflammatory response in adjuvant rat joints. That Ets-1 and H IF-la co- 
localize in areas o f hypoxia in inflamed synovial tissue, suggests that both hypoxia and 
H IF-la  may be involved in the upregulation of ets-1 during joint inflammation.
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Others have demonstrated that ets-1 transcription factor up-regulation correlates 
with tumour invasion (Vandenbunder et al 1994, Wemert et al., 1994). Since I carried out 
this study, the same group have also identified ets-1 in the endothelium of synovial blood 
vessels (Wemert et al., 2002), however they made no observation o f ets-1 in the pannus, 
probably because their research is primarily orientated to angiogenesis in tumour biology. 
As well as showing ets-1 expression in the blood vessel endothelium, my results also 
localize ets-1 in cells on the edge o f the invasive pannus. These are clearly hypoxic, as 
indicated by both hypoxyprobe labelling and H IF -la  expression and are distant from blood 
vessels. Ets-1 expression would be expected to be present in the endothelium if  the blood 
vessels of the synovium were promoting angiogenic messages. Indeed, as discussed in the 
introduction (1.6), there is accumulating evidence to show that pro-angiogenic signals and 
abnormal blood vessel formation has been associated with rheumatoid arthritis (Walsh et 
al., 1999). That Ets-1 and H IF -la  co-localize in areas o f hypoxia in inflamed synovial 
tissue, suggests that both hypoxia and H IF-la may be involved in the upregulation of ets-1 
during joint inflammation.
The localisation o f ets-1 in the invasive pannus is indicative o f ets-1 involvement in 
the invasion o f synovial joint cartilage and bone by proliferating synovium. This theory is 
further supported when you consider the broad range o f target genes for ets-1. This has 
been extensively reviewed (Lelievre et al., 2001), areas o f particular relevance to the 
pathology o f arthritis being its involvement in angiogenesis and extracellular matrix 
remodelling. Matrix metalloproteinases (MMPs) and tissue inhibitors o f metalloproteinases 
(TIMPs) such as collagenase 1 (MMP-1), stromelysin (MMP-3), gelatinase B (MMP-9) and 
TIMP-1 are all gene targets o f ets-1 and have been shown to be elevated in patients with
157
RA (Vincenti et al., 1994 and Klimiuk et al., 2002). Indeed more recent work by Czuwara- 
Ladykowska (2002) has shown that elevated etsl expression in fibroblasts alters their 
response to TGFp in favour o f matrix degradation. These results could implicate ets-1 as a 
key player in the destruction o f the bone and cartilage in rheumatoid arthritis by fibroblast 
like synoviocytes and independent o f its role in angiogenesis. I propose that hypoxia in the 
inflamed rheumatoid joint results in increased H IF -la  expression; H IF -la  binds to hypoxic 
response like binding sequences on the ets-1 promoter which leads to increased expression 
o f etsl by fibroblast like synoviocytes. This throws a switch in the direction o f matrix 
degradation and thus the destruction o f the joint.
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CHAPTER 6: Effect of Induced Hypoxia on Transcription Factors Invitro
6.1 Introduction
A distinctive characteristic o f the rheumatoid joint is rapid synovial proliferation 
which outstrips neovascularization (Stevens et al., 1991). This may result in metabolic 
hypoxia in proliferating cells and it has been shown by oxygen electrode studies that low 
oxygen tensions (<10mm/Hg) do exist in the rheumatoid joint cavity (Blake et al., 1997). 
Hypoxia is a potent inducer o f cytokines, matrix degrading enzymes and angiogenic factors 
and has a central role in the normal inflammatory response. Moreover, hypoxia-driven 
angiogenesis is critical for tissue remodelling (Steinbrech et al., 1999). Critically, cartilage 
and bone are invaded by the proliferating synovium (pannus) resulting in erosion and joint 
destruction. The reason for this invasiveness is not understood but in tumours, invasiveness 
is marked by upregulation o f the ets-1 transcription factor (Wemert. 1994). Ets-1 is 
particularly relevant to the rheumatoid joint as it can be induced during hypoxia by 
activation o f a second transcription factor, hypoxia-inducible factor 1 (HIF-1).
In chapter 5, I demonstrated the presence o f Hypoxia and ets-1 expression in the 
inflamed joint of an animal model. The objective o f this chapter is to validate and support 
the in vivo studies by the use o f an in vitro system to expose synoviocytes to hypoxia and 
compare them to normoxic cells, ets-1 and HEF-1 expression is determined in vitro, in 
hypoxic rheumatoid synovial fibroblasts (RSF) and hypoxic adjuvant rat synovium.
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6.2 Materials and Methods
Adjuvant arthritis was induced in female Lewis rats 130-150g (n=10) using methods 
described in chapter 2.1.5. A second group o f non-injected rats (n=10) served as naive 
controls. Disease progression was monitored daily using a standard clinical scoring system 
described in 2.1.6. Animals were killed by cervical dislocation on reaching a maximum 
clinical score o f 4 in two hind feet. Naive rats were sacrificed at the same time. The knee 
patella suspensory ligaments were dissected and used in an explant culture technique 
developed within the School o f Health at the University o f Bath and described in chapter 
2.4.6. Synovial fibroblasts from rheumatoid arthritis patients were obtained with patient’s 
consent according to local ethical committee procedures and kindly donated by Dr. D. 
Speden. The cells used for experiments were passage 1-5 and had been checked for 
fibroblast phenotype using specific antibodies Mouse Monoclonal Anti Fibroblast 5B5 
clone (DAKO, Ely, UK) via immunocytochemisty by Dr. D. Speden. The cells were 
cultured by methods described in chapter 2.4. A microflow anaerobic System (M.D.H Ltd., 
Hampshire, UK.) was used to incubate the cells and explants under quantifiable hypoxic 
conditions (p02 <10 mm Hg at 37°C) for two weeks and compared to matched normoxic 
controls (method described in chapter 2.5). The culture media was then removed and 
frozen at -70°C for future studies. Explants were fixed and embedded for histological 
studies (methods described chapter 2.2). Protein was isolated from the cells by treatment 
with 2ml RNAase (AMS Biotechnologies, Oxford, UK) which was then stored in -70°C till 
use. The ets-1 and H IF -la  protein was measured using SDS-PAGE on 7.5% gels and 
Western blotting with chemiluminescence methods described in chapter 2.6 to 2.8.6. The 
antibodies were those used previously in immunohistochemistry for the expression of
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transcription factor ets-1 and H IF -la  (see 2.2.4). JURKAT, rat kidney explant (DAKO, 
UK) and HeLa cells (section 2.4.2) were used as positive controls and negative control 
primary antibodies mouse monoclonal anti-Aspergillus niger glucose oxidase and rabbit 
IgG (section 2.2.4) were also used. Blots were analyzed by scanning densitometry (Scion 
Image Beta 4.02 - Scion Corporation, Maryland, USA.)
6.3 Results
6.3.1 Effect of hypoxia on ets-1 and H IF-la protein expression in synovial fibroblasts 
from rheumatoid patients (RSF).
Having demonstrated the presence o f hypoxia and ets-1 expression in the inflamed 
joint o f an animal model an in vitro system was utilized to expose synovial fibroblasts from 
rheumatoid arthritis patients to hypoxia and compare them to normoxic cells. I expected an 
increase in H IF -la  protein expression in RA synovial fibroblasts exposed to hypoxia 
compared to normoxic fibroblasts; my results in figure 16a,b showed this. Figure 17a,b 
shows the concurrent increase in ets-1 protein expression in hypoxic RA synovial 
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Figure 16a. W estern Blot: Effect of hypoxia on H IF -la  protein expression. 
Figure 16b. Effect of hypoxia on H IF - la  protein expression densitometry
measurement.
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Figure 17a. W estern Blot: Effect of hypoxia on ets-1 protein expression. 
Figure 17b. Effect of hypoxia on ets-1 protein expression densitometry 
measurement.
6.3.2 Effect of hypoxia on ets-1 and H IF - la  protein expression in ra t tissue explants
Results for ets-1 protein expression from the rat tissue explants were not analysable 
by Sion software. An example of these westerns can be seen in Figure 18. Westerns for 
H IF -la  protein expression showed analysable results as seen figures 19 to 22, however no 
discemable pattern for levels of H IF -la  expression between hypoxic and normoxic, 
adjuvant and naive samples could be detected.
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Key
NN1 = Normoxic Naive Sample N um ber 1 
NN2 = Normoxic Naive Sample N um ber 2 
HN1 = Hypoxic Naive Sample N um ber 1 
HN2 = Hypoxic Naive Sample N um ber 2 
NA1 = Normoxic Adjuvant Sample N um ber 1 
NA2 = Normoxic Adjuvant Sample N um ber 2 
HA1 = Hypoxic Adjuvant Sample Num ber 1 
HA2 = Hypoxic Adjuvant Sample Num ber 2 
+ve C o n tro l, -ve control
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Figure 19a. W estern Blot: Effect of hypoxia on H IF - la  protein expression by 
adjuvant and naive ra t tissue explants.
Figure 19b. Effect of hypoxia on HIF-la protein expression by adjuvant and nai’ve
rat tissue explants densitometry measurement.
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Figure 20a. W estern Blot: Effect of hypoxia on H IF - la  protein expression by 
adjuvant and naive ra t tissue explants.
Figure 20b. Effect of hypoxia on HIF-la protein expression by adjuvant and naive
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Figure 21a. W estern Blot: Effect of hypoxia on H IF - la  protein expression by 
adjuvant and naive ra t tissue explants.
Figure 21b. Effect of hypoxia on HIF-la protein expression by adjuvant and naive






n  ■ -  3! _ < / ) ( / )
£  C (5 
_Q G) 0
«- "O P





























































































Figure 22a. W estern Blot: Effect of hypoxia on H IF - la  protein expression by 
adjuvant and naive ra t tissue explants.
Figure 22b. Effect of hypoxia on HIF-la protein expression by adjuvant and naive
rat tissue explants densitometry measurement.
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6.3.3 Histological assessment of rat tissue explants from normoxic and hypoxic culture
A representative set o f stained sections presented in Plates. 6.1 to 6.6 show the 
histology o f patella suspensory ligaments that have been cultured at either 0% or 20% 
oxygen compared to patella suspensory ligaments that have just been fixed and embedded 
without culture. These slides show a qualitative reduction in the number o f cells present 
within the tissue o f cultured samples compared to those that have not been cultured. This 
result was observable in both naive and inflamed adjuvant samples.
169
Plate 6.1 Adjuvant knee synovium (x5, wax section, haematoxylin and eosin) with 
a high clinical score (3). Not cultured, observe high density o f cells proliferating at 
the synovium edge [arrows] compared to plate 7.2.
• f V >  '
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Plate 6.2 Adjuvant knee synovium (x5, wax section, haematoxylin and eosin) with 





Plate 6.3 Adjuvant knee synovium (x5, wax section, haematoxylin and eosin) with 
a high clinical score (3). Cultured in 20%O2, there are few cells scattered in the 




Plate 6.4 Naive knee synovium (x5, wax section, haematoxylin and eosin) with zero 
clinical score. Not cultured, observe greater cellularity throughout the synovium 
[S] compared to plate 7.5.
micron
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Plate 6.5 Naive knee synovium (x5, wax section, haematoxylin and eosin) with a
zero clinical score. Cultured in 0% 0 2. There are few cells in the synovium [S].
micron
Plate 6.6 Naive knee synovium (x5, wax section, haematoxylin and eosin) with a 
zero clinical score. Cultured in 20%O2. There are few cells in the synovium [S] 




Plate 6.1 is a haematoxylin and eosin stained section o f a patella suspensory 
ligament from an adjuvant rat with a high clinical score that has not been cultured. Observe 
the high concentration o f cells in the synovium edge compared to plate 6.2 where an 
explant with identical clinical score has been cultured for 14 days in 0% O2, and is 
essentialy acellular. Under higher oxygen concentrations it would be expected that perhaps 
there would be more cells present but again Plate 6.3 shows a haematoxylin and eosin 
stained section o f a patella suspensory ligament from the same adjuvant rat as plate 6.2 that 
has been cultured for 14 days in 20% O2, with few cells in the synovium. The difference 
here is that small aggregations o f cells appear to be using the synovium edge as a growth 
matrix.
A similar situation is observable in the naive samples. Plate 6.4 for example is a 
haematoxylin and eosin stained section o f a patella suspensory ligament from a naive rat 
with a zero clinical score that has not been cultured. There is a high concentration o f cells 
at the synovium edge compared to plate 6.5 with a matched zero clinical score that has been 
cultured for 14 days in 0% O2 . There are few cells in the synovium. As in the adjuvant 
rats, higher oxygen concentrations are not associated with greater cellularity as shown in 
Plate 6.6. This plate shows a haematoxylin and eosin stained section o f a patella 
suspensory ligament from the same naive rat as plate 6.5 that has been cultured for 14 days 
in 20% O2, with a low concentration of cells in the synovium.
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6.4 Discussion
These studies represent preliminary results. O f studies that warrant further 
investigation.
The antibody to H IF -la  detects a band at 110 KD, however in all o f my western 
blots the only band visible was at 60 KD. Having run appropriate controls (both negative 
and positive) and discussing the results with the antibody manufacturer, I was left to 
conclude that as all my negative controls had no bands and all my positive controls had a 
band at 60 KD that this band at was H IF -la  which had probably been broken down during 
protein retrieval. The band is possibly a dimer; hence the occasional double band 
appearance seen in figure 16a. Results from the rheumatoid knee synovial fibroblast 
western blots clearly show an increase in H IF -la  protein expression and a concurrent 
increase in etsl protein expression when cultured in 0% oxygen compared to cells cultured 
in 20% oxygen. This is the first work in this thesis involving human cells instead of rat 
tissue and it reassuring to see that results corroborate my studies linking an increase in 
hypoxia with increase in H IF -la  and etsl expression in the adjuvant arthritis model. Also 
because these cells are synovial fibroblasts it substantiates my previously mentioned theory 
that an increase in ets-1 expression does not have to be associated with angiogenesis in the 
rheumatoid synovium but could be more involved with the invasive characteristics of RA 
synovium. This is not implausible as others have demonstrated that ets-1 transcription 
factor up-regulation correlates with tumour invasion (Vandenbunder et al 1994, Wemert et 
al., 1994). If  time had allowed it would have been interesting to see if  hypoxic culture 
conditions also lead upregulation o f matrix metalloproteinases (MMPs) and tissue 
inhibitors o f metalloproteinases (TIMPs) like collagenase 1 (MMP-1), stromelysin (MMP-
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3), gelatinase B (MMP-9) and TIMP-1. All are gene targets o f ets-1 and have been shown 
to be elevated in patients with RA (Vincenti et al., 1994, Lelievre et al., 2001 and Klimiuk 
et al., 2002).
From this work and my previous studies in adjuvant arthritis it would have been 
logical to hypothesise that rat synovium either inflamed or naive would show an increased 
expression o f H IF -la  and etsl protein under conditions o f hypoxia. However, it can be 
seen from my results in this section (6.3.2) that this was not the case ex vivo. The results 
are inconsistent and there seems to be no pattern to the transcription factor protein 
expression. Repetition o f these westerns did not result in any improvement o f outcomes.
I hypothesised that there was a reduction in cells growing out from the explants 
which lead to the protein being retrieved from non viable cells and cellular debris. 
Therefore explants cultured were removed for subsequent histological examination and 
these did show a remarkable level o f acellularity. An additional problem caused by a large 
amount o f cell death is this may also result in antigen breakdown and inconsistent results. I 
suggest that the lack o f cellular proliferation may be due to a defieciency o f cytokines in 
this experimental system. It would be interesting to observe the effects o f the addition of 
inflammatory cytokines, for example basic fibroblastic growth factor which has been 
shown to simulate growth in many cells (Goddard et al., 1992) and transforming growth 
factor p (TGF-P), because it modulates fibroblast recruitment and proliferation (Berse, 
1999).
I feel that some o f the most potentially interesting results of this chapter come from 
embedded rat patella suspensory ligaments that had been cultured, sectioned and compared 
to tissue that had not been cultured, section 6.3.3. The histology o f sections shows a
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qualitative reduction in the number of cells present within the tissue o f cultured samples 
compared to those that have not been cultured irrespective o f oxygen concentration. This 
result was observable in both naive and inflamed adjuvant samples. There are a number of 
possible explanations for this the most probable being that whilst undergoing 14 days of 
culture, cell death occurred and this would account for the lack o f cells in the tissue 
explants and also the poor results observed in the western blots mentioned earlier. But 
could there be more to this than cell death? Observation o f the slides showed no cell or 
nuclear debris that I would expect to see if  there was apoptosis occurring. In rheumatoid 
synovium it has been suggested that part o f the proliferative characteristic o f RA synovium 
may be due to impaired apoptosis (Nakajima et al, 1995). Franz et al (2000) found marked 
expression o f the antiapoptotic molecule sentrin in rheumatoid synovial tissue, but not in 
osteoarthritis or normal synovium. This work has been supported by animal models of 
synovium which also demonstrate reduced apoptosis (Soo, 1999). Time and resources 
allowing, it would have been interesting to have measured markers o f apoptosis in my 
study.
If the cells are not dying where are they? A theory I would like to propose is that 
the cells may have migrated, in search o f more favorable oxygen concentrations. After all 
0% oxygen is too little oxygen to sustain cells that favor aerobic conditions and 20% 
oxygen is probably hyperoxia compared to the normal oxygen tensions o f the knee. This 
might account for why the cells still appear to be growing along the edges o f rat tissue 
explants cultured in 20% oxygen. There is no evidence in my current study to substantiate 
this theory but perhaps it warrants further investigation through the study o f markers of 
motility in inflamed synoviocytes. Could this be another characteristic o f the transformed
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synoviocyte, the ability to migrate to environments of optimal oxygen concentrations and 
therefore away from areas o f hypoxia?
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CHAPTER 7: Summary of Conclusions and General Discussion
The hypothesis behind this thesis is that global hypoxia in the diseased joint 
includes hypoxic synovial cells that produce pro-inflammatory cytokines and transcription 
factors that provide a potential target for bioreductive and other novel therapies. The aim 
of my study was to use the adjuvant arthritis model to identify at what stage during disease 
progression the joint becomes hypoxic. To examine the phenotype o f hypoxic cells and to 
identify cytokines and transcription factors produced.
The adjuvant arthritis model was used in this study because historically it 
has been used in previous studies demonstrating hypoxia in the inflamed joint (Bmce, 
1992), the resources were most accessible and it presents the disease aspects o f interest 
namely: inflammation, synovial hyperplasia, pannus formation and erosion o f bone and 
cartilage. However, unlike the Bruce (1992) study which measured oxygen tensions in the 
inflamed joint with a probe, my study aimed to identify hypoxia in the inflamed joint at a 
cellular level.
To achieve this hypoxyprobe-1, a commercially available injectable preparation of 
pimonidazole (a modified 2-nitromidizole) was employed. This is taken up by all tissues in 
the body but binds only to cells with a pC>2 o f 10 mm Hg (or less) at 37°C. Hypoxyprobe- 
1MAB1 is a monoclonal antibody that binds to specific protein adducts o f Hypoxyprobe 
produced in hypoxic cells and this allows their detection in tissues exvivo. At the time that 
this study was carried out pimonidazole had only been used to measure low oxygen in 
animal and human tumours as an index of radiation resistance (Kim et al., 1993, Kennedy 
et al., 1997). As this study used the model adjuvant arthritis in the Lewis rat a pilot study 
(chapter 3) was carried out to determine an appropriate method and preliminary qualitative
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results for hypoxic cell labeling in the adjuvant rat. From this study, a 6-hour time point for 
dosage of the animals prior to termination was chosen because it was the shortest time that 
gave specific labeling.
The objective o f chapter 4 was to quantitatively compare the level o f hypoxia in the 
adjuvant arthritis inflamed joint to the naive matched controls and establish at what point 
during the disease progression the joint becomes hypoxic. This study showed, for the first 
time that as the clinical symptoms o f adjuvant arthritis develop so the inflamed joint 
becomes hypoxic and that this hypoxia is significantly higher than in naive controls. 
Hypoxyprobe-1 adducts in the adjuvant foot tissue involved all structures including the 
synovium, pannus, bone marrow and articular cartilage chondrocytes. Further work 
(chapter 5) was carried out to try and identify the cell types that labelled with hypoxyprobe- 
1 adduct. Several key markers were examined: fibroblast and macrophage markers; 
cytokines, iNOS, VCAM-1 and VEGF; transcription factors, H IF -la  and ets-1. It is 
unfortunate that the studies in this chapter failed to identify specific cell type markers 
associated with hypoxic cells. This is probably due to problems I had maintaining sample 
preservation and antigenicity through the process o f fixation and decalcification required 
for the examination o f bony samples. Indeed, an increase in the cells expressing ED2 and 
to lesser extent EDI macrophage markers and an increase in both iNOS and VEGF were 
observed, though there was no co-localization with areas o f hypoxia. From this I conclude 
that hypoxia does not play as significant a role in their expression as do other factors. 
These are likely to be cytokines like TN Fa and IL-1. Such results support recently 
published work that indicates that an increase o f the VEGF/KDR (kinase insert domain
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protein receptor) pathway can occur independent of increases in HIF-alpha expression in 
rheumatoid arthritis (Giatromanolaki et al., 2003).
Like hypoxyprobe, hypoxia inducible factor-la an endogenous marker o f hypoxia 
involved all structures including the synovium, pannus, bone marrow and articular cartilage 
chondrocytes o f the adjuvant foot tissue however this contrasts with work carried out by 
Hollander et al., (2001), who demonstrated that H IF -la  localised to macrophages. My 
study compares very well to similar studies carried out more recently in rheumatoid 
synovium. Two groups Hitchon et al., (2002) and Giatromanolaki et al., (2003) published 
immunohistochemical studies that localized H IF-la  in synoviocytes lining the inflamed 
synovial tissue. Finally in this chapter I demonstrated an increased cellular hypoxia to be 
associated with a concurrent increase in the expression o f ets-1 transcription factor protein 
during the inflammatory response in adjuvant rat joints. From this I concluded that hypoxia 
and H IF-la  may be involved in the upregulation o f ets-1 during joint inflammation.
My final experimental chapter (chapter 6) sought to determine ets-1 and HIF-1 
expression in vitro, in hypoxic rheumatoid synovial fibroblasts (RSF) and hypoxic adjuvant 
rat synovium. The RA fibroblasts showed an increase in H IF -la  protein expression and a 
concurrent increase in etsl protein expression when cultured in 0% oxygen conditions 
compared to cells cultured in 20% oxygen conditions. This work corroborates my theory 
that an increase in ets-1 expression does not have to be associated with angiogenesis in the 
rheumatoid synovium but could be more involved with the invasive characteristics o f RA 
synovium. Others have demonstrated that ets-1 transcription factor up-regulation correlates 
with tumour invasion (Vandenbunder et al 1994, Wemert et al., 1994). My localisation of 
ets-1 in the invasive pannus is indicative o f ets-1 involvement in the invasion o f synovial
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joint cartilage and bone by proliferating synovium. This theory is further supported by the 
broad range o f target genes for ets-1: matrix metalloproteinases (MMPs) and tissue 
inhibitors o f metalloproteinases (TIMPs) such as collagenase 1 (MMP-1), stromelysin 
(MMP-3), gelatinase B (MMP-9) and TIMP-1 are all gene targets o f ets-1 (Lelievre et al., 
2001) and have been shown to be elevated in patients with RA (Vincenti et al., 1994 and 
Klimiuk et al., 2002). Indeed Czuwara-Ladykowska (2002) has shown that elevated etsl 
expression in fibroblasts alters their response to TGFp in favour o f matrix degradation. 
From the evidence o f my studies I propose that hypoxia arises in the inflamed rheumatoid 
joint as a result o f inflamed and proliferating tissue has a high metabolic demand but poor 
neovasculature, which is unable to meet the oxygen demand. This leads to increased HIF- 
l a  expression; H IF -la  binds to hypoxic response like binding sequences on the ets-1 
promoter which leads to increased expression o f etsl by fibroblast like synoviocytes. This 
throws a switch in the direction o f matrix degradation and thus the destruction o f the joint.
Increased hypoxia has been associated with a number o f diseases such as cancer 
(Brahimi-Hom et al., 2001; and Giatromanolaki and Harris, 2001); cardiovascular disease 
(Schmedtje and Ji, 1998), respiratory disease (Semenza, 2000 and Semenza, 2001) and 
rheumatoid arthritis (Mapp et al., 1995 and Bodamyali et al,. 1998) and this has lead to the 
concept o f hypoxia-targeted therapies. Some o f the first therapies to target hypoxic tissue 
in disease were bioreductive drugs. Bioreductive drugs are prodrugs that are metabolised to 
either generate or release an active species in the presence o f reducing environment (e.g., 
hypoxia or reductive enzymes). These reducing enzymes include NADP(H) 
oxidoreductase, NADPH cytochrome c (P450) reductase, cytochrome b5 reductase, 
carbonyl reductase and xanthine oxidase/xanthine dehydrogenase (Jaffar et al., 2001). In
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particular the xanthine oxidase system has been demonstrated in the rheumatoid synovium 
(Stevens et al., 1991).
Gene therapy is the introduction o f therapeutic genes to human cells for the 
treatment of disease (Hollander et al., 2001). Hypoxia inducible factor la  expression is 
abundant in rheumatoid synovium (Hitchon et al., 2002, Giatromanolaki et al., 2003) so 
strategies that target HIF-1 could be effective in treating rheumatoid arthritis. In cancer this 
goal has already been achieved through the use o f HIF-1 anti-sense (Sun et al., 2001) and 
through inhibiting the interaction between HIF-1 and the specific co-factors required for 
HIF-1 mediated transcription (Kung et al., 2000).
Hypoxia can also be used to target gene therapy to certain diseased areas. This 
concept exploits the fact that HIF-1 is degraded by exposure to oxygen but activated and 
stabilized under conditions of hypoxia (Wiesener et al., 1998). The expression o f a 
therapeutic gene o f interest is regulated by the inclusion o f a hypoxia responsive element 
(HRE) upstream o f the therapeutic gene in an expression vector. This concept was first 
demonstrated using human fibrosarcoma cells (HT1080) where the expression o f a stably 
transfected gene could be induced by hypoxia (both in vitro and in vivo) by the presence o f 
a HRE enhancer sequence (Dachs et al., 1997). It has been shown that macrophages can be 
transfected with HRE-regulated transgenes and used to deliver them to hypoxic sites in 
tumours (Griffiths et al., 2000).
At this time it is not possible to know if  ets-1 has a role in hypoxia-regulated gene 
therapy for arthritis, as it is not fully understood whether other factors present in-vivo would 
also activate ets-1 in a gene transfer delivery vehicle. Nevertheless, because this study has
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demonstrated both increased hypoxia and an increase in ets-1 expression at the site of 
cartilage and bone destruction, it is likely that HIF-1 mediated systems could be used.
This study clearly shows adjuvant arthritis to be a suitable model for in vivo 
research into the likely efficacy o f hypoxia-regulated therapies in the treatment of 
rheumatoid arthritis.
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CHAPTER 8: Future Work
This thesis demonstrated the labeling hypoxic cells in adjuvant arthritis a model that 
mirrors much o f the pathology o f rheumatoid arthritis (RA). It showed, for the first time, 
that as the clinical symptoms of adjuvant arthritis develops so the inflamed joint becomes 
hypoxic and that this hypoxia is significantly higher than naive controls. The main aim of 
future studies would be to see if  these results could be replicated in patients. Although this 
study would require ethical consideration it is within the realms o f possibility, as 
Hypoxyprobe-1 is already approved for use in human cancer research.
It is unfortunate that my studies have not identified specific cell type marker 
associated with cells labelling with hypoxyprobe. This was probably due to antigenicity 
loss during sample processing. It would be useful for future studies to investigate methods 
for achieving better antigen preservation during prcessing o f boney tissues. However, in 
the end even with the best antibody specificity possible, it is probable that the hypoxic cells 
identified in the inflamed joint are a heterogeneous population with phenotypical 
characteristics from both fibroblast and macrophage lineage. Further work should be 
carried out to improve the western blot methodology and maybe even look into messenger 
RNA for upregulation o f matrix metalloproteinases (MMPs) in the in vitro system 
employed to investigate the affect of induced hypoxia on normal and inflamed synovium. 
It would also be interesting to observe the effects o f the addition o f inflammatory cytokines 
to the in vitro studies for example basic fibroblastic growth factor which has been shown to 
simulate growth in many cells (Goddard et al., 1992) and transforming growth factor p 
(TGF-P), because it modulates fibroblast recruitment and proliferation (Berse, 1999).
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It would also be desirable to investigate further the upstream control of ets-1 
expression in the inflamed synovium,
I feel some of the most curious results from my study came from a decision to 
embed some o f the rat patella suspensory ligaments and compare the histology of sections 
that had been cultured at either 0% or 20% oxygen compared to patella suspensory 
ligaments that have just been fixed and embedded without culture. These slides show a 
qualitative reduction in the number o f cells present within the tissue o f cultured samples 
compared to those that have not been cultured. I feel this is worth further investigation, 
since in rheumatoid synovium it has been suggested that part o f the proliferative 
characteristic o f RA synovium may be due to impaired apoptosis (Nakajima et al, 1995). It 
would be interesting to measure markers o f apoptosis in a repetition o f my study. A theory 
I have proposed is that the cells may have migrated, in search o f more favorable oxygen 
concentrations. There is no evidence in my current study to substantiate this theory but 
perhaps it could be further investigated through the study o f markers o f motility in inflamed 
synoviocytes.
Finally I believe my study has shown adjuvant arthritis to be a suitable model for 
future in vivo research into the likely efficacy o f hypoxia-regulated therapies like 
bioreductive and hypoxia mediated gene therapy in the treatment o f rheumatoid arthritis.
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Appendix A
Stacking Buffer - 100ml 
Tris base: 6.05g 
ddWater: 100ml 
pH 6.8 with HCI
Running Buffer - 100ml 
Tris base: 18.17g 
ddWater: 100ml 
pH8.8 with HCI
7.5% Acrvlamide Running Gel 
Running buffer: 6.5ml 
ddWater: 13.7ml 
1 0% SDS: 0.25ml 




5% Acrylamide Stacking Gel
Stacking buffer: 0.5ml 
ddWater: 3.036ml 
1 0% SDS: 40pl 







Bromophenol blue: lm g
Take 750pl o f above solution and add 2-mercaptoethanol: 50pl
Electrophoresis Buffer 
Glycine: 14.4g 
Tris base: 3g 
10% SDS: 10ml







Make up to 1000ml with dd water
Coomassie Blue Staining Solution 
Coomassie Brilliant Blue: 1.25mg 
Methanol: 45ml
6M Acetic Acid: 10ml (34ml: glacial acetic acid + 63ml dd water = 6M solution) 
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The Transcription Factors Hypoxia-Inducible Factor la  and 
Ets-1 Colocalize in the Hypoxic Synovium of Inflamed Joints in
Adjuvant-Induced Arthritis
C. L. Peters,1 C. J. Morris,1 P. I. Mapp,1 D. R. Blake,1 C. E. Lewis,2 and V. R. Winrow1
Objective. To determine the relationship between 
hypoxia and the expression of Ets-1 and hypoxia- 
inducible factor la  (HIF-la) in both normal and in­
flamed joints. Adjuvant-induced arthritis (AIA) was 
used as the model system, since it mirrors many aspects 
of the pathology of rheumatoid arthritis.
Methods. Adjuvant arthritis was induced in a 
group of 10 female Lewis rats. A second group of 10 
uniifiected female Lewis rats served as naive controls. 
When a maximum clinical joint score was achieved in 
the AIA group, all 20 rats were injected with the specific 
hypoxic cell marker Hypoxyprobe-1 and subsequently 
killed. Hypoxyprobe-1 adducts, Ets-1, and HIF-la were 
localized in the joints of the hind feet from these groups 
using immunohistochemistry.
Results. Compared with the joints from control 
rats, inflamed joints contained markedly more cells with 
Hypoxyprobe-1 adduct immunoreactivity, Ets-1- 
immunoreactive nuclei, and nuclear immunoreactivity 
for both Ets-1 and HIF-la.
Conclusion. Our results demonstrate the pres­
ence of hypoxia in inflamed joints in this experimental 
model of arthritis. The colocalization of Ets-1 and 
HIF-la in these hypoxic areas suggests that hypoxia
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may induce Ets-1 and HIF-la expression during joint 
inflammation.
Rheumatoid arthritis (RA) is characterized by a 
progressive and proliferative synovitis that is invasive but 
not malignant, which results in joint destruction. The 
synovium is hypoxic, probably as a result of synovial 
tissue proliferation outpacing angiogenesis (1). Hypoxia 
is a potent inducer of cytokines, matrix-degrading en­
zymes, and angiogenic factors and plays a central role in 
the normal inflammatory response. Moreover, hypoxia- 
driven angiogenesis is critical for extracellular matrix 
formation and tissue remodeling (2). The Ets-1 tran­
scription factor, which was identified in endothelial cells 
during angiogenesis and as a marker of tumor invasion 
(3), can be induced following activation of a second 
transcription factor, hypoxia-inducible factor 1 (HIF-1), 
and both Ets-1 and HIF-1 are overexpressed in rheuma­
toid synovial tissue (4,5).
Since inhibitors of angiogenesis can modulate 
disease in experimental arthritis (6), we examined the 
relationship between cellular hypoxia, HIF-1, and Ets-1 
expression in the joints of rats with adjuvant-induced 
arthritis (AIA). This model mirrors much of  
the pathology of RA, including synovial tissue prolifer­
ation, pannus formation, and the destruction of bone 
and cartilage in the synovial joint. To visualize hypoxic 
cells, we used Hypoxyprobe-1 (pimonidazole; Chemicon 
Europe, Chandlers Ford, UK), a recently developed 
compound which is taken up by all body tissues in vivo 
but which binds only to cells with a low oxygen tension 
(Po2 <10 mm Hg at 37°C). The monoclonal antibody 
Hypoxyprobe-1-Mabl binds to protein adducts of Hy- 
poxyprobe produced in hypoxic cells, allowing their 
immunohistochemical identification in tissues ex vivo. 
The reductive metabolism of this hypoxia marker is 
highly specifically regulated by oxygen tension indepen­
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dently of the pyridine nucleotide redox state (7). Pi- 
monidazole was first used to quantify hypoxic tumor 
tissue as an index of radiation resistance (8) and has 
since become widely used in cancer research.
MATERIALS AND METHODS
Induction of adjuvant arthritis. Female Lewis rats 
(Charles River UK, Kent, UK) weighing 130-150 grams were 
housed in 4 groups of 5 rats and were exposed to a 12-hour 
light/dark cycle and a mean temperature of 20°C (±2°C). All 
animals were allowed access to tap water and a standard rat 
diet (SDS, Witham, UK) ad libitum. Adjuvant arthritis was 
induced using a method we have previously described (9). AIA 
rats (n =  10) were injected intradermally into the base of the 
tail with 100 p \ of a suspension of pulverized, heat-killed 
Mycobacterium tuberculosis (Central Veterinary Laboratory, 
Weybridge, UK), 10 mg/ml in light paraffin oil. A  second group 
of uninjected rats (n =  10) served as naive controls.
Disease progression was monitored daily using a stan­
dard clinical scoring system (0 =  no inflammation, 4 =  severe 
joint inflammation and deformity) (9). When a maximum 
clinical score of 4 was reached in 1 hind foot, the animals were 
killed by cervical dislocation. Naive rats were killed at the same 
time. Six hours prior to death, all 20 rats were injected 
intraperitoneally with 60 mg/kg of Hypoxyprobe-1 (Chemicon 
Europe) dissolved in 1 ml of 0.8% sterile saline (Sigma, Poole, 
UK). Optimization studies had been carried out previously 
(data not shown) to determine how tissue hypoxia detected by 
Hypoxyprobe adducts varied with AIA disease progression. 
Hypoxia was detectable as soon as clinical symptoms devel­
oped and increased with the degree of inflammation, as 
quantified by the joint score. The end point o f this study was 
the maximum joint score, as dictated by The Home Office 
(UK).
Tissue sectioning/mounting. Five micrometer-thick al­
ternate downward- and upward-facing (flip-flop) and consec­
utive sections were cut from decalcified hind feet (joint score 
4). The sections were mounted on glass slides and dried in an 
oven at 60°C overnight.
Immunostaining for Hypoxyprobe. Pronase (0.01% )- 
treated dewaxed sections were blocked with normal horse 
serum in phosphate buffered saline (PBS) (1/200 volume/ 
volume) for 20 minutes at ambient temperature. Sections were 
overlaid with 200 pi o f mouse monoclonal anti-Hypoxyprobe 
antibody (Hypoxyprobe-1-Mabl; Chemicon Europe), diluted 
1:50 in PBS containing 1/200 v/v normal horse serum, and kept 
at 4°C overnight. Negative controls were incubated in the same 
dilution of an isotype-matched mouse monoclonal antibody to 
an irrelevant antigen, Aspergillus niger glucose oxidase. Bound 
antibody was detected using an avidin-biotin-peroxidase com­
plex (ABC) phosphatase kit (Vector Laboratories, Peterbor­
ough, UK), and phosphatase activity was revealed using a fast 
red substrate. All slides were counterstained with Mayer’s 
hematoxylin, blued in tap water, and mounted in Aquamount 
under standard conditions.
Immunostaining for Ets-1. Dewaxed tissue sections 
were blocked with normal goat serum in PBS (1/200 v/v) for 20 
minutes at ambient temperature. Rabbit polyclonal anti-Ets-1
antibody (Autogen Bioclear, Caine, UK) in PBS (1/500 v/v) 
was applied to the slides, which were kept at 4°C overnight. 
Negative controls were similarly treated in the same dilution of 
normal rabbit IgG l. Bound antibody was detected using an 
ABC phosphatase kit, and phosphatase activity was revealed 
using a fast red substrate. All tissue sections were counter- 
stained with Mayer’s hematoxylin.
Immunostaining for H IF -la. Dewaxed tissue sections 
were stained for H IF -la  using a catalyzed signal amplification 
system. Sections were washed in 3% H20 2 in distilled water 
followed by PBS and blocked with protein block for 20 minutes 
at ambient temperature. A  mouse anti-H IF-la antibody (Ab­
eam, Cambridge, UK) diluted 1:500 in background-reducing 
antibody diluent (DakoCytomation, Ely, UK) was applied to 
the sections, which were maintained at 4°C overnight. Negative 
controls were similarly maintained in the same dilution of an 
isotype-matched mouse monoclonal antibody to an irrelevant 
antigen, A niger glucose oxidase. Sections were treated with 
link antibody followed by streptavidin-biotin complex, ampli­
fication agent, and, finally, streptavidin-peroxidase reagent. 
Peroxidase activity was revealed using a 3,3'-diaminobenzidine 
substrate, and sections were counterstained with Mayer’s hema­
toxylin.
Image analysis. Sections were examined by two inde­
pendent observers using an Axioskop II microscope (Zeiss, 
Wetzlar, Germany) fitted with a 3-charge-coupled device 
camera (JVC, Tokyo, Japan) for digital imaging and white light 
illumination. Photographic records were stored as jpeg images.
Quantitative analysis o f hypoxia by detection of 
Hypoxyprobe-1 adducts. We used a modified version of a 
method used for the quantification of Hypoxyprobe-1 adducts 
in mouse radiation-induced fibrosarcoma-1 tumors (10). Three 
sections from each o f 10 hind feet were assessed using a 20 x  
microscope objective. For arthritic animals, only hind feet with 
a maximum clinical score of 4 (n =  10) were used. Equivalent 
hind feet of naive animals (n = 10) were also quantified. Image 
analysis was carried out on all areas o f joint tissue to determine 
the percentage of stained area compared with unstained area.
Sections were assessed in a blinded manner using a 
program written for the KS 300 Imaging System, version 3.0 
(Imaging Associates, Bicester, UK). This program analyzes a 
framed area of 800 x  600 pixels. It removes from the analysis 
any area <10  /xm, thus removing small histologic artifacts. 
Large histologic artifacts were manually removed from the 
analysis by outlining them. Hypoxic regions were thresholded 
based upon a pimonidazole adduct density converted to a 
red-blue-green level which was consistent throughout the 
images. The spatial transition between peak density and 0% 
(nonhypoxic area) was distinct, providing a reproducible 
method to demarcate hypoxic areas. Finally, the program 
calculated the demarcated area as a percentage of the whole 
framed area. These data were then tabulated using Prism 
software (GraphPad Software, San Diego, CA) for statistical 
analysis.
Quantitative analysis of positive H IF -la  and Ets-1 
immunoreactivity. Three alternate downward-facing and 
upward-facing (flip-flop) sections from 10 hind feet were 
surveyed for areas of identical tissue architecture using a 40X 
microscope objective. Image analysis was limited to synovial 
tissue lining the joint cavity and synovial tissue attached to the 
bone. A program written for the KS 300 Imaging System
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version 3.0 was used. This program enabled the counting of 
nuclei with positive immunoreactivity for Ets-1 to be expressed 
as a proportion of the total cell population counted in a framed 
area of 100 x  100 /xm. The proportion of nuclei showing 
immunoreactivity for both Ets-1 and H IF -la  was also assessed. 
These data were then tabulated using Prism software (Graph- 
Pad Software).
RESULTS
Clinically detectable swelling was present in the 
distal joints of the hind feet from day 11; this increased 
in severity and led to ankle joint deformation by day 15. 
At this time, sections of AIA rat feet showed synovial 
hyperplasia, increased cellular infiltration, and bone 
destruction.
Quantitative analysis. In hind feet from AIA 
rats, there was a highly significant increase (P  <  0.0001) 
in the proportion of cells having nuclei with positive 
immunoreactivity for Ets-1 compared with hind feet 
from naive control rats (Figures 1A, 2A, and 2B). AIA 
rats also had significantly (P <  0.0001) more hypoxic 
tissue compared with naive control rats, as demonstrated 
by positive immunoreactivity for Hypoxyprobe-1 ad­
ducts, measured by the binding of Hypoxyprobe-1-Mabl 
(Figures IB, 2C, and 2D). Hind feet from AIA rats 
showed a highly significant increase (P <  0.0001) in the 
proportion of cells having nuclei with positive immuno­
reactivity for both Ets-1 and H IF-la compared with 
hind feet from naive control rats (Figures 1C, 2E, and 
2F). Statistical comparisons were made using the Mann- 
Whitney U test.
Immunohistochemical assessment. In the foot 
tissue of AIA rats, positive immunoreactivity for both 
Hypoxyprobe-1 adducts and H IF-la involved all struc­
tures, including the synovium, pannus, bone marrow, 
and articular cartilage chondrocytes. Immunostained 
sections showed that positive immunoreactivity for Ets-1 
was mainly found in the inflammatory infiltrate and 
invasive pannus of the inflamed synovial joint (Figure 
2A). The histologically normal hind feet from naive rats 
showed a low level of positive immunoreactivity for 
Ets-1 in the subintimal synoviocytes (Figure 2B). The 
same was true o f positive immunoreactivity for 
Hypoxyprobe-1 adducts (Figures 2C and D). In cell 
nuclei of AIA rats, positive immunoreactivity for Ets-1 
(Figure 2E) colocalized with strong positive immunore­
activity for H IF-la in 5-/xm flip-flop sections (Figure 
2F), mainly in inflammatory infiltrate and invasive pan­
nus of the inflamed synovial joint. Interestingly, colocal­
ization was not 100% (Figures 1C, 2E, and 2F). Figures 
2G and H represent nonstaining negative controls
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Figure 1. A, Proportion of cells expressing Ets-1 transcription factor 
in single hind feet (n = 10). Ets-1 expression in the foot joints of rats with 
adjuvant-induced arthritis (AIA) (■) is significantly higher than that in the 
foot joints of naive rats (A) (P < 0.0001 by Mann-Whitney U test). B, 
Percentage of total area examined that was hypoxic (Po2 s lO  mm Hg), as 
indicated by positive immunoreactivity for Hypoxyprobe-1 adducts. The 
percentage of hypoxic tissue in the hind feet of AIA rats is significantly 
higher than that in the hind feet of naive rats (P <  0.0001 by Mann- 
Whitney U test). C, Proportion of the cell population coexpressing Ets-1 
transcription factor and hypoxia-inducible factor l a  (H IF-la) in each of 
10 hind foot samples. The hind feet from AIA rats showed a highly 
significant increase in the proportion of cells having nuclei with positive 
immunoreactivity for both Ets-1 and H IF -la  compared with the hind feet 
from naive rats (P  <  0.0001 by Mann-Whitney U test). Etsl-ir = 
immunoreactivity for Ets-1; H IF la-ir =  immunoreactivity for H IF-la.
(isotype-matched mouse monoclonal antibody to an 
irrelevant antigen \A niger glucose oxidase] and rabbit 
IgGl, respectively).
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Figure 2. Immunohistochemical assessments of immunoreactivity in hind foot sections from AIA and naive rats. A, Hind foot from an AIA rat 
showing nuclear localization of positive immunoreactivity (red) for Ets-1. B, Hind foot from a naive rat showing a low level of positive 
immunoreactivity for Ets-1. C, Hind foot from an AIA rat showing inflammatory infiltrate with positive immunoreactivity (red) for Hypoxyprobe-1 
adducts. D, In the hind foot from a naive rat, the synovium shows no immunoreactivity for Hypoxyprobe-1 adducts. E, In the hind foot from 
an AIA rat, the synovium shows proliferating synoviocytes with positive immunoreactivity (red) for Ets-1 (arrows). F, Alternate flip-flop 
section of same hind foot shown in E reveals nuclei with strong positive immunoreactivity for H IF -la  (brown; arrows) colocalizing with 
positive immunoreactivity for Ets-1. Colocalization does not involve all nuclei (see Figure 1C). G, Isotype-matched mouse monoclonal 
antibody to an irrelevant antigen (Aspergillus niger glucose oxidase) as a negative control for mouse antibodies in inflamed tissue. H, Rabbit 
IgG l as a negative control in inflamed tissue. See Figure 1 for definitions.
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DISCUSSION
Using a definitive marker, we have shown that 
joint inflammation is associated with an increase in 
cellular hypoxia. This is concordant with the situation in 
the rheumatoid joint as demonstrated by H IF-la expres­
sion (11). Since the Ets-1 promoter has been shown to 
contain hypoxia-responsive element (HRE)-like se­
quences (12), we would expect increased cellular hyp­
oxia to be associated with a concurrent increase in the 
expression o f Ets-1. This was verified by our results: the 
joints of all 10 feet from the AIA rats had a minimum of 
40% Ets-1-positive nuclei in the total cell population, 
while in the 10 naive joint samples, no more than 15% of 
the nuclei expressed detectable Ets-1. Furthermore, 
65-75% of nuclei expressing Ets-1 in the samples from 
AIA rats also expressed H IF-la. This clearly demon­
strates an induction of hypoxia and expression of Ets-1 
during the inflammatory response in AIA rat joints.
Other investigators have demonstrated that Ets-1 
transcription factor up-regulation correlates with tumor 
invasion (3), and our localization of Ets-1 in the invasive 
pannus is indicative of its involvement in the invasion of 
synovial joint cartilage and bone by proliferating syno­
vium. Additionally, our demonstration that Ets-1 and 
H IF-la colocalize in areas of hypoxia in inflamed syno­
vial tissue suggests that both hypoxia and H IF-la may be 
involved in the up-regulation of Ets-1 during joint 
inflammation.
The broad range of target genes for Ets-1 has 
been extensively reviewed (13). Of particular relevance 
to the pathology of arthritis is its involvement in angio­
genesis and extracellular matrix remodeling. Matrix met- 
alloproteinases (MMPs), such as collagenase 1 (MMP- 
1), stromelysin 1 (MMP-3), and gelatinase B (MMP-9), 
and tissue inhibitors of metalloproteinases (TIMPs), 
such as TIMP-1, are all gene targets of Ets-1 and have 
been shown to be elevated in patients with RA (14).
Increased hypoxia has been associated with RA 
(2), and this has led to the concept of hypoxia-targeted 
therapies, including gene therapy. H IF-la expression is 
abundant in rheumatoid synovium (5), so strategies that 
target HIF-1 could be effective in treating RA. Hypoxia 
can also be used to target gene therapy to certain 
diseased areas. This concept exploits the fact that HIF-1 
is degraded by exposure to oxygen but activated and 
stabilized under conditions of hypoxia (15). The expres­
sion of a therapeutic gene of interest is regulated by the 
inclusion of an HRE upstream of the therapeutic gene in 
an expression vector. At this time, we cannot confirm 
that Ets-1 has a role in hypoxia-regulated gene therapy
for arthritis, since it is not fully understood whether 
other factors present in vivo would also activate Ets-1 in 
a gene transfer delivery vehicle. A previous report from 
investigators in our group (5) suggested that macro­
phages are the main expressors of H IF-la during the 
inflammatory response in RA. However, our study re­
ported here indicates that other cells appear to be 
involved as well.
Further research is under way to identify the cell 
phenotype expressing both H IF-la and Ets-1. Neverthe­
less, because we have demonstrated both increased 
hypoxia and Ets-1 expression in cells at the site of 
cartilage and bone destruction, these could be targeted 
using HIF-l-mediated systems to limit joint damage. 
Our study clearly provides further evidence that AIA is 
a suitable model for in vivo research into the likely in 
vivo efficacy of hypoxia-regulated therapies in the treat­
ment of RA.
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